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1.1 G PROTEIN COUPLED RECEPTORS 
 
G-protein-coupled receptors (GPCRs) form the largest superfamily of proteins in 
the human body. About 1% of the human genome encodes for over 1000 GPCRs 
1. They are located at the cell surface and are expressed ubiquitously. GPCRs 
regulate diverse intracellular responses and are therefore involved in all kinds of 
diseases, making them interesting therapeutic targets 2. The name GPCRs 
originates from the first step in the signal transduction that comprises the direct 
activation of a hetero-trimeric G protein. However, this is something of a 
misnomer, as G-proteins are able to couple to other proteins which are not 
GPCRs, and GPCRs are able to signal without G-proteins 3. Because of this, 
GPCRs are more recently referred to by some authors as heptahelical, serpentine 
or 7-transmembrane (7-TM) receptors. This last name, 7-TM, is derived from the 
fact that GPCRs are transmembrane proteins, which cross the mebrane seven 
times. Each individual TM domain is an α-helix which is connected to the next 
TM domain via alternating intracellular and extracellular loops. These start with 
an extracellular amino.terminal tail (N-terminal) and end with an intracellular 
carboxyl-terminal tail (C-terminal). This basic motif has recently been verified by 
x-ray crystallography on bovine rhodopsin and human β-adrenergic 4,5 (Figure 
1.1.1). 
 
Figure 1.1.1 Computer model of the human M3 muscarinic receptor, based on the crystal 
structure of rhodopsin 4 (PDB code: 1F88), and prepared using Pymol. The structure is viewed 
from outside of the cell (A) and  parallel to the membrane (B). The structure has five key features: 
1. seven transmembrane α helices;  2. three external loops (1Eloop-3Eloop); 3. three cytosolic 
loops (1ILoop-3ILoop); 4. N-terminal tail (N-tail) and a C-terminal tail (C-tail); and 5. cytosolic 
helix VIII.  
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The superfamily of GPCRs can be activated by a plethora of different stimuli. 
There is a great chemical diversity among the endogenous ligands, including 
protein hormones, lipids, peptides, biogenic amines, nucleotides and ions 6,7. 
Furthermore, the sensation of exogenous stimuli, including light odor and taste, is 
mediated through GPCRs 6,8. The bundle of 7-TM domains forms a cavity large 
enough to fit small ligands, such as biogenic amines. However, larger ligands, 
such as peptides and hormones, generally interact and bind to the N-terminal tail 
and/or extracellular loops 9. 
GPCRs are involved in wide variety of diseases, including asthma, hypertension, 
Parkinson´s disease, cancer, and HIV infection 10,11. The presence of GPCRs at 
the cell surface makes these receptors very accessible to therapeutic drugs. It is 
estimated that more than half of all modern drugs are targeted at GPCRs, and 
several ligands are found among the worldwide top-100-selling pharmaceutical 
products. Sales for individual drugs reach up to several billions of euros per year 
12,13.  
Although all GPCRs belong to one superfamily, these receptors are also highly 
variable and can be subdivided into smaller families on the basis of sequence 
homology and/or pharmacological characteristics. In general, GPCRs are divided 
into three major subfamilies: rhodopsin-like (family A), secretin-like (family B) 
and the metabotropic neurotrasmitter receptor-like (family C). The yeast 
pheromone (family D), the cAMP receptors (family E) and the 
frizzled/smoothened family make up three minor subfamilies 6,7,14,15 (Figure 
1.1.2).  
 
Figure 1.1.2: GPCRs can be divided into different families on the basis of their structural and 
genetic characteristics. The figure shows schematic representations of receptor monomers, and 
illustrates in red circles some key structural aspects of the three main GPCR families (A, B, C). 




Family A forms the largest of the three major subfamilies, and contains 90% of all 
GPCRs. Family A includes, among others, aminergic receptors (muscarinergic, 
dopaminergic, histaminergic, serotonergic and adrenergic receptors), peptides, 
and rhodopsin, as well as the large subfamily of olfactory receptors. The overall 
homology among all type A receptors is low; it is restricted to a number of highly 
conserved key residues. The high degree of conservation among these key 
residues suggests that they play an essential role in the structural or functional 
integrity of the receptors. The only residue consistently present among all family 
A receptors is arginine, found in the Asp- Arg-Tyr (DRY) motif located on the 
cytoplasmic side of TM-3, which is believed to be involved in G protein 
activation 17. However, other fingerprint elements such as the conserved 
NSxxNPxxY motif are also clearly associated with rhodopsin family. In addition, 
six different groups of receptors have been further classified within this subfamily 
of receptors with regards to their phylogeny 18. 
Subfamily B consists of approximately 25 GPCRs 19. A range of neuropeptides 
and peptide hormones, like glucagons, calcitonin and secretin, recognizes these 
GPCRs 20. One of the hallmark features of this family is the large extracellular N-
terminal tail containing numerous cysteines, which probably forms a network of 
disulfide bridges 20. Unlike family A, subfamily B receptors do not contain the 
important DRY motif involved in the activation of family A GPCRs.  
Hallmark features for family C receptors include a short and highly conserved 
intracellular loop 3 (3ILoop), a relatively long C-terminal tail, and an 
exceptionally long N-terminal tail, which is shaped like a Venus-fly trap to 
facilitate ligand binding (500–600 amino acids). This region shares a low but 
significant sequence similarity to bacterial periplasmic binding proteins (PBPs) 
and is considered the glutamate binding site equivalent to the known amino acid 
binding site of PBPs 21. This subfamily includes metabotropic glutamate, γ-
aminobutyric acid (GABA), calcium, vomeronasal, mammalian pheromone 
receptors, and recently identified putative taste receptors. As with subfamilies A 
and B, subamily C receptors contain two putative disulfide-forming cysteines in 
extracellular loops 1 and 2 (ECL 1 and 2). Otherwise, they do not share any 
conserved residues with subfamily A or B receptors. 
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The A-F subclassification of the GPCR superfamily is widely accepted. However, 
Fredriksson et al. performed the first phylogenetic study of the entire superfamily 
of GPCRs (comprising about 2% of the genes in the human genome) and 
proposed a different, more accurate classification 22. Their analysis demonstrated 
that there are five main subfamilies of human GPCRs, and that they share a 
common evolutionary origin within each subfamily. Glutamate, rhodopsin, 
adhesion, frizzled/taste2, and secretin otherwise known as the GRAFS 
classification, based on the initials of each of the subfamily names. Three of these 
subfamilies, the rhodopsin (A), secretin (B), and glutamate (C) families, 
correspond to the A-F clan system, whereas the two other families, adhesion and 
frizzled, were not included in the clan system 23. The rhodopsin receptors make up 
the largest family, divided into four main groups with 13 distinct branches. 
The human genome project has revealed the existence and position of all GPCRs. 
For several GPCRs, however, their respective cognate ligand is still unknown. 
These GPCRs are known as orphan GPCRs. Excluding the olfactory GPCRs, 
approximately 300 full open reading frame (ORFs) have been identified to encode 
putative GPCRs. Out of these 300, about 100 are considered orphan receptors 19. 
Much effort has been invested in attempts to de-orphanize these receptors, as well 
as to link them to possible diseases. In addition to these orphan receptors, many 
gene encoding GPCRs can be alternatively spliced, adding to the complexity and 
magnitude of the superfamily 24.   
 
G PROTEIN COUPLING AND HETEROTRIMERIC G PROTEINS 
CONCEPTS 
 
The interaction of GPCRs with its proper heterotrimeric G protein is the first 
molecular step in signal transduction that regulates cellular functions 25. The G 
protein consists of three subunits, Gα, Gβ and Gγ. The Gα subunit harbours an 
intrinsic GTPase activity, which is able to hydrolyze GTP to GDP. The Gβ and 
Gγ subunits form the dimeric Gβγ-subunit that can either associate to or dissociate 
from the Gα subunit, depending on whether or not the Gα is bound to GDP or 
GTP, respectively. In its resting state, the Gα subunit is bound to GDP and is 
associated to a hetero-dimeric Gβγ-subunit. While bound to the Gα subunit, the 
Gβγ-subunit inhibits the spontaneous release of GDP from the Gα subunit 26,27. 
Introduction 
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Upon agonist binding to the receptor, the activated receptor subsequently 
activates the intracellular heterotrimeric G protein by causing an increase in the 
rate of GDP-GTP exchange in the Gα subunit. Upon activation, the now GTP-
bound Gα subunit dissociates from the Gβγ-subunit, and both the Gα and Gβγ-
subunit subsequently activate their respective effectors. Hydrolysis of GTP to 
GDP by the intrinsic GTPase returns the Gα subunit to its inactive, GDP-bound 
state, followed by re-association with a Gβγ-subunit 3. 
There appear to be more than twenty different α subunits (including splice 
variants), six β subunits, and fourteen γ subunits 28,29. However, only four main 
classes of hetero-trimeric G-proteins can be distinguished: Gαs, Gαi, Gαq, Gα12 30. 
Gs proteins stimulate adenyl cyclase; Gαi proteins inhibit adenyl cyclase and 
activate G proteins coupled inwardly rectifying potassium channels. Gαq proteins 
activate phospholipase Cβ, which leads to the hydrolysis of phosphatidylinositol 
biphosphate (PIP2), resulting in the formation of diacyl glycerol (DAG) and 
inositol triphosphate (InsP3), with corresponding increases in intracellular Ca2+-
ions and protein kinase C (PKC) activation 31,32. Gα12 proteins activate Rho 
guanine-nucleotide exchange factors 32 (Figure 1.1.3). 
A second classification of G proteins can be made based on their sensitivity to 
Vibrio cholerae toxin (CTX) or Bordetella pertussis toxin (PTX). CTX prevents 
the hydrolysis of Gs GTP to its GDP bound state and, as a result, the G protein 
remains in the active state. PTX prevents the release of bound GDP, locking Gα 
in the inactive state. 
Structures of all the subunits have been discovered by x-ray crystallography in 
various activation states and in complexes with various effector and regulatory 
proteins. The α subunit is structurally homologous to other members of the 
guanine nucleotide binding protein superfamily; the β subunit forms a β-propeller 
consisting of toroidal arrangement of β sheet; and the α-helical γ subunit is 
usually found as a complex with the β unit 33-35. 
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Figure 1.1.3: Overview of GPCR signalling pathways. a, G-protein coupling and signalling 
pathways mediated through GPCR activation. GPCRs can be stimulated by a wide assortment of 
ligands like biogenic amines, ions, lipids and hormones. Activated GPCRs can transfer the 
extracellular stimulus into intracellular signals through binding to a variety of G proteins (Gαi, 
Gαq, Gαs, Gα12), which can activate intracellular and nuclear effectors. b, heterotrimeric G 
protein independent signalling mediated by GPCRs. Upon agonist stimulation of a GPCRs, β-
arrestins, GRK and other scaffold/accessory proteins are recruited and activated. They 
subsequently activate or inhibit various signalling pathways.  
 
Originally, receptors were thought to interact with only one type of heterotrimeric 
G-protein. However, it is now understood that, depending on cellular and external 
conditions, GPCRs can interact diversely and signal via multiple pathways 36. In 
addition, ligands have also been discovered that act as agonist in systems devoid 
of constitutive activity, but become inverse agonist in constitutively active 
systems. These ligands are known as protean ligands 37.  
GPCRs can also activate small monomeric G-proteins such as Ras 38. The Gβγ-
dimer can separately activate several different signalling pathways, such as 
adenylyl cyclases, PLC-β, a multitude of kinases, as well as ion channels 32,39. 
Moreover, GPCRs can signal independently of G proteins. This signalling is 
mediated by direct interaction with receptors with scaffold/accessory proteins, 
such as β-arrestin and G-protein receptor kinases (GRK).  This results in the 
activation of cytoplasmic effectors such as Src, Ras and ERK, which ultimately 





GPCR STRUCTURE AND ACTIVATION 
 
The development of therapeutic drugs acting on GPCRs is largely based on two 
different strategies. For a newly identified target, large libraries are tested in a 
high throughput screening (HTS) approach. These libraries frequently consist of a 
selection of known drugs, a large diversity of scaffolds, and a times a selection of 
naturally occurring compounds. A more rational approach to drug design can be 
employed when detailed information is known about the target, especially when 
data is obtained by mutation of the ligand bingind pocket. Rational-based drug 
design may benefit a great deal from the elucidation of the high-resolution 
structures of GPCRs. So far, the crystallization of GPCRs other than rhodopsin 
and the β-adrenergic receptor has not yielded high-resolution structural data 4,5. 
However, using the structure of these receptors as a template, homology models 
of GPCR can be created, which are useful for rational drug design on these 
GPCRs 42.  
Although all GPCRs share the same topology of a 7TM receptor, they do not 
necessarily share a high sequence homology. However, within the large subfamily 
of family A GPCRs, there are several amino acid residues which seem to be 
important for either the structural integrity or signal transduction, and which are 
conserved among these family A GPCRs 18 (Appendix 1). 
Using indirect methods, some progress has been made towards an understanding 
of the conformational changes that are associated with GPCR activation 43. 
Ultimately, however, it may require structures of multiple receptors bound to 
multiple ligands, including inverse agonists, agonists, and antagonists, for us to 
flesh out the details of the conformational changes associated with receptor 
activation. In addition, different agonists may channel individual receptors to 
different G proteins, and thereby to different second messenger systems, a 
phenomenon that would require the existence of multiple active conformations 
and further demonstrate the need for additional high-resolution structures 44. 
Despite everything, the accumulated evidence suggests that GPCR activation may 
involve a change in the relative disposition of H-III and VI 45. Elegant site-
directed spin labelling studies carried out with rhodopsin indicated that rhodopsin 
activation might involve a rigid bodily movement of the cytoplasmatic end of H-
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VI, away from the C terminus of H-III. In agreement with this concept, cross-
linking of the cytoplasmatic ends of H-III and H-VI, either via disulfide bonds in 
rhodopsin or via metal ion bridges in rhodopsin and other GPCRs, prevented 
receptor activation 46.  
Recently, the study of H1 histamine receptor activation revealed that Asn 7.45 
(according to Ballesteros-Weinstein numbering 47 ) might play a crucial role in 
transferring the conformational rearrangement of the receptor upon agonist 
binding, to receptor activation. These residue positions appear to function as link 
between the ligand binding pocket and the conformational transition of Asn 7.49 
(part of the NPxxY motif), which leads to GPCR activation. The amino acids in 
these proposed mechanisms are conserved throughout the family A GPCRs 
(~70%), suggesting that the observed mechanisms may also be applicable to other 
rhodopsin-like GPCRs as well 48. 
Several models have been proposed for GPCR activation. The most widely used 
model, the extended ternary complex, ETC, and its extension the cubic ternary 
complex, CTC, (Figure 1.1.4; for a review, see 9 ), assumes that, in the absence of 
a ligand, there is equilibrium between two functionally and structurally different 
states: the inactive (low affinity) (R) and the active (high affinity) (R*). The 
ability of ligand to induce physiological responses - the efficacy of the ligand - 
varies: a full agonist binds and stabilizes the active state (R*), which has high 
coupling efficiency for a specific G protein (R*G). A partial agonist binds and 
stabilizes the active state less efficiently, and causes only a partial G protein 
activation. A neutral antagonist recognizes all receptor forms equivalently and has 
no effect on the equilibrium between (R) and (R*) states. An inverse agonist binds 
and stabilizes the inactive state (R), thus decreasing the basal, agonist 
independent, G protein activity. The ETC model can describe these different 
events. The CTC model includes the possibility that the inactive receptor forms 
(R and AR) interact with G protein, which is not allowed in the ETC model. 
Although the CTC model is formally more correct than the ETC model, this 
correctness comes at a price of carrying too many parameters to allow for useful 
estimation based on experimental observations. In turn, this can make the model 
less predictive. Therefore, in practical terms, it is worth considering whether the 
more complex CTC model is worth applying to experimental data instead of the 
ETC model. The various binding models do not, however, describe the molecular 
Introduction 
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basis of ligand binding and G protein activation, because of the lack of empirical 
GPCR: ligand: G protein complex structures. 
 
Figure 1.1.4: Models describing GPCR systems. The traditional model merely describes the 
binding of agonist (A) to the receptor (R) and subsequent activation of this complex (AR). The 
ternary complex introduces the G-protein (G) as a third partner, which can interact with the 
activated agonist-receptor complex (AR*). The ternary complex was extended after the discovery 
of ligand-independent activation of the receptor, allowing for the formation of R*G. The cubic 
ternary complex makes up a thermodynamically more complete model. Figure adapted from 49. 
 
GPCR SIGNALLING AND DESENSITIZATION 
 
In addition to the above, biochemical and biophysical studies with various 
members from GPCR family A indicate that some GPCRs, undergo spontaneous 
activation in the absence of agonist 50,51. G protein signalling is not a constant 
process; high activation of GPCR reduces the ability to be stimulated in the future 
(desensitization), whereas low activation increases that ability (sensitization). 
Agonist-induced desensitization has been classified into agonist-specific 
(homologous) or agonist-nonspecific (heterologous) desensitization. After agonist 
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binding, primary desensitization is controlled by the receptor phosphorylation. 
This occurs via second messenger kinases or by a distinct family of GRKs (for 
reviews, see 52,53 ). Heterologous desensitization involves second messenger 
kinases, such as protein kinase A (PKA) and protein kinase C (PKC), directly 
uncoupling GPCRs from their G proteins 54-56. Second messenger kinases can also 
mediate agonist-non-specific desensitization, where kinase activation by one type 
of GPCR causes phosporylation of another GPCR. Homologous desensitization, 
meanwhile, involves GRKs and the two non-visual arrestins (β-arrestin 2 and 3) 
57,58. In this, the agonist-occupied or actived GPCR is phosphorylated by GRKs. 
GRK phosphorylation causes binding of β-arrestin to the GPCR, which inhibits 
binding between GPCR and the G protein. The GRK family of kinases is 
comprised of seven family members (GRK1-7). GRK1 (or rhodopsin kinase), 
GRK2 (or βark1, β-adrenergic receptor kinase), GRK3 (or βark2) and GRK7 are 
cytosolic, whereas GRK4, GRK5 and GRK6 are associated with the plasma 
membrane by some lipidic modification of their amino acids. Their 
phosphorylation usually occurs at serine/threonine clusters. Several research 
groups have shown that mutating the serines and threonines in these clusters to 
alanines abolishes phosphorylation and inhibits internalization 59,60. The vast 
complexity of GPCR signalling has recently been further underlined by results 
suggesting that GPCRs may not exclusively work via heterotrimeric G proteins 
37,38. 
There is continuous movement of receptors between the plasma membrane and 
endosomal vesicles, and between synthesis in the endoplastic reticulum via Golgi 
apparatus and lysosomal degradation (Figure 1.1.5). Agonist activation of the 
receptor usually causes the removal of receptors from the plasma membrane to 
clathrin coated vesicle pits by a process called internalization. After this, 
internalized receptors are either recycled to the plasma membrane 
(resensitization) or targeted for degradation in lysosomes (down regulation). 
Constant stimulus causes receptor loss from the plasma membrane. There are 
several different internalization pathways reported, in addition to internalization 
via clathrin, some of which work via caveolae or uncoated vesicles 58. These 
processes can occur over time frames ranging from seconds (phosphorylation), to 
minutes (endocytosis), to hours (downregulation). The extent of receptor 
desensitization varies from the complete termination of receptor signalling, as 
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observed in the visual and olfactory systems, to the attenuation of agonist potency 
and maximal responsiveness, such as observed for the β2-adrenergic receptor 61-63. 
However, the extent of receptor desensitization is regulated by a number of 
factors that include receptor structure and cellular environment. 
 
Figure 1.1.5: Trafficking and homologous desensitization of GPCRs. Activation of a GPCR by an 
agonist leads to the dissociation of α and βγ subunits. The free βγ dimers recruit G-protein 
receptor kinases (GRKs) to the receptor, where they specifically phosphorylate agonist-occupied 
receptors. This, in turn, leads to the recruitment of β-arrestin to the receptor and targets the 
receptor- β-arrestin complexes to clathrin-coated pits. The receptor is internalised into acidic 
endosomes and then either dephosphorylated and recycled to the cell surface or degraded. Figure 
adapted from 64. 
 
Over the years, numerous reports have addressed the role of receptor 
sequestration in desensitization and resensitization. While some evidence suggests 
that this phenomenon is part of the desensitization process, other evidence 
suggests that internalization is instead one of the means by which receptors are 
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resensitized. Indeed, trafficking of an uncoupled receptor to endosomal 
compartments allows dephosphorylation and recycling of the receptor to the cell 
surface 65. This is in contrast to receptor “downregulation” observed after 
prolonged agonist exposure, which leads to targeting of the receptors to 
degradation pathways 66. Once internalized, receptors are targeted to recycling or 
degradative pathways. Some G-protein-coupled receptors, including the β2- 
adrenergic receptor, can be recycled back to the plasma membrane, as a fully 
competent receptor within minutes of being internalised 67. Other receptors, such 
as the vasopressin type-2 receptor, are detained within the cell for longer time 
periods before being recycled back to the cell surface while others, like the δ-
opioid or thrombin receptors, are degraded 68,69. GRKs and β-arrestins appear to 
be key regulatory molecules for receptor internalization since these proteins have 
been shown to interact with components of the clathrin coated vesicle pathway. In 
response to GPCR activation, cytosolic β-arrestin proteins translocate to the 
plasma membrane and then subsequently redistribute to clathrin/coated pits bound 
to receptors. The clathrin-coated vesicle pathway is the best-characterized 
endocytic route, and is utilized by constitutively recycling receptors, tyrosine 
kinase receptors, and numerous G-protein-coupled receptors. Clathrin is a trimeric 
protein arranged as a triskelion when assembled, and is the major structural 
protein of the characteristic polygonal lattice of the coated pit. Plasma membrane 
coated pits also contain the clathrin adaptor protein AP-2, which binds to β-
arrestins and to clathrin. Nevertheless, not all GPCRs necessarily internalize in a 
β-arrestin-/clathrin-dependent manner. 
Experimental evidence suggests that GPCRs may also be internalized through 
alternative endocytic pathways. Some GPCRs have been found in cholesterol rich 
plasma membrane structures termed caveolae 70,71. These domains are also known 
as signalling domains, but appear to contain proteins involved in the formation 
and budding of vesicles such as the dynamin molecule. The use of biochemical 
agents to disrupt these structures has been effective in modifying the endocytosis 
of certain GPCRs 72-74. Finally, some receptors are suspected to use a third 
alternative endocytic pathway. No coat or adaptor proteins have been identified 
for the generation of these vesicles 75. However, GPCR desensitization and 
endocytosis can act as molecular switches coupling GPCRs to alternative signal 
transduction pathways. β-Arrestins not only function in the molecular switch 
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required for GPCR desensitization and internalization, but also act as scaffolds to 
transduce and compartmentalize the alternative signals. In fact, β-arrestins have 
the ability to interact with a variety of endocytic and signalling proteins such as c-
Src 76, MAPKs and Raf 77. 
Several recent studies suggest that GPCRs can exist as dimers or as part of larger 
oligomeric complexes. Although GPCR dimerization is not essential for GPCR 
function, it might contribute to the diversity of signalling in vivo by directly 
altering ligand binding, desensitization or compartmentalization 78. 
 
GPCR INTERACTING PROTEINS 
 
In cells, multiprotein complexes mediate most of the functions. In neurons these 
complexes are directly involved in the proper neuronal transmission, which is 
responsible for phenomena like learning, memory and development. In the recent 
years, studies based on two-hybrid screens, proteomic, biochemical and cell 
biology approaches have shown that intracellular domains of GPCR contain 
sequence motifs that are known to direct protein-protein interactions and, 
therefore, have the theoretical capacity to interact with a wide range of other 
proteins 79.  These interactions are the basis of a protein network associated to 
these receptors, which includes scaffolding proteins containing one or several 
PDZ (post-synaptic density-95, discs large, zona occludens-1) domains, signalling 
proteins, and proteins of the cytoskeleton. This determines receptor properties, 
such as cellular compartmentalization, signalling and functional integration 79,80. 
The topology of GPCRs allows several potential regions for these interactions; the 
extracellular loops are relatively short and, thus, extracellular interactions are 
likely to be dominated by the longer N-terminal sequences or antibody 
recognition 81. On the intracellular face of the receptors, since both the C-terminal 
tail and the third intracellular loop can be considerable in size, resulting in two 
regions with the major number of interaction that has been found. The extent of 
these GPCR-protein interactions varies, ranging from transitory interactions (i.e. 
signalling purposes) to more stable interactions. However, GPCR-protein 
assemblies should be considered dynamic complexes that contribute to the 
intricate process of downstream signalling 82. 
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A large number of interactions with GPCRs on their intracellular faces have been 
described apart from those classically involved in signal transduction. A classical 
example of proteins that interact with GPCRs involves cytoskeletal associations, 
since several GPCRs interact with cytoskeletal anchoring polypeptides. This is the 
case of α-filamin and dopamine D2 receptors 83, α-actinin and adenosine A2A 
receptors 74 and the Shank family of proteins and several GPCRs including type I 
metabotropic glutamate receptor 1 (mGluR1) or somatostatin receptor type 2 
(SSTR2) 84.  
In the last few years, interactions between GPCRs and PDZ-domain containing 
proteins have been reported. PDZ domains are commonly present in a variety of 
multi-domain proteins and play a role in organizing signalling cascades, 
anchoring proteins to specific subcellular compartments, and regulating cell 
signalling by orchestrating assembly/disassembly of macro-molecular complexes.  
There are three general classes of PDZ domains based on their recognition 
specificity: class I domains, which interacts with carboxyl-terminal motifs S/T-X-
Φ (where Φ indicates a hydrophobic residue and X any aminoacid), Class II 
domains, which recognize the Φ-X-Φ motif, and class III domains, which 
preferentially bind to D/E-X-Φ sequences 85.  For example, β2AR contains the 
DSLL motif at the carboxyl terminus, whereas β1AR displays an ESKV motif. 
Such differences determine their association to different PDZ domain-containing 
proteins. Six β1AR-interacting PDZ proteins, including PSD-95, MAGI-2, 
MAGI-3, CNrasGEF, GPIC and CAL have been identified to date by several 
approaches (two-hybrid screening, co-immunoprecipitation and fusion protein 
overlays and pull-down experiments) 86-88. PSD-95, MAGI-2 and CAL have a 
dramatic impact on β1AR receptor trafficking, while the other PDZ proteins affect 
receptor by signal modulation 89. NHERF (Na+/H+ exchanger regulatory factor) 
interaction with the β2-adrenergic receptor has been shown to promote both its 
clustering and endocytosis 90. The Homer-1b protein interaction with the mGluR1 
has been demonstrated to modulate Ca2+ induced mobilization of these receptors 
91. In addition, a direct interaction of calmodulin (CaM) with the 3ILoop of the 
dopamine D2 receptor 92, M1 muscarinic receptor and μ-opioid receptors 93 has 
been described. Calmodulin was found to bind to the human D2 receptor at the 
AA 208-226 domain in a Ca2+ dependent manner. In line with these results, Ca2+ 
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induced activation of calmodulin inhibits G-protein activation by the D2 receptor 
92. 
Spinophilin, a protein phosphatase regulatory protein that is enriched in the 
dentritic spines 94 has been found to interact with both, dopamine D2 receptor and 
α2-adrenergic receptor through a novel non-PDZ domain-mediated mechanism, 
allowing it to act as a scaffold that links these GPCRs with cell signal proteins 
like PP1 (Protein phosphatase 1). 14-3-3ξ is another protein that interacts with the 
3ILoop of the β2-adrenergic receptor in its basal or inactive state, but not upon 
receptor stimulation and control receptor retention at the basolateral surface 95. 
Also, the 3Iloop of some GPCRs, such as β1AR/β3AR and D4R, contains 
polyproline motifs that bind to SH3 domain-containing proteins. β1AR interacts 
with endophilins, a protein family that forms complexes with amphiphisyn, 
synaptojanin and dynamin, all of which are involved in presynaptic vesicle 
trafficking. Endophilin binding increases agonist-dependent β1AR internalization, 
probably by acting as an adaptor protein between receptor-containing vesicles and 
endocytic components such as dynamin, which is required for clathrin-coated 
vesicle fission 96.  
Direct interaction between RGS2 and the 3Iloop of muscarinic, adrenergic, and 
dopamine receptors has been reported 97,98. An intriguing aspect of RGS 
functioning is how specificity is attained in order to regulate different G proteins 
linked to different receptors, since RGS can non-selectively inhibit several G 
protein families. In line with this, basal association of RGS2 with the third 
intracellular loop of the β1aAR, but not the β1AR 99, has been reported. Such 
interaction allows for the formation of a pre-complex of RGS proteins with 
defined receptors, so RGS is positioned to rapidly modulate G protein upon 
agonist challenge. For example, M1 muscarinic receptors specifically bind RGS2, 
but not the closely related RGS16 100. 
In addition to direct protein interactions at the intracellular domains of GPCRs, 
there is increasing evidence that extracellular protein-protein interactions might 
play roles in modulating the pharmacology of GPCRs or their subcellular 
localization. The enzyme adenosine deaminase (ADA), a multifunctional protein 
that is anchored to different proteins on the cell surface, constitutes an example of 
this type of protein. In fact, evidence has been obtained to show that ADA could 
form heteromeric complexes with the both adenosine A1 and A2B receptors 
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101,102, an interaction which appears to be essential for high affinity agonist 
binding to adenosine receptors.  
Apart from the interactions taking place in the intracellular and extracellular sides 
of the membrane, GPCRs are able to display protein-protein interactions at the 
membrane level with other receptors or ion channels 82. The widely recognized 
role of dimerization for many cell surface proteins contrasts with the classic 
models proposed for GPCRs, which were generally believed to function as 
monomers and to signal through downstream G-proteins in a 1:1 stoichiometric 
ratio. Until recently, it was believed that distinct sets of intramolecular 
interactions within the receptor would characterize the active and inactive 
conformations upon ligands binding. Recent data indicates that, in addition to the 
specific intramolecular interactions defining the activation states of the receptor, 
intermolecular receptor interactions might also be important 103.  
Both receptor dimerization, as well as receptor interactions with accessory 
proteins, have been documented and are proposed to participate in GPCR activity 
80. Furthermore, during the last decade, several findings have pointed out that 
GPCR dimerization is not limited to homodimers, but that they can interact with 
both closely and distantly related members of other GPCR subfamilies to form 
heterodimers (hetero-oligomers) 103-106 (Table 1.1.1). 
Table 1.1.1: Overview of homo- and hetero-oligomerization of GPCRs superfamily. Specificy of 
hetero-oligomers is depicted by listing receptors that have been reported as not being able to form 
hetero-oligomers with relevant receptors. Abbreviations: CCR5, chemokine receptor; CCKR, 
cholecystokinin receptor; V2R, vasopressin receptor; A1R, angiotensin type 1 receptor. 
Rptor Homo- Hetero-oligomerization Specificity 
α1a-AR 107,108 Α1b-AR 107, δOR 108 M71 109, α1d-AR 110 
α1b-AR 107,111,11
2 
α1a-AR 107, α1d-AR 110,113, H1R 
111,112, CCR5 107 
M71 109, CCR5 107 
α1d-AR  Α1b-AR 110,113, β2-AR 110 M71 109, α1a-AR 114, α2-AR, 
β1-AR, H1-3R, M1-5R, D1-2R 
α2a-AR 115 ΜOR 116, β1-AR 117 α1d-AR 110, M71 109 
β1-AR 118,118,11
9 
Α2a-AR, β2-AR 118,120 α1d-AR 110, M71 109 
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β2-AR 118-123 β1-AR 118,120, M71 109, β3-AR 
124, α1d-AR 110, κOR 125 
CCR5 121, CCKR 126, MT1aR 
121, MT2R 123, κOR 127, 
D2SR 119,127,128, GABABR1-2 
118,122 
β3-AR 124 Β2-AR 124 M71 109 
D1 129,130 D2LR 131-133, NMDA 134, A1R 135 α1d-AR 110, α2a-AR 136 
D2LR 129,137-
141 
SSTR5 142, D1-3R 131-133,139,143, 5-
HT1BR 140, α2a-AR 136,144,145 
α1d-AR 110, A1R 135,146, M4R 
115 
D2SR 139 D2LR 139 β2-AR 147 
D3R 129,148,14
9 
Α2a-AR 149, D2LR 143  
CCR2 150,151 CCR5 151  
H1R 152 Α1b-AR 111,112 α1d-AR 110, H4R 153 
5-HT1AR 154 5-HT1BR 154, 5-HT1DR 154  
5-HT1BR 140,154-
157 





5-HT1AR 154, 5-HT1BR 154,156,157  
5-HT2CR 159,160 M4R 160 CCR5 161 
5-HT4DR 162 β2-AR 162, 5-HT4GR 162, 
GABABR2 154 
 
M1R 163 M2R 163 α1d-AR 110, Smoothened 163 
M2R 164-167 M1R 163, M3R 163,168,169 Δor 167, κOR 167, μOR 167, 
α1d-AR 110, Smoothened 163 
M3R 163,169-
171 
α2c-AR 169,171,172, M1R 163, M2R 
163,168,169 
M1R 170, M2R 170, V2R 170, 
α1d-AR 110, Smoothened 163 
M4R 115 5-HT2CR 160 α1d-AR 110, D2LR 115 
ΔOR 173,174 Α1a-AR 108, β2-AR 97 , μOR 175 M2R 167 
ΚOR 173,174 Β2-AR 127, μOR 176 M2R 167, β2-AR 127 
ΜOR 173,174 Α2a-AR, δOR 175, κOR 176 M2R 167 
V2R 177 V1R 105,177, Oxytocin 177 M3R 170 
GABABR
1 
 GABABR2 178-180 β2-AR 122 
GABABR
2 
 5-HT1AR 154, GABABR1 178-180 β2-AR 118 
mGluR1 173 A1AR 144,181  
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Homodimerization is defined as the physical association between identical 
proteins, whereas heteromerization is defined as the association between non-
identical proteins. This association can be between two monomers to form 
dimmers, or between multiple monomers to form receptor oligomers. As available 
techniques do not allow for a distinction between dimers or higher-order 
oligomers, the term dimers is often used, being the simplest form of an oligomer’s 
functional unit that can explain the observations. 
 
1.2 MUSCARINIC RECEPTOR FAMILY 
 
Acetylcholine and acetylcholine receptors 
Since the beginning of the last century, when Sir Henry Dale (1914) presented his 
Acetylcholine  (ACh) classification and Otto Löwi (1921) revealed for the first 
time that a chemical transmitter, "Vagusstoff", released from vagal nerve termini 
decelerated the beating of the heart, ACh, has been described as the naturally 
occurring neurotransmitter for muscarinic receptors. Ach is synthesized in the 
cytoplasm of nerve terminals by the enzyme choline acetyltransferase, and is then 
transported into synaptic vesicle. Depolarization of the nerve terminal causes an 
influx of calcium into the nerve terminal and evokes the release of Ach into the 
synaptic cleft. The actions of Ach are determined by the enzymes 
acetylcholinesterase (AChE) and the plasma butyrylcholinesterase, which 
hydrolyzes Ach 182. The actions of Ach are mediated through two classes of 
receptors: nicotinic and muscarinic receptors. Classification is based in their 
pharmacological properties and protein structure 183.  
Muscarinic Ach receptors (mAChRs) are now known to belong to the members of 
the superfamily of GPCRs 184,185. They are abundant in the central nervous system 
as well as in non-neural tissues that are innervated by the parasympathetic 
nervous system, such as cardiac and smooth muscle and many exocrine glands. 
Five genes (m1 - m5) encode muscarinic receptor proteins exhibiting a rhodpsin-
like architecture with seven transmembrane domains 186. They exhibit high 
sequence homology with each other and with other GPCRs within their seven 
transmembrane helices, whereas the sequences are more variable at the amino 
terminal extracellular region, lying at the entrance of ligands, and at the third 
intracellular loop. In particular, the carboxyl-terminal end of the third intracellular 
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loop of the receptor has been implicated in the specificity of G protein coupling 
and shows extensive homology within M1, M3, and M5 receptors and between M2 
and M4 receptors 184,187,188. Conserved regions in the second intracellular loop also 
confer specificity for proper G protein recognition 186,189. 
The five muscarinic receptor subtypes have been identified and cloned (M1 - M5) 
190 (Table 1.2.1). The odd-numbered receptors (M1, M3, and M5) couple to Gq/11, 
and thus activate phospholipase C, which initiates the phosphatidylinositol 
trisphosphate cascade. This leads to the dissociation of phosphatidyl 4,5- 
bisphosphates (PIP2) into two components, i.e., inositol 1,4,5-trisphosphate (IP 3) 
and diacylglycerol (DAG). IP3 mediates Ca2+ release from the intracellular pool 
(endoplasmic reticulum), whereas DAG is responsible for activation of protein 
kinase C. On the other hand, PIP2 is required for the activation of several 
membrane proteins, such as the “M current” channel and Na+/Ca2+ exchangers, 
and muscarinic receptor-dependent depletion of PIP2 inhibits the function of these 
proteins 191-194. Depending upon the variety of downstream effectors, different 
cells exhibit diverse functional muscarinic responses. For example, in vascular 
smooth muscle cells, muscarinic M3 receptor activation leads to elevation of 
intracellular Ca2+ to induce contraction of the cells, whereas the signal from the 
same receptor (M3) in vascular endothelial cells activates the endothelial nitric 
oxide synthase (NOS), leading to NO production and causing the relaxation of 
adjacent vascular smooth muscle cells 195,196. In glandular tissues, M3 receptor-
mediated phosphatidylinositol turnover leads to hormone secretion 197,198. In the 
brain, activation of postsynaptic M1 or M3 receptors leads to inhibition of a 
potassium channel, called the “M current”, via depletion of PIP2, which mediates 
basal control of neuronal excitability 199,200. Activation of the post-synaptic 
muscarinic receptor, that is, inhibition of the M current, does not appear to lead 
directly to the firing of the action potential, but rather enhances the neuronal 
response to excitatory input.  
The even-numbered receptors (M2 and M4) are coupled to the Gi/o class of G 
proteins, and inhibit adenylyl cyclase activity. These receptors also activate G 
protein-gated potassium channels, which leads to hyperpolarization of the 
membrane in excitable cells. In the heart, M2 muscarinic receptor dependent 
activation of this channel contributes to the deceleration of the beating of the heart 
201,202. In neurons, both M2 and M4 muscarinic receptors are present on the axon 
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terminals and inhibit neuronal excitability, which results in the negative feedback 
of neurotransmitter release. In smooth muscle cells, the M2 receptor inhibits 
adenylyl cyclase and counteracts the adrenergic responses 203. As shown in Table 
1.2.1, there are many agonists and antagonists for the muscarinic receptors. Some 
of them are selective for certain receptor subtypes and are often used as 
pharmacological tools for dissecting the function of the individual muscarinic 
ACh receptors 204,205. However, their specificity is not absolute and it is usually 
difficult to explicitly identify the precise physiological roles of individual 
muscarinic ACh receptors in vivo. 
Table 1.2.1: Muscarinic receptor subtypes and their pharmacology. Table adapted from 200 





































Acetylcholine (muscarinic & nicotinic), Carbachol (muscarinic & 
nicotinic), Muscarine (muscarinic receptor specific), Pilocarpine 
(muscarinic receptor specific), Oxotremorine-M (muscarinic receptor 
specific), Metoclopramide (muscarinic receptor specific), 























































GENE AND RECEPTOR STRUCTURAL UNDERSTANDING 
 
Muscarinic ACh receptors are among the earliest members of the seven-
transmembrane G protein-coupled receptor family to be defined 
pharmacologically. They are generated from 5 different genes in the human 
genome (NCBI, Map Viewer at http://www.ncbi.nlm.nih.gov/mapviewer) and 
diverged from a common ancestor, with this evolutionary relationship reflected in 
their structures. Similarly to several other members of the GPCR gene family, 
they are coded by intronless open reading frames formed by a TATA-less 
promoter, with large intron and initiation consensus elements. So far only few 
single nucleotide polymorphisms have been identified and could not be associated 
with either atopic asthma or schizophrenia 206-208.  
 
Figure 1.2.1: Amino acid sequence and secondary structure model of human M3 muscarinic 
receptor. The residues crucial for the binding to acetylcholine, shown as filled white circles, are 
found within in the TM regions. Cysteines residues in the 1Eloop and 2Eloop form a disulphide 
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bridge that is shown as a solid line. The most conserved motifs (DRY and NPxxY) are represented 
by black circles. Predicted N-glycosylation sites are shown as  a root in the N-terminal tail. 
Palmitoylation of two conserved cysteines in the C-terminal tail are also highlight. 
 
 Muscarinic receptors share essential homology with rhodopsin, are palmitoylated 
in the C-terminal tail and potentially N-glycosilated in the N-terminal tail based 
on the presence of consensus N-glycosilation sites 209 (Figure1.2.1). 
Analyses using scanning mutagenesis and homology modelling suggested that 
similar activation mechanisms exist for several of the cationic amine receptors, 
including mAChRs, and the neuropeptide receptors 6. Alanine substitution 
mutation and scanning mutagenesis have allowed the identification of most of the 
residues in the transmembrane region that possess the binding site for ACh in the 
mAChR 45,210,211 (Figure 1.2.1). A negatively charged residue in TM3, Asp3.32, is 
suggested to associate with the polar head of ACh, and is conserved among all the 
amine receptors, but not among the other peptide receptors 212. Mutation of Thr5.39 
and Thr5.42 impaired agonist binding and/or activation, and T5.42C was affinity 
labelled by an agonist derivative 210,213. Most of these hydrophilic residues appear 
to be aligned to a plane in the transmembrane regions and comprise the ACh-
binding pocket 214. In addition, in the M1 receptor, Ala5.46 has also been implicated 
in agonist binding 210. Many aminergic ligands also form critical interactions with 
residues in H-V. The critical H-V residues are not as conserved as is Asp3.32, but 
the positions and interactions nonetheless appear to be conserved. These theories 
have been well confirmed by the homology modelling of the M1 mAChR 
structure and docking simulation with Ach 186.  
As described above, M1, M3 and M5 receptors (called “Group I”) activate Gαq/11, 
whereas the M2 and M4 receptors (“Group II”) activate PTX-sensitive Gαi/o. 
Amino acid position and length analysis revealed that amino acid length of the N-
terminal regions is highly variable, with from 20 to over 100 amino acid residues, 
whereas the C-terminal region is more conservative, being 40-45 amino acid 
residues long.  However, frequency distribution revealed high variability for both 
tails. In contrast to the three extracellular loops and the first and second 
intracellular loop, with a short length, a large length characterizes 3Iloop (more 
than 140 residues). The amino acid residues along this loop are well conserved 
within “Group I” or “Group II”, but the homology is relatively low between 
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“Group I” and “Group II”. The specificity for the coupling between the receptor 
and the G protein α-subunit is considered to be determined within the area of 
3ILoop just beneath the membrane, which should be associated with the N- and 
C-terminal regions of the Gα subunit. The residues in the M2 receptor, Val, Thr, 
Ile and Leu, in 3ILoop ~ TM6 (VTIL motif) are shown to be crucial to the 
interaction with the C-terminus of the PTX-sensitive Gαi/o subunit, whereas the 
residues in the M3 receptor, Ala, Ala, Leu and Ser in the corresponding region 
3ILoop ~ TM6 (AALS motif) are suggested to be important in coupling to the C-
terminus of the Gαq subunit 215. On the other hand, Asp-Arg-Tyr residues in the 
second intracellular loop (2ILoop) (DRY motif) are well conserved among many 
GPCRs, including rhodopsin, and the 2ILoop is reported to be crucial for the 
activation of several G protein α-subunits 216. 2Iloop, together with the first 
intracellular loop (1ILoop), is also characterized by the presence of basic residues 
in the membrane junction, which has been associated with the stable interaction of 
helix with phospholipids.  
 
REGULATION OF MUSCARINIC RECEPTOR SIGNALLING AND 
DESENSITIZATION 
 
Prolonged agonist activation of mAChRs decreases their action, which is referred 
as “receptor desensitization”. Desensitization means a weakening of the signal 
transmission under conditions of a long-lasting stimulation by ligands. Despite the 
persistent effect of extracellular stimuli, the signal is no longer passed into the cell 
interior, or only in a weakened form, during desensitizing conditions. Receptor 
desensitization is achieved by three mechanisms that are different in their time-
courses; (1) uncoupling between the receptor and G protein (~ 2~3 minutes), (2) 
reversible decrease in the number of cell surface receptors by internalization 
(~10~30 minutes), and (3) down-regulation of the transcription of the mAChR (~ 
2~3 hours) 186,217,218. For mAChRs and most other GPCRs, agonist-induced 
phosphorylation of the receptor facilitates receptor internalization. 
Receptor phosphorylation is mediated by kinases, including G protein receptor 
kinases (GRKs), casein kinase 1α (CK1α), and diacylglycerol-regulated protein 
kinase C (PKC) 219,220. PKC phosphorylated in an agonist-independent and Gβγ-
independent manner both in vitro and in vivo alike has been shown for M1 and M3 
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receptors. Particularly, serine and threonine residues in the C-terminus (likely 
candidates are Ser451, Thr455, and Ser457) and the C-terminal portion of Loop3I 
(likely candidates are Thr354 and Ser356) of the M1 receptor have been 
described. Mammalian M2 receptors do not appear to serve as substrate for PKC 
221-223. In contrast, GRKs recognize the agonist-bound form of the receptor and 
mainly phosphorylate serine and threonine residues in the middle of the 3ILoop of 
mAChRs 53. Alanine substitution mutagenesis of the putative phosphorylation 
sites in the 3ILoop of the M1 (Ser/Thr residues in 
Ser284MetGluSerLeuThrSerSerGlu292) 224, M2 (Ser/ Thr residues in 
Ser286ThrSerValSer290 and Thr307ValSerThr Ser311) 224,225, and M3 receptors 
(Ser residues in 349Ser AlaSerSer352) markedly decreases receptor 
internalization 224.  
Once they are phosphorylated by the GRKs, mAChRs are bound to β-arrestin, 
which can interact with clathrin, the major structural component of the clathrin-
based endocytic machinery (Figure 1.1.5) 226,227. Phosphorylated and β-arrestin 
bound receptors are then internalized within clathrin-coated vesicles. The budding 
of clathrin-coated vesicles from the plasma membrane is regulated by dynamin 
GTPases, which are also activated by β-arrestin via the action of c-Src. In the 
GTP-bound form, dynamin is thought to form a collar at the neck of the clathrin-
coated pit and to catalyze the fission of the vesicles 228. Expression of a dominant-
negative β–arrestin 1 mutant, who binds with high affinity to clathrin but is 
significantly impaired in its ability to interact with phosphorylated GPCRs, 
significantly suppresses internalization of M1, M3 and M4 mAChRs in HEK293 
cells 75,229. Moreover, expression of another dominant-negative β-arrestin, β-
arrestin S412D, which binds to phosphorylated GPCRs with similar affinity, but 
not to clathrin, inhibits M1 mAChR in HEK293 cells 58. These results are 
consistent with observations that internalized M1 receptors colocalize with β-
arrestin and clathrin in HEK293 and RBL-2H3 cells 230,231. These studies 
concluded that in HEK293 cells, M1, M3 and M4 mAChRs are internalized in a β-
arrestin dependent manner via clathrin-coated vesicles. On the other hand, M2 
mAChRs have been shown to internalize in a β-arrestin and clathrin-independent 
manner 230,232. It has also been shown that a peptide sequence derived from the 
third cytoplasmic loop of the M2 mAChR that contains the GRK2 
phosphorylation sites and a putative β-arrestin binding site, does not bind β-
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arrestin, whereas a peptide sequence derived from the third cytoplasmic loop of 
the M3 mAChR is able to bind to β-arrestin 233. These observations indicate that 
other cytosolic proteins can associate with phosphorylated M2 mAChRs to 
mediate clathrin-independent internalization. 
It is important to note that receptor desensitization does not necessarily require 
receptor phosphorylation. The activation of α1B-adrenergic receptors in SH-SY5Y 
human neuroblastoma cells reduces M3 receptor-Gαq/11 protein coupling without 
an increase in M3 receptor phosphorylation 234. Direct activation of M3 receptors, 
in contrast, was found to induce M3 receptor phosphorylation and desensitization. 
It has been postulated that this heterologous desensitization of mAChRs is caused 
by sequestration of Gα q/11 following activation of the more abundant α1B-
adrenergic receptor. In opposite manner, receptor phosphorylation may not be 
associated with receptor desensitization. CK1α binds to the Loop3I of the human 
M3 receptor in a Gβγ subunit-independent manner (putative CK1α binding site is 
contained in the amino acid sequence His374-Val391) and robustly 
phosphorylates serine and threonine residues in the Loop3I of agonist-stimulated 
human M3 receptors 219,235. These putative CK1α phosphorylation sites are 
downstream from the putative Gβγ binding site and GRK2 phosphorylation sites 
236. In accordance with this, CK1α-mediated phosphorylation is not accompanied 
by significantly reduced M3 receptor coupling to PLC or Ca2+-ions increases in 
CHO cells. Very interestingly, CK1α-mediated phosphorylation of the M3 
receptor contributes to the mechanism of M3 receptor-mediated activation of the 
mitogen-activated protein kinase pathway ERK1/2 237. 
In many cells, exposure to muscarinic agonists induces rapid desensitization and 
internalization of the cell surface mAChRs that is followed by a loss of total 
number of cellular receptors in the following hours. This process, also termed 
down-regulation, can only be overcome by de novo receptor synthesis. This 
process requires an intact cytoskeleton, as demonstrated by the inhibitory effect of 
colchicines, on agonist-induced mAChR down-regulation 238. Until now, only a 
few domains in the M1–M3 receptors have been implicated in regulating mAChR 
down-regulation. First, deletion of 123 of the 156 amino acids in the Loop3I of 
the mouse M1 receptor (i.e., residues 221–343) decreases the magnitude of (but 
does not abolish) agonist-induced receptor down-regulation by ~55% in Y1 
adrenal carcinoma cells 239,240. Second, four mutations in the M1 receptor 
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specifically impair M1 receptor down-regulation in CHO cells 241. These 
mutations are located either in the second intracellular loop (i.e., Val127Ala) or in 
the N- and C-terminal regions of the Loop3I (i.e., Ile211Ala, Glu360Ala, and 
Lys362Ala). Deletion of a large part of Loop3I of the human M2 receptor 
(residues 234–381) significantly (but not completely) inhibits M2 receptor down-
regulation in CHO cells 242. In addition to residues in the third cytoplasmic loop, 
the lone tyrosine residue in the C-terminus of the porcine M2 receptor (Tyr459) 
has been identified as another important amino acid for M2 receptor down-
regulation in JEG-3 cells 243. Down-regulation of human M3 receptors in CHO 
cells requires three threonine residues (Thr550, Thr553, and Thr554) in the C-
terminus of the receptor protein. Interestingly, the down-regulation-defective 
phenotype of all mAChR mutants in the above studies is not correlated with 
reduced signalling to PLC or adenylyl cyclase. Thus, "classical" signalling of the 
M1–M3 receptors to Gαq/11 and Gαi proteins does not seem to be required for 
down-regulation of these mAChR subtypes 244.  
 
SPECIFIC LIGANDS AND THERAPEUTIC DRUG TARGETING 
 
To date, there have been many therapeutic drugs targeting muscarinic 
acetylcholine receptors [reviewed in 245,246, see Figure 1.2.2]. Among them, the 
oldest and the most common are atropine and scopolamine. Atropine, which is a 
non-specific antagonist for muscarinic acetylcholine receptor, is an alkaloid 
extracted from deadly nightshade (Atropa belladonna). It is a secondary 
metabolite of these plants and a drug with a wide variety of effects. Preparations 
of belladonna were known to the ancient Hindus and have been used by 
physicians for many centuries. During the time of the Roman Empire and in the 
Middle Ages, the deadly nightshade shrub was frequently used to produce obscure 
and often prolonged poisoning. This prompted Linnaeus to name the shrub Atropa 
belladonna, after Atropos, the oldest of the three Fates, who cuts the thread of 
life. The name belladonna derives from the alleged use of this preparation by 
Italian women to dilate their pupils. Today, belladonna is still used to dilate pupils 
(mydriasis) before eye examinations. The mechanism of this action involves 
blocking the contraction of the pupillary sphincter muscle. Atropine is often used 
as a premedication for anesthesia because it reduces bronchial and salivary 
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secretion (which are also directed by the parasympathetic system). Injections of 
atropine are used in the treatment of bradycardia and pulseless electrical activity 
(PEA) in cardiac arrest in order to block the vagus nerve termini and to accerelate 
the beating of the heart. Atropine is also used in the treatment of poisoning by 
organophosphate insecticides and nerve gases (chemical weapons) [reviewed in 
247]. Scopolamine (l-hyoscine) is found chiefly in Hyoscyamus niger (henbane). In 
India, the root and leaves of the jimson weed plant were burned and the smoke 
inhaled to treat asthma. British colonists observed this ritual and introduced the 
belladonna alkaloids into western medicine in the early 1800s. 
 
 
Figure 1.2.2: Chemical structure of several muscarinic receptor ligands. 
 
Another kind of muscaric antagonist, butylscopolamine, is a commonly used anti-
muscarinic drug for treating cramps in gastrointestinal, urinary, uterine and biliary 
ducts. It exhibits antiemetic and antispasmodic effects by preventing the 
hypercontractions in visceral smooth muscles. Pirenzepine is an M1/ M3-selective 
anti-muscarinic agent that inhibits gastric acid secretion at relatively lower doses 
than are required to affect gastrointestinal motility, salivery secretion, central 
nervous system, cardiovascular, ocular and urinary functions 248. 
Pilocarpine is the chief alkaloid obtained from the leaflets of South American 
shrubs of the genus Pilocarpus. Although it was long known by the natives that 
chewing of the leaves of Pilocarpus plants caused salivation, the Brazilian 
physician Coutinhou apparently performed the first experiments in 1874. The 
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alkaloid was isolated in 1875, and shortly thereafter Weber described the actions 
of pilocarpine on the pupil and on the sweat and salivary glands. The muscarinic 
agonist pilocarpine has been used for treatment of chronic open-angle glaucoma 
and acute angleclosure glaucoma for more than 100 years. Intraocular pressure is 
determined by the balance between production of aqueous humor production by 
the ciliary body cells and drainage at the Canal of Schlemm. Muscarinic receptor 
activation leads to both an increase in drainage and a decrease in humor 
production 249. The former mechanism involves dilation of the smooth muscle in 
the Canal of Schlemm, whereas the latter effect results from the muscarinic 
activation-induced production of nitric oxide and subsequent inhibition of 
Na+/K+-ATPase 250. 
The poisonous effects of certain species of mushrooms have been known since 
ancient times, but it was not until Schmiedeberg isolated the alkaloid muscarine 
from Amanita muscaria in 1869 that its properties could be systematically 
investigated 251. Arecoline is the chief alkaloid of areca or betel nuts, the seeds of 
Areca catechu. The red-staining betel nut is consumed as a euphoretic by the 
natives of the Indian subcontinent and East Indies in a masticatory mixture known 
as betel and composed of the nut, shell lime, and leaves of Piper betle, a climbing 
species of pepper 252.  
The accumulated knowledge of the muscarinic receptor subtypes and their 
specific roles has begun to stimulate the development of novel, specific and 
therapeutically useful muscarinic receptor ligands. 
Cevimeline, originally described in the neuroscience literature as AF102B, is an 
M1/ M3R-selective agonist that is clinically used for treating the dry mouth and 
eyes in Sjögren’s syndrome 253. Sjögren’s syndrome is a systemic autoimmune 
disorder with relatively high incidence (0.5-1% in adult women) that is 
characterized by the infiltration of lymphocytes and destruction of grandular 
tissues. The major complaint of the patients suffering from Sjögren’s syndrome is 
dry mouth/eyes, due to the decrease in saliva and eyewater. The M3R is present 
and stimulates glandular secretion in both salivary gland and lacrimal glands, and 
therefore cevimeline is therapeutically beneficial for alleviating the symptoms in 
Sjögren’s syndrome 254. Recently, anti-muscarinic agents have been emerging as 
novel therapeutic drugs for disorders of smooth muscle hyperactivity, including 
overactive bladder (incontinence) and chronic obstructive pulmonary diseases 255. 
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For the treatment for overactive bladder, several compounds (oxybutynin 256, 
tolterodine 257, solifenacin and darifenacin 258) have been used clinically. These 
drugs are muscarinic receptor antagonists that are relatively specific for the M2 
and M3 receptors, and inhibit bladder responsiveness without any side effects. The 
antagonist tiotropium has been suggested as a firstline approach for the treatment 
of chronic obstructive pulmonary disorders, such as emphysema pulmonum 259, 
because its effect is superior to the conventional therapeutics using 
bronchodilators, such as theophilline 260. 
 
PHYSIOLOGICAL ROLES AND FUNCTION OF EACH RECEPTOR 
SUBTYPE 
 
The precise physiological roles of the individual mAChR subtypes have not 
previously been fully identified because of the nonselective effect of the ligands 
and the redundant expression of multiple receptor subtypes in many tissue and 
cell types 183. In order to circumvent these limitations, the gene targeting 
techniques have been exploited to generate mutant mice that are deficient in one 
of the five mAChR subtypes 261. M1 – M5 receptor knockout mice are viable, 
fertile and essentially healthy (Table 1.2.2). 
M1 Muscarinic Receptor 
The M1 receptor gene was the first gene encoding for a muscarinic receptor that 
was ablated in mice 262. M1 receptors are predominantly expressed in the 
forebrain, including the cerebral cortex, hippocampus and corpus striatum, where 
this sub-type contributes by 50-60% to the total of the muscarinic receptors. 
Consistent with this observation, some behavioral deficits and altered responses to 
pharmacological agents have been detected in M1R knockout mice 262-264. 
Systemic administration of pilocarpine, a muscarinic receptor agonist, causes 
epileptic seizures in wild-type, but not in M1R knockout mice, suggesting that 
M1R might contribute to the pathogenesis of some kinds of epileptic seizures 262. 
Behavioral studies revealed that M1R-deficient mice exhibited a remarkable 
increase in locomotor activity 263, which was probably caused by an increase in 
dopamine release in the striatum 264. These findings suggest that pharmacological 
blockade of the M1 receptor in the central nervous system might be 
therapeutically effective for Parkinson’s disease by increasing dopamine release 
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from the striatum. In contrast to the behavioural disorder, there were little obvious 
cognitive deficits (in learning and memory) in M1R-knockout mice, although 
long-term potentiation (LTP) in response to burst stimulation in the hippocampus 
was slightly reduced 265. 
Table 1.2.2: Phenotype of Muscarinic Acetylcholine Receptor-Deficient Mice.Adapted from 266 
Rptor 
subtypes 
Phenotype in central nervous 
system 
Phenotype in periphery 
Absence of pilocarpine-induced 
seizure activity 
Increase in locomotors activity 
Lack of mAChR-mediated 
inhibition of M current in 




   M1R 





No obvious deficits are detected 
Absence of oxotremorine-
mediated tremor and akinesia 
Slight reduction in carbachol-




   M2R 
Reduction of mAChR-mediated 
analgesia 
Lack of carbachol-mediated 
bradycardia 
~25% reduction in body weight 
Significant reduction (~40-95%) in 





    




No obvious deficits are detected 
Slight reduction in pilocarpine 
induced salivary secretion 
    
    M4R 
Increase in basal locomotors 
activity 
 
Reduced auto-inhibition of ACh-
release in heart atria and urinary 
bladder 
 
    M5R 
Reduction of oxotremorine 
mediated dopamine release in the 
striatum 
Reduction in ACh-induced dilation 




The “M current” is a constitutively active, voltagedependent potassium channel 
current that can be inhibited by mAChR agonists 199,267. It was identified in 
sympathetic ganglion cells and in hippocampal pyramidal neurons. 
Electrophysiological analysis has demonstrated that inhibition of the M current by 
carbachol (CCh) in sympathetic ganglion neurons was completely abolished in 
M1R knockout mice 262. However, no significant change was observed in 
inhibition of the M current in hippocampal CA1 pyramidal neurons in the same 
mice 268. 
M2 Muscarinic Receptor 
Previous studies have suggested that the administration of centrally active 
muscarinic agonists such as scopolamine exhibits remarkable analgesic effects 269. 
Muscarinic agonist-induced analgesia can be as effective as morphine-induced 
analgesia in animal models, and muscarinic analgesia is of considerable interest 
because it leads to less addiction and tolerance 269,270. In M2R-deficient mice, the 
oxotremorine (muscarinic receptor agonist)-mediated antinociceptive response 
was greatly attenuated in both tail-flick and hot plate tests 271, suggesting that the 
M2R plays a crucial role in muscarinic agonist-induced analgesia. On the other 
hand, electrophysiological examination demonstrated that the muscarinic 
receptor-dependent inhibition of the neuronal (Nand P/Q- type) calcium channel 
was abolished in sympathetic ganglion neurons from M2R-deficient mice 272. The 
muscarinic agonist, carbachol (CCh), induced bradycardia in spontaneously 
beating sinoatrial node cells and atria; an effect that was completely abolished in 
M2R deficient mice 271,273, indicating that the M2R is responsible for cholinergic 
deceleration of the beating heart. In M2R knockout mice, the carbachol-mediated 
contraction of a smooth muscle preparation (from stomach, urinary bladder and 
trachea) was slightly attenuated 273. 
M3 Muscarinic Receptor 
M3 muscarinic receptors are broadly expressed in the brain, although the 
expression level is not high when compared to that of M1 and M2 receptors. In the 
periphery, M3 receptors are predominantly expressed in smooth muscle and 
glandular tissues 274. No obvious behavioural or cognitive defects were observed 
in M3R-deficient mice 275. Interestingly, M3R-deficient mice exhibited a 
remarkable (~25%) reduction in body weight. The body weight loss could be 
reversed when the mice were offered a wet paste diet in place of a standard dry 
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diet 276, suggesting that the body weight loss may partially due to reduced salivary 
flow during the intake of food. In fact, in M3R-deficient mice, the pilocarpine- 
induced salivary secretion was decreased 276. In M3R-knockout mice, a significant 
reduction (~40-95%) in carbachol-induced contraction of smooth muscle (urinary 
bladder, ileum, stomach fundus, trachea and gallbladder) was detected, and 
especially in urinary bladder, carbacholinduced contraction of smooth muscle was 
almost absent in M3R-knockout mice, but present in M2R-knockout mice, 
suggesting the crucial role of the M3 receptor for inducing contraction in this 
tissue 276,277. Mydriasis was observed due to the lack of parasympathetic control 
of the papillary sphincter muscle 276. 
M4 Muscarinic Receptor 
The Muscarinic M4 receptor is known to be abundantly expressed in the striatum 
274. Consistent with this fact, locomotor activity was significantly increased in 
M4R-deficient mice 278. This may also be caused by an increase in dopamine- 
release from the striatum, as administration of a dopamine D1 receptor agonist 
enhanced the locomotor activity 278,279. 
M5 Muscarinic Receptor 
The M5 receptor was the last muscarinic acetylcholine receptor cloned. 
Localization studies have revealed that the M5R is abundantly expressed in 
dopamine-containing neurons of the substantia nigra par compacta, an area of the 
midbrain providing dopaminergic innervation to the striatum 274. 
Concordantly, oxotremorine-mediated dopamine release in the striatum was 
markedly decreased in M5R-deficient mice 280. More intriguingly, in M5R-
deficient mice, acetylcholineinduced dilation of cerebral arteries and arterioles 
was greatly attenuated 280, suggesting that the M5 receptor might be a suitable 










1.3 SCOPES AND AIM OF THIS THESIS 
 
Muscarinic receptors comprise a large family of G protein-coupled receptors 
(GPCRs) involved in regulating the activity of many important functions of the 
central and peripheral nervous system. In order to relay such diversity of 
physiological outcomes, muscarinic receptors not only interact with 
heterotrimeric G proteins to activate or inhibit classical downstream effector 
molecules, but also with accessory molecules termed GPCR interacting proteins 
(GIPs). Such proteins are diverse in nature, involving scaffold molecules, ion 
channels, enzymatic activities as well as other GPCRs, thus leading to receptor 
homo- or heterodimerization and multiprotein complex formation (also called 
signalsome or receptosome). By means of these novel interactions, muscarinic 
receptors can acquire unappreciated abilities for ligand recognition, signalling and 
regulation. However, the dynamics of such a complex are not well understood. 
Many questions remain unsolved. For instance: Is the signalsome stabilized by 
agonist binding to the receptor? Or is the agonist the responsible for the initiation 
of the signal transduction complex de novo? Can signalsome organization be 
influencing the duration or magnitude of the signal? Which of the various 
identified protein interactors share a mutually exclusive site? And what are their 
roles? 
The overall aim of this thesis was to gain insight into molecular aspects of the 
protein-protein interaction of the muscarinic receptor family. Specifically, the 
present work is focused on the recognition of novel interacting proteins of the M3 
subtype. The questions outlined above are addressed throughout the next chapters, 
and some of them are answered or partially answered. 
The widely recognized role of dimerization for many cell surface proteins 
contrasts with the classic models proposed for GPCRs, which were generally 
believed to function as monomers and to signal through downstream G-proteins in 
a 1:1 stoichiometric ratio. Thus, the firsts aim for this thesis has therefore been: 
1. To characterize the molecular interaction between M3 and M5 muscarinic 
receptor subtypes and to get insight into the physiological role of muscarinic 
receptor heterodimerization. 
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Topology of GPCRs allows several potential regions for protein-protein 
interaction (Extracellular (N-terminal) and intracellular loops (3Iloop and C-
terminal tail)). A large number of interactions between aminergic receptors and 
their intracellular faces have been described in addition to those classically 
involved in signal transduction.  
Therefore, the second aim of this thesis has been: 
2. To identify interacting proteins of M3 and M5 muscarinic receptor 
subtypes within the large 3Iloop using Tandem Affinity Purification methods 
and mass spectrometry analysis. 
3. To delineate the molecular interaction and functional roles of the C-
terminal tail and its function as an antiapoptotic peptide, as well as 
determined their therapeutic uses and pharmacological implications. 
Accumulating evidence indicates that signalling efficiency/specificity for 
mAChRs is determined in part by accessory proteins that physically interact with 
key domain/motif or are found in the microenvironment of the receptor. The 
extent of these GPCR-protein interactions varies, ranging from transitory 
interactions (i.e. signalling purposes) to more stable interactions. Therefore, 
GPCR-protein assemblies might be considered as dynamic complexes that 
contribute to the intricate process of downstream signalling and their regulation. 
4. To characterize subtype-specific receptor signalling, both in the 
mechanisms involved in receptor regulation, as well as in the unveiling of 
novel receptor-interacting proteins mediated by the conserved motif (NPxxY 
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             2.1 Homo-and heterodimerization of M3-M5 
muscarinic receptors in non-neuronal cholinergic system 
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Polytechnical University of Catalonia, Colom 1, Terrassa 08222, Spain. 
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Although previous pharmacological, biochemical and biophysical data supports 
the notion that muscarinic receptors form homo- and heterodimers; and non-
neuronal cholinergic system in lymphocytes, in both T- and B-cells, is 
characterized by highly expression of M3 and M5 muscarinic receptor subtypes; 
direct and functional interactions between M3 and M5 receptors and their 
underlying mechanism(s) have not been well explored today. By means of 
coimmunoprecipitation and bioluminescence resonance energy transfer, we 
demonstrated that M3 and M5 muscarinic receptors could form constitutive homo- 
and heterodimers in the cell surface of cotransfected cells. We find that co-
expression of both receptors leads to a significant increase in the level of BRET 
signals with similar affinity values when compared to M3 homodimerization, but 
with relatively higher affinity values with respect to M5 homodimerization. 
Oligomerization statuses, which are not seen to be modified upon agonist 
stimulation, are, however, affected by the expression of minigenes derived from 
the third intracellular loop of each subtype.  Signal transduction analysis in 
lymphocytes T-cells revealed that a proper receptor heteromer is required for 
mitogen-activated protein kinase phosphorylation and the positive modulation of 
cell growth. This suggests that the oligomeric association of muscarinic receptors 
provides a molecular mechanism for the increased diversity of cholinergic 
signalling in lymphocytes cells, and can be consider during therapeutic treatment 
of the immune system. 





Over the last decade, G protein-coupled receptors (GPCRs) have been shown to 
have a constitutive association with each other or with members of a related 
family to form homo- or hetero-oligomers 281,282. GPCR oligomerization leads to 
alterations in receptor function, and has been implicated in many aspects of 
receptor pharmacology, such as maturation, ligand binding, activation, signaling, 
desensitization, endocytosis, and trafficking 78,105,106. 
Recently, several studies showed that muscarinic acetylcholine receptors 
(mAChRs), like other GPCRs, may be arranged in oligomeric complexes 
168,283,284. Complexes binding curves of muscarinic receptors expressed in rabbit 
heart, rat brain stem, and computer simulations of agonist binding properties at 
M2 muscarinic receptors expressed in cultured cells were consistent with the 
notion of binding sites located on dimeric receptor molecules 285,286. Likewise, 
studies using purified muscarinic receptors suggest that the complex binding 
properties of muscarinic agonists are due to multiple states of affinity of the 
receptor proteins themselves, and are not caused by the association of receptors 
with different classes of G proteins 287. Maggio et al., using chimeric α2-
adrenergic/M3 muscarinic receptors, not only provided additional 
pharmacological evidence that mAChRs can form dimmers, but also 
demonstrated that intermolecular interactions between two inactive receptors 
could result in a dimeric complex with the restoration of receptor function 
properties 288,289. Site-directed mutagenesis and coimmunoprecipitation of 
solubilized epitope-tagged M3 mAChR has also been employed to demonstrate 
the existence of mAChRs oligomers in a direct fashion 290. This biochemical 
approach revealed that the M3 mAChR is capable of forming disulfide-linked as 
well as noncovalent dimers/multimers 291. More recently, using bioluminescence 
resonance energy transfer (BRET), the occurrence of constitutive homo- and 
hetero-oligomers among M1, M2, and M3 mAChRs has been demonstrated in 
living cells 163. 
Previous studies have provided evidence of the existence of a non-neuronal 
cholinergic system 292. RT-PCR and pharmacology analysis have revealed that 
lymphocytes express most of the cholinergic components which expressed in 
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neurons, and constitute an independent cholinergic system that can be regulated in 
an autocrine fashion 293. Stimulation of T and B cells with muscarinic receptor 
agonists elicits intracellular calcium signalling, up-regulation of c-fos expression, 
and increased in nitric oxide synthesis and cytokine production 294-296. 
Furthermore, wide arrays of combination of mAChR subtypes are expressed 
among lymphocytes cells.  Immunohistochemical, western-blot and RT-PCR 
studies show that the M3, M4 and M5 subtypes are the most highly expressed and 
are responsible for immune cell function 297,298. It has also been revealed that 
different muscarinic agonists affect immune functions in different ways. For 
instance, oxotremorine treatment enhances and arecoline suppresses IL-2 
production and cell proliferation 299,300. Another study showed that pilocarpine did 
not inhibit cytokine production, but decreased the number of interleukin receptor 
bearing cells 301. M5 KO mice suggest that the muscarinic receptor is involving in 
the modulation of antibody classes switching from IgM to IgG1 296. Also, in vivo 
experiments have shown that direct interaction between T-lynphocites and target 
cells (B-lynphocytes or antigen presenting cells) leads to up-regulation of the 
gene expression of M5 receptor subtypes 302. Thus, M3 and M5 muscarinic 
receptors are expressed on the same lynphocytes elements, displaying a complex 
signalling interaction. To date, however, no studies have examined the molecular 
mechanism underlying the interactions between these two receptors and their 
functional role in signal transudation modulation in lymphocytes cells. 
In this study, we examined the M3 muscarinic receptor as a potential partner for 
association with the M5 receptor subtype, as well as each receptor subtype’s 
ability to associate with the other in order to form homodimers. Using MAPK 
phosphorylation and cytokine production assays we determined the functional 
implications of heterodimer formation, as well as demonstrated that the activation 




Functional characterization of the tagged receptors 
The affinities of the GFP2- or Rluc-tagged receptors for the receptor-specific 
ligands were indistinguishable from those of the non-fused receptors, as shown in 
Table 2.1.1. The expression levels of the various receptors ranged between 400-
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600 fmol/mg. And although co-expression of these fused or non-fused receptors 
showed no significant changes in their ligand binding affinities, the expression 
level of M3-GFP2 decreased a little by co-expression with M3-Rluc.  
Coupling of the different muscarinic constructs to the Gq/PLC pathway was 
assessed as their ability to mediate carbachol stimulated IP accumulation. The IP 
accumulation mediated by the differently tagged M3 or M5 was similar overall to 
that of the wild type receptor.  
 
Table 2.1.1: Ligand binding properties of M3 and M5 mAChR constructs. Radioligand binding 
studies of transfected HEK-293 cells with RLuc-tagged, GFP2-tagged, or nontagged (WT) mAChR 
were carried out as described under "Experimental Procedures." Curves were fitted by nonlinear 
regression analysis by assuming a single binding site, and KD values were determined by using 
GraphPad Prism software. Results represent means ± S.E. (n = 4). 






3 x HA-M3 529.1 ± 42.5 63.2 ± 20.8 
3 x HA-M3-Rluc 483.0 ± 39.3 58.3 ± 19.2 
3 x HA-M3-GFP2 513.1 ± 41.6 60.6 ± 21.4 
3 x HA-M5 520.2 ± 27.8 86.2 ± 16.5 
3 x HA-M5-Rluc 541.5 ± 32.7 92.1 ±  15.3 
3 x HA-M5-GFP2 557.8 ± 37.5 89.9 ± 22.7 
 
M3/M5 colocalization in the cell surface of Molt-3 cells 
A number of behavioral studies in lymphocytes cells have previously 
demonstrated functional interactions between muscarinic receptors; the 
mechanism(s) underlying these are not clearly understood. One possible 
mechanism could be direct interactions between receptor subtypes. 
Using immunocytochemistry and a co-immunoprecipitation approach we 
confirmed the preferential colocalization of the M3 and M5 muscarinic receptor in 
both co-transfected HEK-293 cells and endogenously expressing Molt-3 cells 
(Figure 2.1.1).  
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Figure 2.1.1 a) Co-immunoprecipitation and colocalization of M3 and M5 muscarinic receptors. 
Non-permebilized Molt-3 cells endogenously expressing M3 and M5 receptor subtypes and HEK 
cells transfected with M3, M5, or both receptors simultaneously (coexpression) were 
immunostained with rabbit anti-M3 monoclonal antibody and rabbit anti-M5 monoclonal antibody. 
The bound primary antibodies were detected using either Alexa Fluor 488-conjugated goat anti-
mouse IgG antibody or Texas Red-conjugated goat anti-rabbit. Cells were analyzed by double 
immunofluorescence with confocal microscopy. Superimposition of images reveals M3/M5 cell 
surface colocalization in yellow (merge). b) Coimmunoprecipitation of M3 and M5 receptors. 
HEK-293 cells transiently expressing HA-M5 alone (lane 1), HA-M5 plus M3 (lane 2), or M3 (lane 
3) were washed, solubilized, and processed for immunoprecipitation using anti-HA monoclonal 
antibody (2 µg/ml; IP: HA) or anti-M3 monoclonal antibody (2 µg/ml; IP: M3). Solubilized 
membranes (Crude) and immunoprecipitates (IP) were analyzed by SDS-PAGE and 
immunoblotted using rabbit anti-HA polyclonal antibody (1:2000) or rabbit anti-M3 polyclonal 
antibody (1:1000) and HRP-conjugated goat anti-rabbit IgG as a secondary antibody. These blots 
are representative of four different experiments with similar qualitative results. IB, Immunoblot. 
 
Quantification of images of specific immunostaining of M3 and M5 muscarinic 
receptor in Molt-3 cells (n = 4) showed there to be a 70 ± 5% (in means ± SEM) 
 Homo-and heterodimerization… 
 52
of Molt-3 cytoplasm membrane cell and internal compartments that are 
immunoreactive for both M3 and M5, and whereas 14  ± 3% are endowed with M3 
but not with M5, only 3 ± 1% are endowed with M5 but not with M3 (Figure 2.1.1, 
top). The number of cytoplasm membrane cells that do not express any of the 
receptors is < 15%. Therefore, distribution of both receptor subtypes in co-
transfected HEK-293 cells was localized in the vicinity of the plasma membrane 
and internal compartments (Figure 2.1.1, bottom). These merged images revealed 
that a striking overlap in the distribution of both receptors likely happens in Molt-
3 cells. 
Immunoprecipitation reactions were carried out on HEK 293 cells transiently 
expressing 3x HA-tagged M5 receptors, M3 wild type receptors, or both, using 
anti-HA antibody resin. After separation of the proteins by SDS-PAGE, Western 
immunoblotting was performed using a rabbit anti-HA antibody (Sigma-Aldrich). 
As shown in Figure 2.1.1, an antibody against 3x HA-M5 was able to 
immunoprecipitate M3 receptor from solubilized cells and vice verse. This band 
did not appear in immunoprecipitates from cells only transfected with the cDNA 
for either 3x HA-M5 or M3 (Fig. 2.1.1). 
 
Homo-oligomerization of M3 and M5 muscarinic receptors 
In HEK-293 cells we examined the possibility of direct receptor-receptor 
interaction by constructing quantitative BRET saturation curves in cells co-
transfected with a constant amount of receptor-Rluc construct and increasing 
concentrations of the receptor-GFP2 plasmids.  
Although from curves generated by fluorescence- and luminescence- directed 
measurements provide the theoretical behaviour sufficient to predict receptor 
oligomerization complexes, they do not provide enough information about the 
binding parameters required for proper quantitative analysis of receptor-receptor 
interactions. Because of this, we decided to do BRET analysis in a quantitative 
fashion. To complete this analysis, we conducted saturation experiments in which 
the amount of each receptor effectively expressed in transfected cells was 
monitored for each individual experiment by correlating both total luminescence 
and total fluorescence in the number of [3H]-NMS-binding sites in permeabilized 
cells. Total luminescence and total fluorescence emitted by the Rluc and GFP2 
fusion proteins were measured following the addition of the Rluc substrate 
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coelenterazine H and direct excitation of the GFP2 at 400 nm, respectively. 
Correlation obtained between the numbers of total binding sites and either the 
luminescence or fluorescence emitted by each of the receptor fusion molecules 
was linear, and the slopes were similar for the two receptors considered 
(Appendix 2). The linear regression equations derived from “Appendix 2” were 
thus used to transform the luminescence and fluorescence value in the receptor 
number. BRET signals were plotted as a function of the ratio between the 
receptor-GFP2/receptor-Rluc numbers. 
As shown in Figure 2.1.2 top, significant quantitative BRET signals were 
observed for the M3/M3 and M5/M5 pairs, confirming previous findings that M3 
receptor subtypes can form homodimers 163,303. Albeit to a higher extent, in 
respect to M5 receptor subtype homodimers, co-expression of the two subtypes 
also led to a sizable BRET signal (Figure 2.1.2 bottom). In all cases, BRET 
increased as a hyperbolic function of the concentration of the GFP2 fusion 
construct increased (assessed by the fluorescence emitted upon direct excitation at 
400 nm), reaching an asymptote at the highest concentrations used. Co-expression 
of M3-Rluc with soluble GFP2 led to marginal signals that increased linearly with 
an increasing amount of GFP2 added. 
When comparing the BRET saturation curves obtained for the M3 homo- and 
heterodimers (Table 2.1.2), similar BRET50 values were obtained, indicating 
that the receptors had similar relative affinities with one another. However, 
BRET50 of M5 heterodimers showed little high affinity with respect to M5 
homodimers. This has important implications, because it suggests that, under 
basal conditions, M3 homo- and heterodimers have a similar probability of 
forming when the two receptors are heterologously expressed. Instead, it is very 
probably that M5 receptor subtypes might form heterodimers when are co-
expressed with M3 receptor subtypes. Previous reports highlight that 
heterotrimeric formation between homologous receptors is highly probable 108. 
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Figure 2.1.2 Quantitative analysis of M3 and M5 homo- and hetero-dimerization. BRET donor 
saturation curves of M3 and M5 mAChR homo (top, middle)- and hetero (bottom)-dimers were 
performed by transfecting HEK 293 cells with a constant DNA concentration of acceptor receptor-
Rluc and increasing concentrations of donor receptor-GFP2 constructs. BRET, total fluorescence, and 
total luminescence values were determined as described under "Experimental Procedures." 
Fluorescence and luminescence values were transformed into receptor numbers using slope values 
from standard titration curves shown in supplemental material. Heterodimerization analysis was also 
performed in cells co-expressing both receptor subtypes in addition to the 3-5μg of minigene 
construction that codifies for a peptide of the third intracellular loop of the M5 muscarinic receptor. 
BRET values were plotted as a function of the (receptor-GFP2)/(receptor-RLuc) ratio. The curves 
represent 9 saturation curves that were fitted using a non-linear regression equation assuming a single 
binding site.  
 
In addition, the BRETmax value for each donor-acceptor pair was found to be 
significantly similar. This could indicate that energy transfer between RLuc and GFP2 
within each donor-acceptor pair were similarly efficient.  
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Table 2.1.2 Parameters from BRET saturation curves.  
Pair Transfected BRET max BRET 50 
M3-Rluc/M3-GFP2 0.10 ± 0.05 1.59 ± 0.29 
M5-Rluc/M5-GFP2 0.10 ± 0.01 1.76 ± 0.32 
M3-Rluc/M5-GFP2 0.10 ± 0.01 1.58 ± 0.27 
M3-Rluc/M5-GFP2 + 3ILoop 0.07 ± 0.01 1.78 ± 0.33 
The BRETmax is the maximal BRET ratio obtained for a given pair. The BRET50 represents the 
acceptor/donor ratio required to reach half-maximal BRET values. Results are the mean ± S.E. of 9 
experiments performed in duplicate. 
 
 Several interesting findings regarding the effect of ligand binding on the formation of 
homo- or hetero-oligomers have been reported 116,133,304. Eventually, changes in the 
BRET signal reflect either variations in dimer formation or simply conformational 
changes within pre-existing dimmers. In contrast, other studies have failed to show 
BRET changes upon agonist treatment 107,123,153,162. In our experiments, stimulation 
with the agonist carbachol (10 μM) did not promote any consistent change in the 
BRET saturation curves, indicating that the dimers form constitutively and that 
receptor activation does not affect their oligomerization state (Supplementary 
materials).  
 
Structural determinants potentially involved in hetero-oligomerization 
So far, the mechanism by which muscarinic receptors form oligomers has been poorly 
elucidated at a molecular level. Several reports have suggested transmembrane 
domain swap, disulfide cross linking, or dimerization motifs within the 
transmembrane helices and third intracellular loop 305. Among the structural 
determinants of the muscarinic receptor potentially involved in receptor 
oligomerization, we investigated the role of its large third intracellular loop in M3 and 
M5 hetero-dimerization. 
To investigate whether the third intracellular loop played a role in receptor 
oligomerization, we co-expressed a constant among M3-Rluc cDNA and a variable 
among M5-GFP2 with or without a minigene construct encoding for a peptide of the 
third intracellular loop. Previous reports have described that the use of peptides from 
regions implicated in receptor dimerization might induce reduction in BRET levels as 
result of either a dissociation of the protomers leading to monomerization or a 
conformational change within the dimer that increases the distance or negatively 
affects the dipole orientations of the energy donor and acceptor without disrupting the 
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dimmer 306. In an effort to distinguish between these two possibilities, BRET titration 
experiments were carried out to determine the relative affinity between each of the 
protomers, as described previously 120. Indeed, if the peptide promotes a dissociation 
of the protomers, one would predict that third intracellular loop should decrease the 
apparent affinity of the receptors for one another. As shown in Figure 2.1.2 bottom, 
the expression of the peptide of the third intracellular loop of the M5 receptor led to a 
reduction in the BRETmax and a little, but significant, reduction in value of BRET50 
(see Table 2.1.2). These results strongly indicate that the third intracellular loop of the 
M5 muscarinic receptor (and by analogy, the third intracellular loop of M3) acts by 
affecting the conformational organization of the dimmer, and also by promoting a 
little dissociation into monomers of the hetero-complex.  
 
M3/M5 heteromeric complexes; receptor signal and T-cell immune response 
Given that both M3 and M5 mAChR are coexpressed in many lymphocytes cells and 
that they were also found to form heterodimers  (Fig. 2.1.2), we asked whether M3 
and M5 heterodimerization could modify carbachol enhanced IL-2 production, which 
is the first in a series of lymphocytotrophic hormones and has a pivotal role in the 
generation and regulation of immune response. Previous reports described that 
muscarinic agonist oxotremorine M (Oxo-M) enhanced phytohemagglutinin (PHA)-
induced IL-2 production in T-cells. PHA-induced IL-2 production was enhanced 
when cell were pretreated > 1hr with Oxo-M, and a 24 hr Oxo-M pre-treatment 
doubled PHA-induced cytokine production. As shown in Figure 2.1.2 bottom, 
transfection of cells with a peptide of the third intracellular loop resulted in a low 
affinity of M3 and M5 receptors to form a heteromer. Thus, we treated Molt-3 cells 
endogenously expressing M3 and M5 mAChR with 10-µM carbachol for 24 hr in the 
presence or absence of the minigene (5-µg cDNA) and determined the extent of 
cytokine production by ELISA (IL-2). Incubation of Molt-3 cell with PHA (10 -
µg/ml) and 10-µM of CCh for 24 hr enhanced IL-2 production by 74 %. However, 
Molt-3 cell transfected with minigene construction only showed and agonist-
enhancement of 57% (1.3–fold in less, ANOVA, P<0.01) (figure 2.1.3).  
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Figure 2.1.3 Effect of heterodimerization disruption in carbachol enhanced PHA- IL-2 production. 
Molt-3 cells were transfected with vehicle (■) or minigene construction (□), preincubated with 10-µM 
CCh for 0-24 hr, following 24 hr of 10 -µg/ml PHA treatment; subsequently, the amount of IL-2 was 
measured. Values are expressed as IU (1IU/ml= 0.2 ng/ml). Data are means ± S.D. from a 
representative experiment preformed in triplicate. 
 
Next, we examined if the modulation of the receptor-enhanced cytokine production 
seen in Molt-3 cells endogenous expressing M3/M5 receptors can be observed using 
another GPCR signaling assay. For this, we monitored the extent of phosphorylation 
of extracellular signal-regulated kinases (ERK1/2) in response to carbachol in the 
absence or presence of the minigene construct. We find that treatment with carbachol 
(1-10 μM) leads to a significant increase in the extent of phosphorylation of ERK1/2 
(Figure 2.1.4). However, carbachol stimulation of Molt-3 cells transfected with 
minigene (3-5 μg of cDNA) leads to a small but significant decrease in the extent of 
ERK1/2 phosphorylation (Figure 2.1.4). As a control, we examined the effect of the 
minigene construct in HEK-293 cells expressing M3 homodimers on ERK1/2 
phosphorylation. We find that expression of the minigene construct does not affect 
agonist-increase in ERK1/2 phosphorylation as in vehicle cells (pcDNA3.1). Results 
appear to be associated with an increased lower affinity of receptor 
heterodimerization with a consequent decrease in receptor signal. It has shown that 
mAChR subtypes exhibit different sensitivities to agonist-induced ERK½ 
phosphorylation. More exactly, in COS cells it has been demonstrated that the paired 
activation of the two components of the M3 muscarinic receptor dimmer is required 
for induction of MAPK activation.  
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Figure 2.1.4 Activation of ERK½ in Molt-3 cells endogenously expressing M3 and M5 muscarinic 
receptors. Cells were treated with agonist for 5 min at 37°C and then lysed directly into SDS-PAGE 
loading buffer. After Western immunoblot, phospho- ERK½ immunoreactivity was determined by 
densitometry. (A and B) Time-dependent course of ERK ½ activation on carbachol-stimulated Molt-3 
cells and after overnight pretreatment with 100-ng/ml pertussis toxin. Cells were incubated with 1 mM 
of CCh for the indicated time points. (C) Activation of ERK½ in Molt-3 cells after 5 min of agonist 
stimulation in absence (lane 3) or presence (lane 4) of the minigene construct (5μg). Molt-3 cells non-
stimulated with carbachol (Lane 1) and carbachol-stimulated in presence of MAPK specific inhibitor 
PD-98059 (lane 2) were performed as an internal control. Equal loading was confirmed with 
antibodies against total ERK ½. Means ±S.E.M is shown; n= 4. *: Significantly different when 




Muscarinic receptor families are capable of forming homo- and hetero-oligomers, 
which has been demonstrated by a wide variety of approaches, including 
pharmacological analysis of ligand-receptor interactions, coimmunoprecipitation, or, 
more recentl,y resonance energy transfer approaches (fluorescence resonance energy 
transfer and BRET) 163,307,308. However, the existence of homo- and hetero-oligomers 
constituted by M5 muscarinic receptor subtypes has not been reported yet, despite the 
large amount of experimental evidence that supports the active role of this receptor 
subtype in the non-neuronal cholinergic system.  
In the present study we provide for a first time biochemical, biophysical, and 
functional evidence of the existence of receptor-receptor interaction between M3 and 
M5 muscarinic receptors and with each other. Our results from quantitative BRET 
saturation analysis show that M3 and M5 can form homoligomers in intact HEK 293 
cells. Analysis of BRET parameters (BRET50 and BRETmax) supported the 
existence of constitutive M3 and M5 mAChR homodimers in live cells (Table 2.2). 
Results in agreement with previous pharmacological and BRET signal demonstrated 
M1, M2 and M3 muscarinic receptor homodimerization 163, although BRET50 values 
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for M5 muscarinic receptors were significantly higher than those determine for M3 
homodimers. This indicated that the likelihood of homodimer formation of the M3 
subtype appears to be slightly but consistently higher than with M5 receptors subtypes 
(Table 2.1.2). Therefore, our data suggests that both mAChR subtypes in a given 
tissue results in a combination of homodimers, whose proportions depend on both the 
relative affinity between interacting species and their expression levels, and a minor 
complement of monomers. 
Following the quantitative BRET saturation curve approach, we also demonstrated 
that co-expression of M3 and M5 muscarinic receptor subtypes can form heterodimers 
in HEK-293 living cells. Our results from BRET saturation curves clearly indicate 
that M3 and M5 receptors can form heterodimers. These results are also confirmed by 
co-immunoprecipitation experiments.  BRET50 values from M3/M5 
heterodimerization did not differ from values found for M3 mAChR 
homodimerization curves. However, they were significantly lower than those 
determined for M5 mAChR homodimers (Table 2.1.2). These results support the idea 
that the M5 muscarinic receptor subtype exists as a combination of a high affinity 
homo- and hetero-dimers receptor population, but with a high affinity to form 
heterodimers when it is co-expressed with M3 subtypes.  
Although previous reports have demonstrated that GPCR agonist binding induces or 
stabilized receptor oligomerizatio, we cannot observe any change in the BRET 
parameters when cells were incubated in the presence of a carbachol agonist. It seems 
that for the muscarinic receptor family, agonist binding does not promote any 
conformational changes that disestablish the receptor dimerization state. By using 
SDS-PAGE and Western blot analysis of membrane extracts from COS-7 cells 
expressing a mutant M3 mAChR, Zeng and Wess showed that agonist-induced 
receptor stimulation had no significant effect on M3 mAChR dimerization 291. In 
addition, carbachol treatment of HEK 293 cells expressing homologous or 
heterologous combinations of M1, M2, and M3 mAChR fusion proteins revealed no 
significant changes in the BRET signal, as compared with control untreated co-
transfected cells 163. 
In an attempt to better understand the structural determinants involved in M3/M5 
heterodimerization, we investigated the effects of the third intracellular loop on 
structural dimer organization. Previous studies using peptide strategies have identified 
structural determinants that can affect both GPCR dimers and function. For instance, 
a peptide derived from the TM6 domain of the 2-AR was found not only to decrease 
the amount of receptor dimers detected in co-immunoprecipitation studies, but also to 
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inhibit receptor-stimulated AC activity, leading the authors to conclude that 
dimerization may be important in receptor function 309. Likewise, Banères et al. found 
that a peptide mimicking the TM6 domain inhibited the dimerization of the BLT 1 
receptor and affected the ability of the receptor to interact with the G protein 310. In 
addition, Granier et al. demonstrated that a peptide mimicking the V2 receptor third 
intracellular loop inhibits the receptor function through a modification of its dimeric 
structural organization and direct action on G proteins 306. In our studies, cells co-
expressing M3-Rluc and M5-GFP2 in the presence or absence of minigene 
construction encoding for a peptide for the third intracellular loop of the M5 receptor 
subtype revealed a low but significant difference in BRET50. Therefore a significant 
inhibition in the BRETmax signal was observed. These results strongly suggest that the 
minigene construct would modify the distance and/or orientation between M3-Rluc 
and M5-GFP2 engaged in dimer formation affecting the oligomerization state itself. It 
also supports the notion that the peptide changes the conformation of a pre-existing 
dimer with promoting disassembly of protomers. 
However it is important to notice that this effect was not higher (increased in 1,1 fold 
respect to BRET50 of cell without minigene expression). Probably indicating that in 
muscarinic receptor heterodimerization, specifically for M3 and M5, other structural 
components can actively participate in protomer organization and assembly. Based on 
mutagenesis and cross-linking experiments, helix VI for -AR 309, helix IV for 
dopamine D2 137, or helices I and II for Ste2 pheromone receptor oligomers 311 have 
been proposed to provide inter-monomeric contacts. In the prototypical GPCR, 
rhodopsin, intradimeric contacts involving helices II, IV and V, as well as the 
cytoplasmic third intracellular loop are too involved in the formation of dimer rows 
312.  Whereas the C terminus is implicated in the GABAB-R1/GABAB-R2 receptor 
oligomerization 313, the glycophorin motif seems to be involved in the formation of 2-
AR homo-oligomers 309, and the role of the N terminus int the oligomerization of the 
bradykinin and calcium receptors was reported 314,315. Also, in the muscarinic receptor 
family, specifically the M3 subtype, the functional role of the third intracellular loop 
in receptor dimerization has been demonstrated 316. Altogether, these results support 
the notion that GPCR oligomerization involves the participation of different structural 
determinants whose role might differ among receptors. 
The documented coexpression of M3 and M5 receptors in many acetylcholine-
sensitive tissues like striatal dopamine neurons 317, the gastrointestinal tract 318 and T 
and B lymphocytes cells 297, suggests that heterodimerization could indeed occur in 
native mammalian tissues, assuming simultaneous expression of both receptors in the 
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same cells. As shown for the M5 receptor, some receptors may form homodimers but 
preferentially engage with heterodimers. This may also be the case for the 1D-
adrenergic receptor (1D-AR) 113, reflecting that a large spectrum of affinities is likely 
to exist for the formation of different GPCR heterodimers. 
The determination of functional consequences of muscarinic receptor 
heterodimerization is difficult to achieve using classic radioligand competition 
binding assays and a specific pharmacological profile, particularly for heterodimers 
composed of M3-M5 subtypes that display similar affinities for the same radioligand. 
Understanding, in part, the structural determinants of M3-M5 heterodimers allows us 
to study the role of heterodimerization in signal transduction and cytokine production 
in lymphocytes T-cells by the use of a minigene construct which promotes a 
disestablishing effect in M3/M5 heterodimerization.  
When Molt-3 cells endogenously expressing M3 and M5 receptor subtypes were 
transfected with the minigene construct, agonist stimulation led to a low level in ERK 
phosphorylation. Similar extensions were observed in agonist enhanced PHA-
induced-IL-2 production. Theses results revealed that proper receptor heteromer is 
required for proper acetylcholine receptor response and function.  
Our previous results demonstrated that the heterogeneous population of both M3 and 
M5 mAChR is composed of homodimers together with a significant fraction of 
heterodimers, whose proportion depends on both receptor subtypes and the relative 
affinity values for both homodimers and the M3/M5 heterodimer. Such a 
heterogeneous population of receptors oligomerization will provide a molecular 
mechanism for an increased diversity of cholinergic signalling in lymphocytes cells, a 
fact which might be considered during therapeutic treatment of the immune system. 
In summary, we investigated M3 and M5 muscarinic receptor homo- and hetero-
dimerization using BRET technology. The relative propensity for muscarinic receptor 
homo- and heterodimer formation was determined in quantitative BRET donor 
saturation assay and showed that M3/M5 heterodimers are formed at low expression 
levels and at a probability higher than the corresponding homodimers. We also 
determined the role of the third intracellular loop as a structural determinant in M3/M5 
heterodimerization. In addition, our data suggest that agonist-induced mAChR signals 
in T lymphocyte cells are enhanced as a result of M3/M5 heterodimerization.  
 
MATERIALS AND METHODS 
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Materials. [3H]-Quinuclidinyl benzilate ([3H]-QNB, 42 Ci/mmol) and N-[3H]-
methylscopolamine ([3H]-NMS, 81 Ci/mmol) were purchased from Amersham Biosciences. 
Dulbecco's modified Eagle's medium, penicillin/streptomycin, and fetal bovine serum were 
purchased from Invitrogen. Restriction enzymes were from New England Biolabs (Beverly, 
MA), and coelenterazine h was obtained from Promega (Madison, WI). The anti-HA 
polyclonal antibody (HA.11) was purchased from Covance (Berkeley, CA). Carbamylcholine 
chloride (carbachol), atropine sulfate and all other reagents were purchased from Sigma.  
cDNA Construction. The constructs presented herein were made using standard molecular 
biology techniques employing PCR and fragment replacement strategies. The cDNAs of the 
human M3 muscarinic receptor (kindly provided by T. Bonner, NIH, USA) and human M5 
muscarinic receptors (provided by D. Bello, ETH, Switzerland) were subcloned into the 
mammalian expression vector pcDNA-3.1-3xHA (gift from P. Calvo, SFU, CA) giving the 
3xHA-M3-pcDNA and 3xHA-M5-pcDNA vectors. Basically, 1.9 and 1.7-kb fragments 
encoding the human M3, M5 receptors were respectively amplified from their cDNAs using 
sense and antisense primers harboring unique EcoRV and XbaI sites, then subcloned into the 
mammalian pcDNA3.1-3xHA vector using EcoRV/XbaI.  
The cDNAs fragment encoding a fragment of the third intracellular loop of M3 and M5 
muscarinic receptor (123 and 100 amino acid residues respectively) were subcloned into the 
InterPlay® mammalian TAP system, pNTAP-B vector (Stratagene, USA) resulting in the 
pTAP-3IL-frag-M3 and pTAP-3IL-frag-M5 vectors. 3ILoop was amplified from the 3xHA-
M3-pcDNA vectors using the Expand High Fidelity PCR System (Roche, USA) and spliced 
into BamHI/EcoRI sites of the pNTAP-B vector.  
M3-Rluc and M5-Rluc were constructed by ligating the Renilla luciferase (RLuc) to the C-
terminal tail of each receptor subtype. Human M3 and M5 mAChRs coding sequences without 
their stop codons were amplified from 3xHA-M3-pcDNA and 3xHA-M5-pcDNA vectors 
using sense and antisense primers harboring unique XhoI and EcoRI sites. The fragments 
were then subcloned in-frame into humanized pRluc-N2 (h) vectors (Packard Bioscience). In 
a similar manner, M3-GFP2 and M5-GFP2 were constructed using sense and antisense primers 
harbouring unique EcorRI and BamHI sites and subcloned into the pGFP2-N1 vector 
(Packard Bioscience). The reading frame and PCR integrity of all cloned constructs were 
confirmed by DNA sequencing.  
Cell Culture and Transfection. HEK-293T cells were maintained in Dulbecco's modified 
Eagle's medium supplemented with 10% fetal calf serum (FCS), 100 units/ml penicillin and 
100-μg/ml streptomycin, 2 mM L-glutamine (all from Invitrogen) streptomycin at 37°C in a 
humidified 5% CO2 incubator. For transfections, 2 × 106 cells were seeded into 100-mm 
dishes. About 24 h later, cells were transfected with 4 µg of plasmid DNA/dish by using the 
LipofectAMINETM Plus kit (Life Technologies, Inc.) according to the manufacturer's 
instructions. For BRET assays, HEK-293 cells were transfected using PolyEthylenImine 
reagent (PEI, Sigma-Aldrich) as described previously 319. 
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Molt-3 cells were cultured in RPMI 1640 medium supplemented with 10% FCS, 2 mM 
GlutaMAX-1, 1 mM sodium pyruvate, 100 U/ml penicillin G, and 100 µg/ml streptomycin at 
37 °C in a humidified 10% CO2 environment. Molt-3 cells were transiently transfected using 
DEAE-dextran as described previously 320.  
Membrane Preparation and Radioligand Binding Assay. About 48 h after transfection, 
HEK-293 cells were washed twice with cold PBS, harvested and homogenized in binding 
buffer (25 mM HEPES, pH 7.4, 5 mM MgCl2, 1 mM EDTA), using a Polytron tissue 
homogeniser. Cell membranes were collected by centrifugation at 20, 000g for 15 min and 
homogenized as above.  After centrifugation at 40, 000g for 20 min at 4ºC, the final pellet 
was resuspended in binding buffer, and membranes were either used immediately or frozen in 
liquid nitrogen and stored at -80 °C until required. Protein concentration was determined by 
using the Bradford protein assay kit (Bio-Rad, USA). In order to determine the affinity of 
NMS for each sample, membranes were incubated with different concentrations of [3H]-
NMS (ranging from 12.5 pM to 1.5 nM) in 5 mM PBS at 25°C for 60 min. The incubations 
were stopped by filtration through Whatman GF/B filters and washed extensively with ice-
cold 40 mM PBS prior to scintillation counting. Non-specific binding was determined in the 
presence of 10μM atropine.  
Co-immunoprecipitation and western blot. Immunoprecipitation and western blot 
experiments were carried out as described previously (canals M., Burgueño j. 2004). Protein 
immunodetection on membranes was assessed using anti-M3 (1: 1000), anti-M5 (1: 1000) and 
anti-HA (1: 2000) as primary antibodies; and then horseradish-peroxidase (HRP)-conjugated 
goat anti-rabbit IgG (1:60 000) as secondary antibody. 
Immunocytochemistry Staining. For immunocytochemistry, Molt-3 cells (endogenously 
expressed M3 and M5 receptor subtypes) or transiently co-transfected HEK-293 cells were 
grown on poly-D-lysine-coated glass coverslips and fixed with 4% formaldehyde solution for 
20 min followed two washes with PBS containing 20 mM glycine (buffer A) to quench the 
aldehyde groups. Then, after permeabilization with buffer A containing 0.2% Triton X-100 
for 5 min, cells were treated with PBS containing 1% bovine serum albumin (buffer B). After 
1 h at room temperature, cells were labelled with the indicated primary antibody for 1 h, 
extensively washed, and stained with the indicated fluorescently labelled secondary antibody. 
Samples were rinsed and visualized on a Leica SP1/MP confocal microscope (HEK-293 
cells) or Leica DMRB fluorescence microscope (Molt-3). The primary antibodies used were 
as follows: rabbit anti-HA monoclonal antibody (2 µg/ml; Sigma), mouse anti-M3 polyclonal 
antibody and rabbit anti-M5 polyclonal antibody (1:500, Santa Cruz Biotechnology). The 
secondary antibodies used were as follows: Alexa Fluor 488-conjugated goat anti-mouse IgG 
(1:200; Invitrogen, Eugene, OR), Texas Red-conjugated goat anti-rabbit IgG (1:1000; 
Invitrogen).  
BRET assays. Forty-eight hours after transfection HEK-293 cells with a constant (2 μg) or 
increasing amounts of cDNA of Receptor-Rluc (M3 or M5) and Receptor-GFP2 (M3 or M5) 
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respectively were rapidly washed twice in PBS, detached, and resuspended in the same 
buffer. Cell suspension (20 µg of protein) was distributed in duplicated into 96-well 
microplates (either clear-bottomed or white opaque Isoplates) for fluorescence and 
luminescence determinations). The total fluorescence of cell suspensions was quantified and 
then divided by the background (mock-transfected cells) in a Fluostar Optima Fluorimeter 
(BMG, Labtechnologies, Germany) equipped with a high-energy xenon flash lamp, using a 
10 nm bandwidth excitation filter of 400 nm and an emission filter of 510 nm. And Renilla 
luciferase, total luminescence, was determined on samples incubated 10 min with 5-µM 
coelenterazine H (Molecular Probes, Invitrogene, USA) using a Mithras LB 940 (Berthold 
Technologies, Germany) as described bellow.  The background values for total luminescence 
were negligible, and they were subtracted from sample values.  
For BRET measurement, 20 µg of cell suspensions were distributed in duplicate in 96-well 
white opaque microplates (Corning, NY) and incubated for 10 min at 25°C in the absence or 
presence of carbachol. DeepBlueC substrate (Molecular Probes, OR) was added at a final 
concentration of 5 µM, and readings were performed immediately after, using a Mithras LB 
940 (Berthold Technologies, Germany) that allows the sequential integration of the signals 
detected with two filter settings [485 nm (440-500 nm) and 530 nm (510-590 nm)]. The 
BRET ratio is defined as [(GFP2 emission at 500–530)/( Rluc emission 440–500)] – cf., where 
cf. corresponds to (emission at 510–590)/(emission at 440–500) for the Receptor-Rluc 
construct expressed alone in the same experiment.  
Luminescence and fluorescence levels of several receptor-RLuc and receptor-YFP (or 
receptor-GFP) fusion proteins have been found to be linearly correlated with receptor 
numbers (McVey et al., 2001; Ayoub et al., 2002; Mercier et al., 2002; Jockers R, 2004). 
Because this correlation is an intrinsic characteristic of each fusion protein, correlation curves 
have to be established for each construct. HEK 293 cells were transfected with increasing 
cDNA concentrations of the Receptor-Rluc or GFP2 fusion protein constructs. Maximal 
luminescence and fluorescence was determined as described above and correlated with 
relative receptor number determined in the same cells as described under "Radioligand 
Binding Experiments". Luminescence and fluorescence were both plotted against binding 
sites, and linear regression curves were generated. The standard curves generated for each 
single experiment were used to transform fluorescence and luminescence values into 
femtomoles of receptor. Thus, the fluorescence/luminescence ratios were transformed into 
(receptor-YFP)/(receptor-RLuc) ratios, which allowed us to determine accurate BRETmax 
and BRET50 values (Mercier JF. 2002). To control the number of cells and also to express 
receptor numbers in fmol/mg of total cell protein, protein concentration was determined using 
a Bradford assay kit (Bio-Rad).  
ERK phosphorylation.  Transfected Molt-3 cells endogenously expressing the M3 or M5 
receptor subtype with or without the 3ILoop-minigene were grown to 80% confluence and 
rendered quiescent by serum starvation overnight prior to ERK phosphorylation; an 
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additional 2h incubation in fresh serum-free medium was performed to minimize basal 
activity. Cells were subsequently stimulated by addition of medium with or without the 
muscarinic agonist carbachol. Rapid rinsing with ice-cold PBS finished stimulation, and cell 
lysis was performed during 10 min by the addition of 500 µl ice-cold lysis buffer (50 mM 
Tris-HCL, pH 7.4, 150 mM NaCl, 1% TritonX-100, protease and phosphatase inhibitor 
cocktail). The cellular debris was removed by centrifugation at 13, 000g for 5 min at 4°C, and 
the total protein content was measured using BCA Protein Assay Reagent (Pierce, USA). 
Aliquots corresponding to 5 μg of protein were mixed with sodium dodecyl sulfate (SDS) 
loading buffer, applied to 12% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and 
analyzed by Western blot. Extracellular signal regulated kinase ½ (ERK ½) activation was 
assayed by incubating PVDF blots with a mouse anti-phospho-ERK ½ antibody (Sigma-
Aldrich, Germany). Control blots were also run in parallel, and probed with rabbit anti-ERK 
½ antibody (Sigma-Aldrich, Germany) that recognized both unphosphorylated and 
phosphorylated forms. The immunoreactive bands were visualized using horseradish 
peroxidase-linked secondary anti-mouse and anti-rabbit antibodies (Dako, USA) and 
SuperSignal West Pico Chemiluminescent Substrate (Pierce, USA) and then measured by 
quantitative densitometry.  
IL-2 production. The amount of IL-2 produced by Molt-3 cells (transfected with the 3ILoop-
minigene or mock pcDNA3.1) was determined using and ELISA kit for human IL-2 
(DuPont-New England Nuclear). In brief, cell-free culture supernatants were obtained by 
centrifugation at 500-x g for 5 min. Samples were assayed fallowing manufacture’s 
instruction and analysed on an automated ELISA plate reader. Data is expressed as IU (1 
IU/ml = 0.2 ng/ml). 
Data analysis. All binding data were analysed using the commercial program GraphPad 
PRISM 4.0 (GraphPad Software, USA). BRET saturation curves were analyzed using Prism 4 
software. Isotherms were fitted using a nonlinear regression equation assuming a single 
binding site, which provided BRETmax and BRET50 values. The correlation between 
fluorescence or luminescence and receptor density was analyzed by a linear regression curve 
fitting with the same software. For statistical evaluation of the biochemical data, unless 
otherwise specified, one-way analysis of variance (ANOVA) was used. Group differences 
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ABSTRACT 
Several motifs located in the third intracellular loop of the M3 muscarinic 
receptor are critical for G protein activation and scaffold protein interaction. To 
date, however, the dynamic feature of multiprotein complex formation is not fully 
understood. We have constructed a minigene encoding the third intracellular loop 
of the M3 muscarinic receptor in order to explore the feasibility of peptides from 
the intracellular regions of G protein-coupled receptors to act as inhibitors of 
muscarinic multiprotein complex formation and signalling. We find that this 
construct, when co-expressed with the M3 receptor, shows the capacity to act as a 
competitive antagonist of the receptor for G protein and receptor-
scaffold/accessory protein interactions. Transient transfection of human 
embryonic kidney-293 cells with DNA encoding the human M3 and M5 receptor 
subtypes results in a carbachol-dependent increase of inositol phosphate. Co-
transfection of the third cytoplasmic loop minigene dramatically reduces inositol 
phosphate levels and blocks agonist-induced activation of Gq/11 protein for M3 and 
M5 muscarinic receptors. The effect of the minigene expression on the regulation 
of the mitogen-activated protein kinases pathway is suggested by to the lack of 
ERK½ protein activation. Furthermore, minigene expression led to reduced AKT 
activation and deficient NF-κB translocation to the nucleus. These data, together 
with the results of co-immunoprecipitation of different scaffold and kinase 
proteins, provide experimental evidence for the role for the third cytoplasmic loop 
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of the human M3 muscarinic receptor in multiprotein complex formation and G-
protein activation.  
INTRODUCTION 
 
Muscarinic acetylcholine receptors (mAChRs) comprise a class I subfamily of 
heptahelical, transmembrane G-protein coupled receptors (GPCRs) and are 
represented by five distinct subtypes, denoted as M1, M2, M3, M4 and M5 183,266. 
The functional response of mAChRs is through heterotrimeric guanine 
nucleotide-binding proteins (G proteins), involving primarily the third 
intracellular loop (3ILoop). Muscarinic M1, M3 and M5 receptors preferentially 
couple to Gq/11 thereby activating phospholipase C-β, and inducing a subsequent 
increase in intracellular calcium concentration 321. In contrast, M2 and M4 couple 
primarily to G-proteins of the Gi/o classes, typically leading to adenylate cyclase 
inhibition and the activation of inward-rectifier potassium conductance 202,203. 
Among different other possible responses, in a suitable cellular context, all 
mAChR subtypes can regulate a wide network of signalling intermediates, 
including small GTPase Rho, phospholipase D, phosphoinositide-3 kinase, non-
receptor kinases and mitogen-activated protein kinases 322-325. 
Evidence has been mounting in the past years to indicate that signalling 
efficiency/specificity for mAChRs is determined in part by accessory proteins that 
physically interact or are found in the microenvironment of the receptor 326.  A 
number of proteins have been shown to interact with mAChRs, including other 
GPCRs, kinases, and scaffold proteins such as β-arrestin 64,327,328. These proteins 
together with the classical core signalling entities (receptor, G protein and 
effectors) contribute to the formation of a signalsome complex at the 
cytoplasmatic face of the receptor 64. Understanding the nature and dynamic 
features of such a complex, which have not been unambiguously established, may 
be a key step in designing novel strategies for the development of next generation 
of drugs. The sequence similarities of the different subtypes, at the ligand binding 
sites, is the main hurdle for designing and identifying proper subtype-selective 
ligands 329,330. However, important differences in size and homology of the 
intracellular loops across different muscarinic receptors, derived from sequence 
alignment, can be responsible for the specificities of each subtype.  
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Previous studies on muscarinic receptor signalling mechanisms have 
demonstrated that the cytoplasmic domain of these receptors, particularly the 
second and third intracellular loops, is critical in mediating signal transduction by 
G proteins 331. Indeed, previous observations using receptor-derived peptides from 
specific regions of the M1 and M2 receptors have shown that the C-terminal tail of 
the 3ILoop is critical for functional receptor-G-protein interaction 332. These 
observations have confirmed that there are different structural determinants for 
receptor-G-protein coupling and G-protein activation. More recently, specific 
motifs in the 3ILoop of M1 and M3 receptor have been shown to bind some 
accessory proteins with high affinity (calmodulin, oncogenic SET, and small 
GTPase Rho) 64,333-335.  
These observations point to a specific role of 3ILoop in receptor-G protein 
coupling, signal transduction and multiprotein complex formation. Thus, we 
hypothesized that the soluble expressed 3ILoop could act as an analogue of the 
receptor 3ILoop, and as a scaffold protein as well, competing with the receptor for 
its interacting proteins, and therefore inhibiting the specific G-protein-mediated 
downstream effects.  
To verify this hypothesis, we developed a minigene construct capable of 
expressing the   human M3 muscarinic receptor 3Iloop (3ILoop-minigene), and 
measured its ability to inhibit downstream signalling of receptors that couple to 
Gq/11 proteins. Our results suggest that the presence of the 3ILoop-minigene 
construct not only prevents G-protein coupling to M3 receptors but also impairs 
the functional coupling of other GPCRs that selectively interact with the same G 
protein population. We also find that the construct can inhibit the M3 muscarinic 
signal transduction pathway and its functionality, probably by recruiting 
interacting proteins as confirmed by co-immunoprecipitation experiments.  
These results highlight the functional relevance of the interplay among GPCRs 
and selective G-protein pools, a key process for cell regulation. Moreover, 
muscarinic receptor-derived peptides could be used as selective inhibitors for the 
protein-protein interaction in which these receptors are involved. This approach 
could contribute to the development of novel pharmacological strategies aimed at 
suppressing non-desired GPCR hyperactivity (or altered physiological function) 
in some pathological conditions. 
 





Design, construction and expression of 3ILoop-minigene. 
The 3ILoop of the muscarinic receptor family is one of the largest in the GPCR 
superfamily (156-239 amino acids) and shares a low degree of sequence 
homology between mAChRs subtypes, with the exception of amino acids located 
at the C and N flanking regions of the loop (Figure 3.1.1 A). The 3ILoop has been 
shown to be critical for G protein coupling and activation and is one of the main 
target domains for interacting proteins 64. These physical interactions with a wide 
range of proteins often lead to the formation of a multiprotein complex that is able 
to elicit a signal cascade, bypassing the need to couple with the heterotrimeric G-
proteins for signalling 79.  
To determine whether the expression of the 3ILoop could selectively antagonize 
G protein signalling and work as an analogue protein, competing by the same pool 
of scaffold and interacting proteins, we generated a minigene vector that encodes 
a set of peptides (Calmodulin Binding Peptide/Streptavidin Binding 
Peptide/3ILoop) as described under Materials and Methods (Figure 3.1.1 B). 
HEK-293 cells were transiently co-transfected with the minigene and the M3 or 
M5 muscarinic receptor. Total RNA was isolated 48 hours post-transfection and 
analyzed by RT-PCR, using a set of primers that spanned the vector (SBP) and 
inserted sequence (3ILoop), to confirm the transcription of the 3ILoop-minigene. 
Our results confirmed the presence of a single 541-base pair band corresponding 
to the RT-PCR product of the minigene in the transfected cells (Figure 3.1.1C). 
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Figure 3.1.1 Topological model of the M3 human muscarinic receptor and the minigene 
construction. (A) A two-dimensional topology of the M3 human muscarinic receptor sequence is 
represented (extracellular space at the top and the intracellular space at the bottom). Filled 
circles represent the amino acid sequence of peptide 3ILoop employed to construct the minigene. 
(B) Design of the 3ILoop-minigene vector (884 bp) is also depicted: CBP, Calmodulin Binding 
Peptide; SBP, Streptavidin Binding Peptide; 3ILoop (630 bp), the Third Intracellular Loop of the 
M3 human muscarinic receptor. (C) HEK 293 cells were transiently co-transfected with M3 or M5 
receptor subtypes and 3ILoop-minigene vector. To confirm the transiently transfection of 
minigene in HEK 293 cells, total RNA was isolated and subjected to RT-PCR. The PCR analysis 
was achieved using primers specific for a CBP + 3ILoop fragment. Separation of the PCR 
products on 1.5% agarose gels indicates the presence of the 3ILoop-minigene RNA by a single 
541-bp band. Lane 1 is a 1-kilobase pair DNA ladder; lane 2 is a PCR product from cells 
transfected with pcDNA-3xHA-M3; lane 3 correspond to cells co-transfected with pcDNA-3xHA-
M3 and 3ILoop-minigene; lane 4 correspond to cells transfected with pcDNA-3xHA-M5; and lane 
5, to cells co-transfected with pcDNA-3xHA-M5 and 3ILoop-M3 minigene. G3DPH gene was used 
as housekeeping control. 
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We also attempted to demonstrate expression of the minigene construct by 
Western blotting, but due to the poor quality of available antibodies against the 
third intracellular determinants of the M3 subtype, we were not able to detect 
expression of the minigene protein product (data not shown).  
 
3ILoop-minigene effect on receptor binding and expression levels. 
The Kd values for [3H]-NMS binding to membranes obtained from cells 
expressing the M3 receptor in the presence and in the absence of the minigene 
were not significantly different (Table 3.1.1).  
 
Table 3.1.1 Ligand binding and functional properties of M3/M5 muscarinic receptor expressed 
alone or together with the 3Iloop-minigene. 









M3-WT 85.3 ± 17.7 1250 ± 106 7.1 ± 2.2 
M3 + 3ILoop 86.8 ± 27.9 1219 ± 66 3.93 ± 2.3 
M5-WT 164.9 ± 41.4 934 ± 46 6.1 ± 1.1 
M5 + 3ILoop 163.7 ± 55.03 908 ± 32 4.6 ± 2.5 
Affinity constants (KD) for radioligand [3H]-NMS was determined in saturation binding assays. 
Bmax values indicate maximum number of binding sites/mg of membrane protein. Data is presented 
as means ± SEM for two to five (binding studies) or three to six (PI assays) independent 
experiments, each performed in duplicate s.  
 
Parallel experiments were performed with a HEK-293 cell line expressing M5 
muscarinic receptor to determine whether the 3ILoop-minigene has the same 
behaviour when expressed in cells with another Gq/11-coupled receptor.  The M5 
subtype showed similar specific [3H]-NMS binding either in the presence or in the 
absence of the 3ILoop (Table 3.1.1). These results indicate that no major changes 
or modulation of the conformational state of the orthosteric binding site of the 
receptors are detected as a result of the presence of the minigene, and are in 
agreement with those obtained for M3-expressing cells.  
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3ILoop-minigene inhibits agonist-mediated stimulation [35S]-GTPγS binding. 
The 3ILoop is known to be critical for G-protein coupling and activation, and the 
expression of the minigene seems to compete for the same pool of G proteins or 
target the receptor-G protein interface. Therefore, a reasonable step forward was 
to determine whether the presence of the minigene, co-transfected in M3 or M5 
transfected cells, had any effect on G-protein activation. To this aim, agonist-
induced stimulation of [35S]-GTPγS binding to membranes from M3 or M5-HEK-
293 cells after transfection with the minigene or vector in the presence of 1 µM 
GDP was carried out. Cells co-transfected with M3 or M5 receptor subtype with 
the empty vector revealed a 10-fold increase of CCh-stimulated [35S]-GTPγS 
binding for both receptors, but with a lower potency (pEC-50M3= 4.84 ± 0.04 and 
pEC-50M5= 5.77 ± 0.05) in the case of the M5 receptor (Figure 3.1.2). 
 
Figure 3.1.2 3ILoop-minigene effect on agonist-stimulated [35S]-GTPγS binding to membranes 
from cells expressing the M3 or M5 receptor subtypes. Bindings of [
35S]-GTPγS binding (0.3 nM) 
to membranes prepared from transient expressing M3-HEK-293 or M5-HEK-293 cells were 
measured after incubation at different concentrations of carbachol for 1h at 30°C in the presence 
(●) or absence (■) of 3ILoop-minigene (5μg). Values are expressed as percentage (%) of specific 
binding to the sample in the absence of ligand (control). Data are means ± S.D. from a 
representative experiment preformed in triplicate. 
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The co-expression of the minigene with the M3 subtype resulted in a decrease of 
45% in agonist-dependent stimulation of [35S]-GTPγS binding, and a relative 
efficacy decay of 2.2 fold with regard to the M3 control vector (Emax % over 
basal of 56.9 ± 1.9 and 125.3 ± 2.2, respectively). Similar results were obtained in 
cells expressing the M5 subtype. The presence of the minigene reduced carbachol-
mediated stimulation of [35S]-GTPγS binding in about 50% (Figure 3.1.2) 
(EmaxM5+3ILoop= 60.82 ± 2.4, and EmaxM5=124.4 ± 2.0). This suggests that the 
3ILoop-minigene inhibits the agonist-mediated stimulation of [35S]-GTPγS 
binding to Gq/11 proteins mediated by M3 receptor or M3-closely related GPCR 
(for instance the M5 subtype).  
 
Effect of 3ILoop-minigene Expression on PLC Activation. 
We also analyzed agonist-stimulated phosphatidylinositol (1,4,5) trisphosphate 
(Ins-(1,4,5)-P3) formation in HEK-293 cells co-expressing each receptor subtypes 
with the minigene or the empty vector in order to assess whether the presence of 
the minigene could compete and recruit G protein-mediated activation of 
receptors that interact with the same population of G proteins. First, we 
characterized the time- and concentration dependence of carbachol-stimulated 
[3H]-myo-InsPs accumulation in the transfected M3 and M5-HEK-293 cells (data 
not shown). [3H]-myo-InsPs accumulation reached a peak between 5-10 min after 
agonist exposure. Complete desensitization occurred within 30 min of high dose 
stimulation. Non-appreciable carbachol-stimulated [3H]-myo-InsPs accumulation 
was detected in non-transfected cells.   
Figure 3.1.3 shows the concentration-response curves for carbachol-dependent 
stimulation of [3H]-myo-InsPs in M3 and M5-HEK-293 cells co-expressing the 
minigene or the empty vector. Carbachol produced a seven fold stimulation of 
inositol phosphate over basal, suggesting that the presence of endogenous G 
proteins in HEK293 cells can effectively activate PLC. In contrast, expression of 
the minigene vector abolished M3-agonist [3H]-myo-InsPs accumulation 
essentially at all agonist concentrations, with a reduction in relative efficacy in 
approximately 50%. A similar change was observed in cells expressing the M5 
receptor, in which Ins- (1,4,5) P3 release upon carbachol stimulation produced an 
increased of 6 folds in [3H]-myo-InsPs accumulation in contrast with the 
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reduction observed in relative efficacy values (46%) when co-expressed the 
minigene vector.  
 
Figure 3.1.3 Effect of 3ILoop-minigene vector and muscarinic receptor subtypes co-expression on 
PLC activity in CCh-stimulated HEK-293 cells. Cotransfected cells with M3 or M5 receptor 
subtypes and 3ILoop-minigene (●, ○) or empty vector (■, □) were stimulated with CCh as 
indicated, for 1 hr at 37°C in presence of LiCl as described in Materials and Methods. Data are 
presented as increase of InsPs (DPM) above basal levels in the presence of carbachol. Basal 
levels observed with the various receptors were not significantly different. Data represent the 
average ± S.E.M. values of triplicate determinations of three independent experiments.  
 
In addition to the change observed for both subtypes, in the maximum PLC 
response between minigene and control transfection we also observed consistent 
and statistically significant increases in the carbachol concentration needed for 
50% stimulation of Ins- (1,4,5) P3 release for both receptors when co-transfected 
with the minigene (pEC50 in presence of 3ILoop-minigene construct referred to 
the control, decreased in 1.1 ± 0.6 fold for M3 receptor and 1.4 ± 0.5 fold for M5 
receptor). 
In order to ensure that EC50 and Emax changes observed were not due to 
alterations in the receptor density, we plotted the negative logarithm of EC50 vs. 
receptor density for experiments with co-expression of the minigene. This plot 
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shows that receptor expression was rather variable but that the EC50 shifts were 
independent of receptor density (data not shown). 
 
Effect of 3ILoop-minigene expression on ERK ½ activation. 
Previous experimental evidence supports the idea that at least two distinct 
mechanisms are involved in the activation of ERK ½ pathway by muscarinic 
receptors 219,235. The first mechanism is PKC-dependent and is essential for the 
activation of ERK ½, whereas the second mechanism would be dependent on the 
phosphorylation state of the receptor. This second mechanism operates along with 
PKC-dependent activation and could be associated with the activity of a series of 
kinases (CK1α and GRKs) that recognize a specific domain in the third 
intracellular loop (His374-Val391 for M3 subtype) 235.  As mentioned above, the 
expression and binding capacity of M3 and M5 receptor subtypes were unaffected 
by the presence of the minigene vector, whereas coupling to Gq/11 proteins was 
altered, and as a consequence carbachol failed to stimulate phosphatidylinositol 
production. We evaluated whether expression of the minigene could further alter 
ERK ½ signal transduction after agonist stimulation, and if this vector could be 
used as a potential inhibitor of this type of GPCR signalling.  
First, a time course for ERK ½ activation was performed (Figure 3.1.4 A). 
Stimulation of both M3 receptors co-transfected with the empty vector or with the 
minigene, by 20-μM carbachol, caused maximal activation of ERK ½ at 5 min. 
However, figure 3.1.4 B shows that ERK ½ activation by carbachol in cells co-
transfected with minigene was significantly lower than ERK ½ activation in cells 
transfected with the empty vector (4–fold in less, P<0.01). 
Figure 3.1.4 C shows the effects of minigene co-transfection on MAPK activity in 
cells expressing either M3 or M5 receptor subtypes. A significant decrease in ERK 
½ phosphorylation was observed in both cases when compared to activation in the 
presence of the minigene vector. Preincubation with the MEK specific inhibitor 
PD-98059 inhibited carbachol-induced ERK ½ phosphorylation to the same 
extent as that obtained in cells co-transfected with the minigene construct. This 
confirmed that the 3ILoop-minigene vector acts as an efficient inhibitory protein 
of the MAPK signalling pathway after agonist stimulation.  
 
 




                                                                      
 
 
                             
 
                                                                                   
                                                                 
Figure 3.1.4 Expression of the 3ILoop-
minigenes alters agonist-mediated ERK ½ 
phosphorylation upon activation of M3 and 
M5 receptor subtypes. (A) Time-dependent 
course of ERK ½ activation on carbachol-
stimulated M3- HEK-293 cells transfected or 
not with 3ILoop-minigene. Cells were 
incubated with 1 mM of CCh for the 
indicated time points. (B) Densitometry 
analysis of time course of ERK ½ activation 
following carbachol exposition is shown. 
Phosphorylation was quantified by scanning 
densitometry using the NIH Image program 
and normalized against total ERK ½ 
protein. Means ±S.E.M is shown; n= 6. *: 
Significantly different compared to M3-
15min (ANOVA: p<0.05);  **: Significantly 
different compared to M3-5min (ANOVA: 
p<0.01). (C) Western blot analysis for 
phospho-ERK ½ (p-ERK) following 
incubation with 1 mM of carbachol for 5 
min. in HEK-293 cells transiently expressing 
M3 or M5, co-transfected with the 3ILoop-
minigene (5μg) (lane 4 and 6 respectively) 
or empty vector (lane 3 and 5). M3-HEK-293 
cells non stimulated with carbachol (Lane 1) 
and carbachol-stimulated M3-HEK-293 in 
presence of MAPK specific inhibitor PD-
98059 (lane 2) were performed as internal 
control. Equal loading was confirmed with 
antibodies against total ERK ½. 
 
Taking into account this latter result, where a critical decrease in ERK ½ 
phosphorylation in cells expressing the minigene construct was observed, we 
decided to analyse whether scaffold/associate proteins or protein kinases were 
involved in the observed behaviour. As suggested above, at least one of the two 
mechanisms described for MAPK activation by muscarinic receptor family would 
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involve scaffold proteins, like β-arrestin and kinases (GRK-2, GRK-3 and CK1-α) 
in some form of direct complex with the receptor. 
Figure 3.1.5 Effect of 3Iloop-minigene in receptor association with different protein kinas and 
scaffold protein by co-immunoprecipitation experiments. HEK-293 cells co-transfected with M3 
receptor, in the presence or absence of the 3Iloop minigene, plus each of the following proteins 
(β-arrestin-GFP, Flag-GRK-2 or Flag-CK1-α) were stimulated with carbachol (0.5 mM, 5min) 
prior to solubilization. Extracts were immunoprecipitated with anti-HA antibody (or non-immune 
IgG control) before SDS-PAGE and Western blotting. At the top sections, the immunoprecipitation 
was probed with an antibody against the M3 muscarinic receptor (anti-M3 SCB). The middle 
sections show specific co-immunoprecipitation with β-arrestin-GFP (anti-GFP antibody, SCB). A 
low level of specific pulldown of β-arrestin-GFP can be seen when the cells co-expressed with the 
3Iloop minigene construct. Similar effects were observed in the bottom sections when 
immunoprecipitations were probed with anti-FLAG antibody for both kinases (GRK-2 and CK1-α) 
under the same conditions. The left panel (control) represents the input levels of immunoreactive 
M3 receptor, β-arrestin-GFP, Flag-GRK-2 or Flag-CK1-α in original extracts as a positive 
control of each antibody quality. The amount of interacting protein co-immunoprecipitated was 
normalized for the amount of 3xHA-M3 receptor immunoprecipitated. The blots are representative 
of at least three separate experiments. 
 
We carried out co-immunoprecipitation experiments to ascertain if the direct 
complex formation had been altered or blocked by the presence of the 
cytoplasmatic third intracellular loop. Figure 3.1.5 shows co-immunoprecipitation 
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data from HEK-293 cells co-transfected with HA-M3 receptor in the presence or 
absence of the 3ILoop-M3 minigene, plus each of the following vectors (β-
arrestin-GFP, Flag-GRK-2 or Flag-CK1-α). 
Input levels of each protein and the efficiency of M3 receptor 
immunoprecipitation were monitored to ensure a balance between samples (data 
not shown). In addition, we also analysed the input level of immunoreactive M3 
receptor, β-arrestin-GFP, Flag-GRK-2 or Flag-CK1-α in original extracts as a 
positive control of each antibody quality (Figure 3.1.5 right lane). In all cases, low 
levels of immunoreactivity were associated with the receptor in basal conditions. 
However, preincubation of the cells with carbachol caused increased association 
for each protein, as monitored by densitometry of the immunoblots (11 folds 
respect control, means ± S.E., n=2). Exposure of the cell to the 3ILoop-M3 
minigene, and to agonist incubation as well, caused a decrease in the level of 
immunoreactivity for each protein, similar to the immunoreactivity observed 
when the receptor is kept in basal conditions. These low levels of co-
immunoprecipitation probably resulted from the competition of the 3ILoop-
minigene with the same pool of proteins interacting with the receptor, and from 
their capability to block their association. Co-immunoprecipitation results would 
also account for the low signal levels obtained in ERK ½ phosphorylation assays 
in the presence of the 3Iloop. 
 
Inhibition of AKT activation is mediated by the expression of minigene 
construct. 
Carbachol binding to the Gq/11 muscarinic receptors stimulated AKT promoting 
cell growth and survival in many cell types 336. Therefore, the effect of minigene 
expression on carbachol–induced AKT-activation was determined.  
The activation of M3 or M5-expressing cells by carbachol incubation reaches a 
maximum at 10 min after stimulation (Figure 3.1.6). No activation occurred in 
cells preincubated with the PI3K antagonist LY294002 as show in Figure 3.1.6. 
Western blot analysis revealed that, as previously observed in ERK ½ signalling, 
co-transfection of the M3 or M5-HEK-293 expressing cells with the minigene 
vector abolished the phosphorylation of AKT after agonist stimulation (Figure 
3.1.6). 
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Figure 3.1.6 3ILoop effect on AKT phosphorylation mediated upon activation of M3 and M5 
receptor subtypes. (A) HEK-293 cells co-transfected with each receptor subtype and the 3ILoop-
minigene (lane 4 and 6 respectively) or empty vector (lane 3 and 5) were exposed to 1 mM of 
carbachol for 10 min after 48 h of transfection. Cell lysates were resolved in SDS-PAGE (12%) 
and Western blots performed with an antibody against phosphorylated AKT. (p-AKT). M3-HEK-
293 cells non stimulated (Lane 1) and carbachol-stimulated M3-HEK-293 in the presence of a 
selective PI3K inhibitor, LY294002 (lane 2) were performed as internal controls. Equal loading 
was confirmed with rabbit anti-AKT antibody. (B) The extent of AKT phosphorylation was 
quantified by scanning densitometry. Means ±S.E.M is shown; n= 4. **: Significantly different 




The precise structural determinants important for mediating intermolecular 
interactions in the acetylcholine muscarinic receptor family are being recognized 
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and found to be prominent in signalling cascades 170,216,337. Sequence analysis of 
the third intracellular loop of mAChRs showed that these loops are some of the 
largest in the GPCR superfamily (156-239 amino acids) and contain no homology 
between the mAChRs subtypes except for ~20 amino acids at the N and C 
terminal regions (Appendix 3). Furthermore, the 3ILoop is recognized not only as 
one of the main target domains for interaction with G proteins but also as a 
binding site for direct interaction of accessory proteins that regulate alternative 
signalling pathways 229,338,339.  
As part of an effort to define the potential role of the third intracellular loop in 
protein-protein interactions and multiprotein complex organization, we report 
here the co-expression of a minigene construction that encoded the 3ILoop of the 
M3 human muscarinic receptor along with the intact receptor.  
The rationale of this approach was to explore the ability of this structural 
determinant to interfere with G protein interaction or to compete for other 
interacting proteins that participated in a putative multiprotein complex formation, 
and to analyze its capacity to compete for functionally relevant processes. Our 
efforts were specifically focused on the third intracellular loop of the M3 
muscarinic receptor subtype, because this region was reported to be involved in 
direct G protein binding and activation, and the putative site for interaction of a 
group of scaffold or accessory proteins (arrestin binding, calmodulin and small G 
proteins interactions) 169,340,341. The antecedent for our experimental design can be 
found in previous studies of cellular expression of fragments, or in vitro G protein 
activation assays, which reported the ability of the intracellular loops --or peptides 
derived from these loops-- to interact with the same molecular partners as the 
intact receptor 342-344. Experimental evidence was available showing that these co-
expression experiments could act mimicking the intact receptor, or coupling with 
and activating the relevant G protein345,346. In the current series of experiments, 
the third intracellular loop domain of the M3 receptor was shown to have a 
recognizable impact on the function of the intact M3 receptor subtype. In our 
experiments, proximal events occurring at the level of the plasma membrane were 
dramatically affected as shown by the impairment of receptor-accessory protein 
co-immunoprecipitation in cells co-expressing the minigene construct. The co-
expression of the minigene construct along with the wild-type receptor exhibited 
decreased G protein activation, phosphatidylinositol production, and subsequent 
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signalling, but normal ligand binding and receptor membrane expression (Figure 
3.1.7). Therefore, our results indicate that the co-expression of the 3ILoop of the 
M3 receptor with the M5 subtype produce similar effects, as with previous studies 
in which the expression of the third intracellular loop of the μ-opioid receptor 
altered the functionality not only when co-expressed with the intact μ -opioid 
receptor but also when co-expressed with other classes of GPCR 347.  
While we only focused on the study of the effect of the third intracellular loop, we 
cannot exclude the possible involvement of the first and second cytoplasmic loops 
or the C-terminal tail.  Thus, although the 3ILoop is the largest intracellular loop, 
and is usually proposed to be one of the main sites for intracellular interaction, 
this does not obviously exclude specific domains in other loops from playing a 
role in protein-protein interactions or from participating in a multiprotein complex 
formation or function. In fact, the C-terminal tail is recognised to be an important 
structural determinant with anti-apoptotic properties within the muscarinic 
receptor family 348. On the other side, the second intracellular loop, together with 
the DRY motif, has also been described to bind the G protein 349. 
In our experimental design, we chose to express the intracellular domain with 
two-epitope tags (CBP-SBP: TAP-system) at the N-terminal domain in order to 
purify the recombinant receptor and for subsequent study by mass spectrometry in 
future experiments to determine the nature of the interacting proteins. The 
possibility of conformational and accessibility changes in potentially critical 
regions adjacent to these tags was not likely due to their small size (less than 15 
aa). However, in order to ensure that the appropriate construct was correctly 
incorporated into the cell, we used a RT-PCR strategy that involved primers 
spanning vector and insert sequences that would have been absent in the intact 
receptor construct. Unfortunately, we were unable to measure the protein 
expression of the minigene construct by Western blot due to the lack of an 
antibody that specifically recognized this sequence. 
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Figure 3.1.7. 3ILoop-minigene expression could interfere with the recruitment of specific M3/M5-
interacting proteins to the plasma membrane.  After receptor activation by neurotransmitter 
(ACh), or pharmacological agonists (carbachol), a large number of proteins participate in a 
receptor-cantered scaffolding complex (β-arrestin, kinases, small G protein and others). (A) These 
multiprotein complexes, specifically for each receptor, can be formed by the stable or transiently 
bound with the third intracellular loop and/or the carboxyl terminus of the receptor. (B) 
Expression of the 3ILoop-minigene probably works as inhibitor protein, competing for the proper 
formation of mutiprotein complexes with M3 receptor at membrane level, and resulting in down-
activation of the signal transduction after agonist stimulation.   
 
We found that our minigene-system was able to block receptor-Gq/11 protein 
coupling as much as 45 % with regards to control, as demonstrated by the low 
efficacy in agonist-induced stimulation of [35S]-GTPγS binding. These 
observations are consistent with the finding of other groups using a similar 
experimental approach with other GPCRs, such as δ-opioid, μ-opioid and α2-
adrenergic receptors 347. Upon co-expression of the minigene with the M5 
subtype, we also observed low affinity levels with agonist-stimulated [35S]-
GTPγS, and a reduction in efficacy. These experiments suggest that the minigene 
interferes with the specific Gq/11 protein pool that couples with M3 as well as with 
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M5 subtypes, probably competing with the same pool based on the loop 
specificity. Supporting this observation, we proceeded to show alterations in the 
second messenger’s levels following expression of the minigene in intact cells. 
Agonist-mediated activation of Ins (1,4,5) P3 accumulation was blocked in the 
presence of the minigene in cells expressing either the M3 or M5 subtypes. 
Nevertheless, in the case of the M5 subtype, the inhibitory effect of the 3ILoop 
was less pronounced. We also observed a reduction, not only in the level of 
maximal accumulation of phosphatidylinositol, but also in the potency of 
carbachol concentration-response curves, indicative of a reversible and 
competitive process. Our results are consistent with those previously reported for 
the angiotensin receptor, where the presence of the second intracellular loop of 
the angiotensin AT1a receptor resulted in a change in the angiotensin II 
concentration needed for 50% stimulation for Ins (1,4,5) P3 release 346.  
These observations can be also interpreted as reflecting the specificity in the 
inhibitory effect of the minigene for receptor coupling to a certain G protein pool, 
or alternatively as a result of cross-reactivity between intracellular loops of the M3 
or M5 receptors at the G protein level. Probably, the low sequence homology 
within these receptors cannot account for the significant effect detected for the 
minigene impairment of the receptor-G protein coupling process, suggesting that 
G-protein interaction sites are similar in both receptors 350. This idea is in 
agreement with the observed blockage of Ins (1,4,5) P3 production and G protein 
activation, which did not decrease more than 50% with regards to the wild type, 
considering that multiple distinct structural domains could be involved in this 
interaction, as observed for dopamine and M1 muscarinic receptors 351. An 
alternative explanation is that the relevant domain that interacts with the G protein 
is exposed in the natural receptor, and that the modified minigene does not 
represent or contain this structure, and therefore does not effectively compete for 
the binding with its homologous partner. 
Several lines of evidence show that muscarinic receptors can activate the MAPK 
pathway in a variety of ways, depending on or independent of the classical G-
protein activation pathway 235. One of these mechanisms is PKC-dependent and is 
essential in ERK activation; it can involve βγ-subunits and Gαq/11-subunits. Other 
mechanisms depend more on the phosphorylation state, and are mediated by a 
group of different kinases, like GRK2/3 or CK1α, recruiting β-arrestin scaffold 
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protein or other adaptor proteins respectively. Our experiments showed that cells 
co-expressing the minigene construct completely failed to phosphorylate ERK ½ 
upon receptor activation, suggesting that PKC-dependent mechanisms, as well as 
other mechanisms, which depend upon a group of kinases and accessory proteins, 
have been blocked.  
In addition, using immunoprecipitations, we analyzed whether or not the intact 
receptor, once activated, loses its ability to recruit and unite CK1α or β-arrestin in 
the presence of the minigene in order to further analyze if the dramatic blockade 
of ERK ½ phosphorylation is or is not the result of the inhibitory effects of the 
minigene construct at the level of the G protein. Our experiments showed a loss of 
binding proteins CK1α and β-arrestin, with regard to the wild type receptor. 
Taking this observation into consideration, one plausible scenario is that the 
minigene construct not only disrupts the G subunit association, as confirmed by 
the different experimental approaches undertaken, but can also act as an inhibitory 
or competitor subunit that potentially disrupts the mutiprotein complex formation, 
thus resulting in a dramatically reduced ERK ½ phosphorylation upon receptor 
activation. 
The third intracellular loop is 256 residues long, containing multiple motifs of 
basic and acid residues and some currently recognized functional sequence 
motifs. This primary sequence pattern is not conserved throughout the G protein-
coupled receptor superfamily and not even within the class A rhodopsin-like 
receptor subfamily that represents the closest structurally-related class of GPCR. 
It is possible that this will ultimately constitute a conformational structural motif 
that will be more broadly representative and determine part of the specificity for 
each receptor in these families. However, no structural data is currently available 
to confirm or refute this hypothesis.  
Interacting proteins for such motifs appearing in modular form can be identified 
by affinity purification approaches, such as yeast two-hybrid screening and 
immunoprecipitation. Our current work, in which the minigene construct 
representing the third intracellular loop of the M3 muscarinic receptor specifically 
influences the intracellular signalling of the intact receptor, probably blocking a 
putative multiprotein complex formation, supports the notion that important 
motifs could be present in this region. The fact that this loop is significantly long 
and that it is a recognized site for post-translational modifications should make it 
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an ideal tool for exploring potential molecular partners that might mediate the 
observed effect under different cellular conditions. The use of a TAP-system 
strategy that complements the co-expression experiments of the construct with the 
intact receptor under different physiological condition, together with 
immunoaffinity purification followed by mass spectrometry analysis, is believed 
to be a productive approach to the investigation of protein-protein interactions, 
not only for muscarinic receptors but also for other types of GPCR. As we learn 
more about the molecular details of multiprotein complex formation events, it 
should help unravel the patterns of the interacting proteins important in the 
control and definition of the receptor’s physiological behavior in time and space 
under each cellular condition. 
 
MATERIALS AND METHODS 
 
Materials. [35S]-GTPγS (1,202 Ci/mmol), [3H]-myo-inositol (3,0 Ci/ml) and [3H]-NMS 
(77 Ci/mmol) were from Amersham Biosciences (Germany). FuGene® transfection 
reagent was purchased from Roche (USA). All receptor ligands, protease and phosphatase 
inhibitor cocktails, and all other reagents were purchased from Sigma-Aldrich 
(Germany). The pcDNA3-Flag-GRK2 encoding the bovine G receptor kinase-2 was 
kindly provided by Y. Chen (FUMC, Shanghai, China) and the pcDNA3-Flag-CK1-α 
encoding the human casein kinase 1-α was provided by M. Bini (Palermo University, 
Italy).  
DNA Constructs. The cDNAs of the human M3 muscarinic receptor (kindly provided by 
T. Bonner, NIH, USA) and human M5 muscarinic receptors (provided by D. Bello, ETH, 
Switzerland) were subcloned into the mammalian expression vector pcDNA-3.1-3xHA 
(gift from P. Calvo, SFU, CA) giving the 3xHA-M3-pcDNA and 3xHA-M5-pcDNA 
vectors. Basically, 1.9 and 1.7-kb fragments encoding the human M3, M5 receptors were 
respectively amplified from their cDNAs using the Expand High Fidelity PCR System 
(Roche, USA) with primer pairs (forward: 5’- ACC GAT ATC TTG CAC AAT AAC 
AGT ACA AC-3’; reverse: 5’-CCC TCT AGA CTA CAA GGC CTG CTC GGG TGC-
3’ and forward: 5’- ACC GAT ATT CAA GCT TGG TAC CAC CAT G-3’; reverse: 5’-
CCC TCT AGC CCG GGT AGC TTG CTG TTC CCC-3’). Each fragment was purified 
by agarose gel electrophoresis (Bio-Rad, USA) and then subcloned into the mammalian 
pcDNA3.1-3xHA vector using EcoRV/XbaI.  
3ILoop-minigene construct.  The cDNAs fragment encoding the entire third 
intracellular loop of M3 muscarinic receptor (315 amino acid residues) were subcloned 
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into the InterPlay® mammalian TAP system, pNTAP-B vector (Stratagene, USA), 
resulting in the pTAP-3ILoop-M3 vector. The 3ILoop was amplified from the 3xHA-M3-
pcDNA vectors using the Expand High Fidelity PCR System (Roche, USA) with primer 
pairs (forward: 5’- GCG GAT CCA CTG GAG GAT CTA TAA GG-3’; reverse: 5’- 
GCG AAT TCC TCC TTG ACC AGG GAC ATC C -3’) and spliced into BamHI/EcoRI 
sites of the pNTAP-B vector. The reading frame and PCR integrity of all cloned 
constructs were confirmed by DNA sequencing.  
Cell Culture and Transfection. HEK-293 cells were grown to 70% confluence in 
Dulbecco’s modified Eagle’s medium (DEMEM) supplemented with 10% fetal calf 
serum (FCS) (Invitrogen, USA), 2 mM L-glutamine, 100-IU/ml penicillin and 100-μg/ml 
streptomycin at 37°C in a humidified 5% CO2 incubator. Cells were co-transfected with 
pTAP-3ILoop-minigene and the corresponding human muscarinic plasmid, by means of 
the calcium phosphate precipitation method or using FuGene® transfection reagent 
(Roche, USA). Equivalent amounts of empty vector pcDNA-3.1 were added, in all co-
transfection experiments, to normalize the total amount of cDNA. Cells were harvested 
48 h after transfection and centrifuged at 30, 000g for 30 min to obtain two separated 
fractions (membranes and supernatant). These fractions were frozen as aliquots in 5 mM 
phosphate buffer saline (PBS), pH 7.4, and stored at -80°C until use. 
3ILoop-minigene transcript analysis. HEK-293 cells were washed with PBS 48h post-
transfection, and total RNA was purified using Quick Prep™ total RNA extraction kit 
(Amersham Bioscience, Germany) and subject to RT-PCR (Access RT-PCR system; 
Promega, USA). Primers were selected according to Gene Bank database resource 
(forward: 5’- GCG GAT CCA CTG GAG GAT CTA TAA GG-3’; reverse: 5’- GCG 
AAT TCG ACC AGG GAC ATC C-3) in order to amplify a segment of 541 bp. A RT-
PCR negative control was performed loading DEPC water instead of cDNAs and a 
positive control was performed using G3DPH primers. 
Membrane Preparation and Radioligand Binding Assay. About 48 h after 
transfection, HEK-293 cells were washed twice with cold PBS, harvested and 
homogenized in a binding buffer (25 mM HEPES, pH 7.4, 5 mM MgCl2, 1 mM EDTA), 
using a Polytron tissue homogeniser. Cell membranes were collected by centrifugation at 
20, 000g for 15 min and homogenized as above.  After centrifugation at 40, 000g for 20 
min at 4ºC, the final pellet was resuspended in binding buffer, and membranes were 
either used immediately or frozen in liquid nitrogen and stored at -80 °C until required. 
Protein concentration was determined by using the Bradford protein assay kit (Bio-Rad, 
USA). In order to determine the affinity of NMS for each sample, membranes were 
incubated with different concentrations of [3H]-NMS (ranging from 12.5 pM to 1.5 nM) 
in 5 mM PBS at 25°C for 60 min. The incubations were stopped by filtration through 
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Whatman GF/B filters and washed extensively with ice-cold 40 mM PBS prior to 
scintillation counting. Non-specific binding was determined in the presence of 10μM 
atropine.  
Inositol Phosphate Determination. Transfected HEK-293 cells were labelled for 18–24 
h with [3H]-myo-inositol (Amersham Biosciences, Germnay) at 3,0 Ci/ml in DMEM 
(high glucose, w/o inositol (Invitrogen, USA). After labelling, cells were washed and pre-
incubated for 5 min in PBS at 37 °C, and subsequently incubated in FCS free medium 
with different concentrations of carbachol -or without carbachol- in the presence of 10 
mM LiCl for 5 min. Reactions were terminated by perchloric acid addition. Inositol 
phosphates were extracted and separated on Dowex AG1-X8 columns (Bio-Rad, USA). 
Total labelled inositol phosphates were then counted by liquid scintillation. 
 
[35S]-GTPγS binding assay. HEK-293 cell membranes were diluted in an ice-cold buffer 
containing 10 mM HEPES and 0.1 mM EDTA, 5Mm deoxycholate (pH 7.4) as 
previously described, pelleted and resuspended in a binding buffer consisting of 10 mM 
HEPES, 10 mM MgCl2, and 100 mM NaCl (pH 7.4) at a final protein concentration of 
125 μg/ml. Incubations were conducted in a final assay volume of 1 ml (125µg total 
protein) for 1 h at 30°C in the presence of 1 µM GDP and 0.3 nM [35S]-GTP S (1,202 
Ci/mmol) and the appropriate ligand concentration (carbachol from 1 nM to 1 mM). The 
reaction was stopped by addition of 5 ml of ice-cold buffer containing HEPES/NaOH 
(10 mM) (pH 7.4) and MgCl2 (1 mM), immediately followed by rapid filtration through 
glass fibre filters (Whatman GF/C) presoaked in the same buffer. The filters were washed 
twice with 5 ml of buffer and the radioactivity was measured by scintillation counting. 
Nonspecific binding was determined in the presence of 10 μM GTP S. Assays were 
performed in triplicate.  
MAPK and AKT assay. Co-transfected HEK-293 cells expressing M3 or M5 receptor 
subtypes with or without the 3ILoop-minigene were grown to 80% confluence and 
rendered quiescent by serum starvation overnight prior to MAPK or AKT 
phosphorylation assay; an additional 2h incubation in fresh serum-free medium was 
performed to minimize basal activity. Cells were subsequently stimulated by the addition 
of a medium with or without the muscarinic agonist carbachol. Rapid rinsing with ice-
cold PBS completed the stimulation, and cell lysis was performed during 10 min by the 
addition of 500 µl ice-cold lysis buffer (50 mM Tris-HCL, pH 7.4, 150 mM NaCl, 1% 
TritonX-100, protease and phosphatase inhibitor cocktail). The cellular debris was 
removed by centrifugation at 13, 000g for 5 min at 4°C, and the total protein content was 
measured using BCA Protein Assay Reagent (Pierce, USA). Aliquots corresponding to 5 
μg of protein were mixed with sodium dodecyl sulfate (SDS) loading buffer, applied to 
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12% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and analyzed by Western 
blot. Extracellular signal regulated kinase ½ (ERK ½) and protein kinase B (AKT) 
activation were assayed by incubating PVDF blots with a mouse anti-phospho-ERK ½ 
antibody (Sigma-Aldrich, Germany) and phospho-AKT antibody (New England Biolabs, 
UK) respectively. Control blots were also run in parallel, and probed with rabbit anti-
ERK ½ antibody (Sigma-Aldrich, Germany) and total-AKT antibody that recognized 
both unphosphorylated and phosphorylated forms. The immunoreactive bands were 
visualized using horseradish peroxidase-linked secondary anti-mouse and anti-rabbit 
antibodies (Dako, USA) and SuperSignal West Pico Chemiluminescent Substrate (Pierce, 
USA).  
Immunoprecipitation. In order to immunoprecipitate the wild-type M3 muscarinic 
receptor with its associated proteins, plasmids encoding the HA-M3 receptor and the β-
arrestin-GFP, Flag-GRK-2 or Flag-CK1-α expressing vectors were transiently co-
transfected into HEK-293 cells. 48 h later, cells were serum-deprived for 4 h., then 
exposed to carbachol (20 μM) -or no drug- for 10 min and washed once with PBS before 
being solubilized in immunoprecipitation buffer (PBS, pH 7.5, 1% CHAPS, 0.75% 
sodium deoxycholate, protease and phosphatase inhibitor cocktail). Carbachol was re-
added where appropriate. Extracts were centrifuged at 15, 000g for 15 min at 4°C to 
remove particulate material and precleared with Protein G/A Sepharose (Santa Cruz 
Biotechnology, USA). After centrifugation, the supernatant was transferred to tubes 
containing either rabbit monoclonal anti-HA (Santa Cruz Biotechnology, USA) or 
nonimmune mouse IgG (Sigma-Aldrich, Germany) with the required amount of Protein 
G/A Sepharose suspension, before rolling at 4°C overnight. Beads were collected by 
centrifugation and washed twice with immunoprecipitation buffer before 35 µl of 2x 
Laemmli buffer (2% SDS, 5% mercaptoethanol, 20 Mm Tris, pH 7.4) was added per ml 
of original supernatant. After SDS-PAGE and electroblotting, Western blot was carried 
out on the sample and the original supernatants to detect immunoprecipitated proteins and 
monitor input levels. The primary antibodies used were an anti-Flag M5 mouse 
monoclonal antibody (Sigma-Aldrich, Germany) and a rabbit polyclonal anti-GFP (gift 
from Y. Mesa; UB, Spain), followed by preabsorbed secondary antibodies to horseradish 
peroxidase (Santa Cruz Biotechnology, USA). Bands were visualized by ECL (Kodak, 
USA) and then measured by quantitative densitometry. 
Data analysis. All binding data were analysed using the commercial program GraphPad 
PRISM 4.0 (GraphPad Software, USA). In the [35S]-GTPγS binding assay, basal binding 
was defined as [35S]-GTPγS binding in the absence of agonist. For each agonist 
concentration, the percentage of binding over basal was calculated to determine the 
agonist-stimulated [35S]-GTPγS binding. Data were fit to a sigmoidal dose-response 
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curve. For statistical evaluation of the biochemical data, unless otherwise specified, one-
way analysis of variance (ANOVA) was used. Group differences after significant 
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ABSTRACT 
G protein-coupled receptors (GPCRs) constitute one of the most important 
families of membrane receptors through which cells respond to extracellular 
stimuli; they likely function in the context of a signal transduction complex. The 
identification and analysis of their components provides insight into a better 
understanding of these receptors’ function and regulation. We used tandem-
affinity purification (TAP) and mass spectrometry as a systematic approach to 
characterizing multiprotein complexes in the muscarinic receptor family as a test 
case. To overcome the limitations of detergent solubilization, we developed a 
strategy in which receptors are co-expressed with a cytoplasmic minigene 
construct, encoding the third intracellular loop and the C-terminal tail tagged to 
the TAP-cassette of each receptor subtype.  Numerous protein complexes were 
identified, including many new interactions in various signalling pathways and 
apoptotic responses; some of which were common to both receptors, while others 
were specific for each subtype. Systematic identification data set together with 
interactions reported in the literature revealed to us a high degree of connectivity, 
allowing for the first time an outline of the muscarinic interactome as a network 
of protein complexes at a level of organization beyond binary interactions. This 
comprehensive map of networks contains fundamental biological information and 
offers context for a more reasoned and informed approach to drug discovery and 
muscarinic receptor subtype specificities. 
 
  




GPCRs constitute the largest family of membrane receptors through which cells 
communicate with each other and respond to a wide variety of extracellular 
stimuli 352. Their medical importance is reflected in their being targeted by about 
half of the drugs prescribed for human diseases, making them extremely valuable 
targets for the pharmaceutical industry 353. In humans, this family of receptors has 
been proposed to contain approximately 1000 members that control physiological 
processes, such as neurotransmission, cellular metabolism, secretion, cell 
differentiation, and growth 1.  
The prototypic topology of GPCRs consists of seven transmembrane domains 
linked by three extracellular and three intracellular loops 354. Amino acids within 
the extracellular and/or hydrophobic 7TM core of the receptor are involved in 
ligand binding, allowing the initiation of conformational change within the 
receptor upon agonist stimulation. These conformational changes are then 
propagated to the intracellular domains of the receptor 355. This results in G 
protein binding and activation, as well as initiation of intracellular events by 
multiprotein complex reorganization356. 
As GPCR-researchers enter the so-called “Post-Genomic” era, they have begun to 
embrace the exciting opportunity of investigating protein-protein interaction and 
multiprotein complex reorganization in high-throughput experiments 357,358. 
However, our knowledge regarding the identity of the interacting proteins of 
specific complexes is limited, and is based on selected biochemical approaches 
and genetic analyses. The only comprehensive protein-interaction studies on 
GPCRs are based on ex vivo and in vitro systems, such as two-hybrid systems and 
proteomics analysis of GPCR-associated protein complexes using receptor-
specific antibodies 359-361. They are limited by the availability of adequate tools 
for each GPCR, and need to be integrated with more physiological approaches, 
which have been fundamental for the biological understanding of their function. 
Despite this limitation, several interacting proteins of GPCRs have been recently 
identified 362-364. Most of these proteins interact with the C-terminal domain via 
their PDZ, Src homology 2 (SH2) and SH3, pleckstrin homology, or Ena/VASP 
homology (EVH) containing domains 359. And in other receptors is the third 
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intracellular loop, which is related to and contains sites that may be implicated in 
protein interactions 365. 
Recently, a tandem affinity purification (TAP) method has been successfully used 
for high throughput identification of soluble proteins engaged in interacting 
complexes in bacterial, yeast and mammalian cells 366-368. This strategy allows for 
fast purification with a high yield of protein complexes under native conditions 
and overcomes the aforementioned limitations 369. In essence, this method is 
based upon the two-step affinity chromatography purification of complexes 
formed in intact cells using a TAP-cassette tagged to the protein concerned 370. 
The protein of interest can be expressed in mammalian cells where subcellular 
localization and post-translational modifications are conserved. In addition, the 
recruitment of protein complexes may be induced by treatment of the cells with 
variety pharmacological compounds or under different physiological conditions 
371,372. 
As part of a broader effort to define protein complexes within GPCRs, and taking 
into consideration previous experimental evidence showing that co-expression of 
intracellular loops of GPCR  -or peptides derived from these loops- could mimic 
the intact receptor, coupling with and activating the relevant G protein or 
interacting with the same molecular partners 347,373-375. We modified a TAP 
method suitable for the purification of associated proteins of the muscarinic 
receptor family, chosen as a model. Essentially, the idea was to co-express a 
cytoplasmic minigene construct (TAP cassette tagged to the 3Iloop and C-
terminal tail of each receptor subtype) along with the intact receptors in human 
SK-N-MC neuroblastome cells, and, after large-scale tandem affinity purification 
of the minigene, identify the interacting protein by LC-MS/MS (An approach that 
we termed Intracellular Loop Tandem Affinity Purification (Iloop-TAP)).  
Using this approach, which provides a global characterization of the interacting 
protein with the intracellular domains of membrane-bound receptors, we have 
performed a comprehensive analysis of the muscarinic receptor interactome as a 
network of protein complexes at an organizational level, a model system relevant 








ILoop Tandem affinity Tag for Purification of Muscarinic receptor 
Interacting proteins 
The ILoop-TAP strategy for purifying and identifying the muscarinic receptor 
associated proteins is illustrated in Figure 3.2.1. We used as TAP tag support the 
modified version TAP system commercialised by Stratagene, composed of a 
Calmodulin binding peptide sequence followed a Streptavidin binding peptide. 
This TAP system combined two high-affinity purification steps as the basic 
concept. This is similar to strategies developed previously, but differs from these 
strategies in the lack of a mild elution using a site-specific protease, although 
protein complex purification with high efficiency and specificity is guaranteed. 
To use a tandem affinity purification that is easy compatible with receptor 
membrane proteins, we chose to construct the minigene tagged to the TAP tag 
instead of the WT receptor (pTAP-mini-M1/5 vectors).  For each receptor subtype, 
only the large third intracellular loop and the C-terminal tail were tagged to the 
TAP cassette. As described previously, this resulted in a vector-containing 
minigene proteins that are soluble expressed and keep their capacity to bind 
interacting proteins by mimicking the endo-facial side of the receptor.  
Each pTAP-mini-M1/5 vectors were co-expressed along with each receptor 
subtypes in human SK-N-MC neuroblastome cells following TAP purification 
procedures. Amicon concentrated elutes proteins were separated by one-
dimensional gel electrophoresis, and proteins were detected either by Coomassie 
Blue (1x109 cell) or by silver staining (1x 107 cells). Whereas only a few bands 
were visible in non-transfected cells, several specific protein bands were 
reproducibly present in each specific-subtype expressing cells. Individual bands 
were excised and digested with trypsin, and the resulting peptides were analysed 
by nano-LC-MS/MS and identified by database search algorithms (Mascot 
software in Swiss-Prot databases).  
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Figure 3.2.1 The ILoop-TAP strategy for identification of muscarinic receptor family interacting 
proteins. a, Schematic representation of minigene construction. Stratagene TAP cassette is 
inserted at the N-terminal of a given 3ILoop and C-terminal tail. b, Overview of complexes 
purification and sample processing. c and d, examples of TAP complexes purified from different 
receptor subtypes on denaturing protein gels and stained with Coomassie and fragment spectra of 
selected peptide ion. e,  Bioinformatic tools used for protein analysis. The MS/MS data was 
analysed and matched to all human protein sequences in the Swiss-Prot database using the 
MASCOT search engine following formatting for import into BIND, the Biomolecular Interaction 
Network Database. The arbitrary molecular interaction network file obtained was then visualized 
as a connectivity organic distribution network using Cytoscape software.  
 
To evaluate the purification efficiency of the receptor complexes, we monitored 
each purification step by immunoblotting. As shown in Figure 3.2.2, TAP-tagged 
minigene-M5 was bound efficiently on calmodulin resin because there was no 
visible amount left in the flow-through after the binding. Proteins eluted from the 
calmodulin resin were subsequently incubated with immobilized Streptavidin 
resin for the second purification step. And the TAP-tagged minigene M5-
containing complexes were efficiently captured on Streptavidin resin as shown in 
Figure 3.2.2, lane 5 (flow-through after Streptavidin binding), demonstrating that 
the TAP-tagged minigene-M5 can be expressed and purified efficiently with the 
condition established in our experiments. Similar results were observed from cells 
expressing other receptor subtypes. 
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Figure 3.2.2. Small-scale ILoop-TAP-M5 purification. The M5 muscarinic receptor complexes 
were efficiently isolated using two-step affinity purification as shown by immunoblotting using 
anti-CBP antibody. Lane 1, Santa Cruz Biotechnology  molecular weight; lane 2, without; lane 3, 
cell lysate; lane 4, unbound fraction after incubation with streptavidin resin; lane 5, wash with 
streptavidin binding buffer; lane 6 elution from streptavidin resin; lane 7, unbound fraction after 
binding to calmodulin resin. The samples were separated by 15% SDS-PAGE, and the minigene 
was detected by western blot using the anti-CBP antibody.  
 
Categorization of detected proteins 
To detect proteins that specifically interact with the intracellular loops of each 
receptor subtype, we performed differential analyses of gel protein patterns 
obtained with each specific (TAP tagged-minigene) and mock (TAP alone) baits. 
A comparison of protein patterns in the gels obtained indicated a selective 
recruitment of different proteins. Also present were several abundantly 
mitochondrial and ribosomal origin proteins unambiguously identified by MS/Ms 
and present in all lanes (control, M1 to M5), which we classified as non-specific or 
contaminant proteins (see Appendix 3.1). We also decided to pragmatically 
exclude from our list purified heat-shock proteins, as these proteins appeared with 
higher frequencies in our analysis. However, it’s important to take care when it 
comes time to interpret this data, as the active role of heat-shock proteins in the 
function of some GPCRs has been reported 376-378  
We generated 252 samples for mass spectrometry and subsequently identified 142 
unique proteins. Ontology classification of identified peptides revelled proteins of 
various subcellular compartments and functions, most of them known to have an 
important role in GPCR signalling (Figure 3.2.3 a, b). The majority of the 
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peptides identified were from proteins known be localized to the plasma 
membrane or cytosol, followed by protein localized in the Reticulum and Golgis 
apparatus. In addition, proteins identified from mass spectrometric determination 
yielded 62% signalling proteins in agreement with classical function of GPCR as 
transducers.  
Figure 3.3.3 c, showing an average of 50% of proteins identified as Gq/11 and 30% 
of those identified as Gi/0 muscarinic receptor associated proteins. Identification of 
specific associated proteins for each receptor subtype from 7 independent 
purifications resulted in mayor specificities for M4 and M3 subtypes, followed by 
M2, M5 and M1 (Figure 3.2.3 d).  
 
 
Figure 3.2.3. Statistic and distribution of protein identified. Numbers outside pie charts represent 
the percentages of total proteins. a,  classification of proteins according to function; b, subcellular 
localization; c, number of proteins per receptor subtypes; d, number of specific proteins per 
receptor subtypes.  
 
Sensitivity, specificity and reliability of ILoop-TAP approach 
Of the 142 purified associated proteins, approximately 80% presented as specific 
interacting proteins, showing that the ILoop-TAP method is very efficient for the 
large-scale retrieval and identification of receptor interacting proteins. Although it 
is difficult to estimate the percentage of interaction proteins, which are covered by 
our data set, a rough estimation, can be made based in the observation that many 
identified proteins (at least 42 %) are likely to interact with other GPCRs and 
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have been associated with their function (crude estimate). We also observed that 
the method failed to detect some known interactions (RGS, GRK). Proteins, 
which likely participate in transient interaction, low stoichiometric complexes, 
and/or interactions that occur only in specific physiological states that were either 
not present or under-represented in our experimental conditions probably cannot 
be identified using this method.  
There are several possible reasons why the remaining 20% of identified proteins 
are non-specific proteins. Particular proteins like ribosome’s protein are 
ubiquitously expressed in the cytosol, and can persistently interfere during 
purification. In other cases, the 12K (relative molecular mass Mr 12,000) TAP tag 
probably binds with some degree of affinity to some proteins. Quality and 
reproducibility of the results obtained for purifications were assessed by 
systematic comparison of our data to the literature (see below) and the 
purification of each receptor complex at least four times. 
 
Dynamic of protein complexes 
It is becoming increasingly clear that GPCRs exist as a large complex of proteins 
involving dimers or oligomers of receptor and associated proteins that, depending 
in their variable composition, determine their function. The ILoop-TAP strategy 
revealed a dynamic composition of muscarinic receptor subtype interactome. The 
dynamics of complex composition are well illustrated by the cellular signalling 
complexes formed around each subtype (see Appendix 3.2). For instance, TAP-
mini-M3/5 purification resulted in the identification of the known G-protein-
coupled receptor (GPCR)-kinase interacting proteins 1 (GIT1), and of the three 
small GTPase, RhoA, Rac1 and Cdc42. GIT1 are ubiquitous multidomain 
proteins involved in diverse cellular processes through interactions with proteins 
including ARF, Rac1 and Cdc42, GTPases, p21- activated kinase (PAK), PAK-
interacting exchange factor (PIX), the kinase MEK1, phospholipase Cγ (PLCγ) 
and paxillin 379. The TAP-mini-M1/3/5-purified complexes were found to 
additionally contain the multidomain paxillin protein, known to participate in the 
organization of actin cytoskeleton and cell motility 380, revealing enough plasticity 
among the different complexes and a cascade of recruitments and association, 
which take the receptor as a reference point.  
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A particular complex is not necessarily of invariable composition nor are all its 
building blocks uniquely associated with that specific complex. Figure 3.2.4 
shows small-scale TAP-mini-M1 complex purification before and upon agonist 
stimulation.  Comparing identified proteins in both cases revealed the presence of 
distinct bands corresponding to different associated proteins. Using the Iloop-TAP 
approach, we determined that some associated proteins (likely core components) 
could be identified and validated independently of cellular state. Whereas more 
dynamic, perhaps regulatory components, may be present differentially depending 
cellular pharmacological treatment or physiological conditions. 
 
Figure 3.2.4. Purification of TAP-mini-M1 associated complexes. Approximately 1x 10 7 SK-N-
MC-TAP-mini-M1 cells (with or without carbachol 10μM treatment) and SK-N-MC-TAP cells 
(Mock) were submitted to the ILoop-TAP strategy protocol. Elutes were separated by 15% SDS-
PAGE gel and proteins were detected by silver staining.  
 
Examples of proteins that have been identified as associated proteins present 
before and upon agonist stimulation have been α-synuclein, serine/threonine-
protein phosphatase 2A (PP2A) and, surprisingly, the Regulatory G protein 
Signalling 2 (RGS2).  RGS proteins have previously been reported to interact 
with GPCRs and their heterotrimeric G-proteins. They were selectively recruited 
upon agonist stimulation of the plasma membrane by G proteins and 
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correspondingly by receptors that activate those G proteins. However, based on 
our results, it seems that M1 muscarinic receptors keep their association with 
specific RGS2 proteins independently of receptor activation. We also identified a 
wide number of proteins that were selectively recruited only upon agonist 
stimulation (see Appendix 3.2), thus indicating that signalling 
efficiency/specificity for mAChRs is determined in part by dynamics change in 
multiprotein complexes reorganization.  
Network map of Muscarinic receptor Interactome 
After assigning individual proteins to each receptor subtype complex, we 
investigated relationships between complexes to understand the integration and 
coordination of the muscarinic receptor process. We represented these 
relationships by linking complexes that share components (Figure 3.2.5). By 
plotting all the data of set interactions described here, together with interactions 
detected by other biochemical methods reported in the literature, we obtained a 
comprehensive view of the network of complexes.  
Connections in this network not only reflect the physical interactions of 
complexes, but may also represent common regulation, localization, turnover or 
architecture. All data sets were imported into BIND database, a database built 
around an ASN.1 specification standard that stores all relevant information about 
the interacting partners, including experimental evidence for the interaction, 
subcellular localization, biochemical function, associated cellular processes and 
links to the primary literature. Using Cytoscape software and the export file 
containing a arbitrary molecular interaction network obtained from the BIND 
database, we constructed and visualized a single large network of muscarinic 
receptor interactome. 
By analysing this large network containing 400 interactions among 100 proteins, 
as well as several smaller networks, we could detect some interesting features. 
First, receptors of similar functions tend to cluster together within the network, 
suggesting that sharing of components reflects functional relationships. Second, 
similar behaviours can be observed with assessor proteins that share a common 
subcellular localization. And third, the network of interaction reveals sets of 
interactions that link cellular process and cross-connections reflecting the central 
role of some proteins in regulating other cellular processes. 
 






Figure 3.2.5.  The muscarinic receptor family interactome. Graphs were generated automatically 
by organic algorithm using Cytoscape software.  Line thickness represents the number of 
experiments describing a given interaction and illustrates the connection between proteins. Lines 
are color-coded according to the experiments: ILoop-TAP results (red), reported in the literature 
(black). Muscarinic receptors subtypes nodes are highlighted in red. Each protein is labeled using 
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Validation of selected identified proteins 
Functional protein–protein interactions were assessed by co-immunoprecipitation 
experiments. In spite of the fact that a comprehensive, step-by-step verification of 
all proteins in our data set will be undertaken using complementary methods, we 
selected and analysed here only several uncharacterised muscarinic-interacting 
proteins for their ability to form a complex with muscarinic receptors. 
GIT-1 and paxillin were selected because of their capacity to interact with each 
other and are involved in diverse cellular processes. While AKAP-150 has been 
described as a scaffold molecule of the prototypical β2-adrenergic receptor, 
orchestrating the interactions of various protein kinases (including tyrosine 
kinases), protein phosphatases (e.g. calcineurin) and cytoskeletal elements 
enabled multivalent signalling. 
Lysates of SK-N-MC cells exogenously expressing the 3xHA-M2/3/5 muscarinic 
receptor subtype were subjected to immunoprecipitation with anti-HA beads and 
analysed by Western blotting with the anti-GIT-1, anti-paxillin, anti-FAK 
antibodies. GIT-1 and paxillin did not coimmunoprecipitate with M2 muscarinic 
receptor subtypes in correspondence with results obtained by ILoop-TAP 
approaches (Fig. 3.2.6). However, bands corresponding to each interacting protein 
were observed in cells expressing M3 and M5 subtypes. Detection of the Focal 
Adhesion kinase (FAK) protein in immunoprecipitated Gq/11 receptor subtypes is 
in agreement with previous reports, which described paxillin and GIT protein as 
multiplatform components that can actively recruit tyrosin kinases such as FAK 
protein (data not shown). This demonstrates dynamic complex formation around 
muscarinic receptors by the cascade recruitment of theses scaffold proteins.  
A similar set of experiments was performed using immunoprecipitation and 
Western blot analysis with the anti-AKAP antibody. Like GIT-1 and paxillin, 
AKAP copurified with Gq/11-coupled receptor subtypes. However, it did not 
coimmunoprecipitate with the M2 muscarinic receptor subtype, a Gi/0-coupled 
receptor (Figure 3.2.6). This confirms a specific interaction also reported by TAP 
purification.  
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Figure 3.2.6. Interaction of the intact muscarinic receptor subtypes with endogenous selected 
interacting proteins (GIT-1, paxillin, AKAP79). SK-N-MC cells transiently transfected with 
pcDNA3-3xHA-M2, or pcDNA3-3xHA-M3, or pcDNA3-3xHA-M5 were lysed in Nonidet-p40 buffer, 
and the receptor was immunoprecipitated as described under “Material and Methods”. The 
membrane transfer was first probed with an anti-GIT1, anti-Paxillin or anti-AKAP79 antibody 
followed by striping and reprobing with anti-HA monoclonal antibody to confirm effective 
receptor immunoprecipitation. The input and supernatant (Supt.) lanes represent ¼ of the lysate 
volume used for each immunoprecipitation (IP). The data are representative of two to three 
independent experiments.  
 
Previous experiments have demonstrated that muscarinic acetylcholine receptor-
stimulation suppress M- type potassium channel current, inhibition which is 
mediated by the multivalent AKAP-150 protein. This protein is particularly 
interesting because, in addition to its role in the inhibition of current channels, it 
also associates with protein kinases, phosphatases and cytoskeleton elements 




To assign cellular functions and identify new interacting proteins of GPCRs, and 
to understand the context in which receptor-protein interactions operate, several 
large-scale approaches have been undertaken. These include co-
immunoprecipitation experiments, yeast two-hybrid screens 381, resonance energy 
transfer studies 382, protein ship and computational in silico methods 383.  
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The ILoop-TAP proteomic approach presented here may well contribute to the 
largest analysis of protein-protein interaction in GPCRs.  Maximizing sensitivity 
and reproducibility over other methods to detect receptor binding partners and 
using muscarinic receptor family as a model system, we identified 148 different 
interacting proteins, of which 57 had been detected previously as muscarinic 
receptor-binding partners. 
The GO classification of the proteins identified by Iloop-TAP strategy revealed 
some interesting avenues of further consideration: first, the presence of 
heterotrimeric G proteins in all receptor subtype-associated protein purifications. 
Consistent with the known coupling of muscarinic receptors to G proteins, we 
identified four Gα-protein for M1/M3/M5 receptor subtypes (Gα-q, Gα-11, Gα-12 
and Gα-13) and three Gα-i isoforms (Gα-i1, Gα-i2 and Gα-i3) for M2/M4 receptor 
subtypes, as well as two different Gβ isoforms (Gβ1 and Gβ4) and three Gγ 
isoforms (Gγ2, Gγ7 and Gγ11). This demonstrates that our approach can clearly 
be used as a method for large-scale protein-protein interaction detection, not only 
for the muscarinic receptor family, but also for other GPCRs. Second, we 
identified several cytoskeletal proteins, including those associated with GPCRs’ 
reorganization and regulation (α- and β-tubulin, filamin A, annexin A2, dynamin 
2, clathrin, IQ-GAP1/3 and paxillin), some of them existing in a common 
complex with specific receptor subtypes. This suggests that muscarinic receptors 
selectively bind to different structural components in the cell and may have a role 
in receptor internalisation and the regulation of cell spreading, migration, and the 
attachment at sites of focal adhesion 384. In support of this notion are recent 
reports pointing toward different mechanisms of internalisation using M2 and M4 
receptors depending of the cellular type 385,386, as well as the active roles of 
tubulin and microtubule reorganization in PLD activation mediated by Gq/11 
muscarinic receptor subtypes 387. More interestingly, using drugs that stabilized or 
destabilized microtubule organization, it was found that the activation of 
muscarinic leads to modulation of ion currents in cardiac myocyte cells 388, 
functions mediated by the direct interaction of the receptor and the G protein with 
the microtubule cytoskeleton. The third and last consideration is the identification 
of several muscarinic receptor subtypes-specific signalling proteins such as ADP-
ribosylation factors, elongation factor 1-A (eEF-1A), oncogenic SET protein, 
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Rac1, and different isoforms of phospholipase C and the protein kinase C (β-1, β-
3, γ and α, δ, τ respectively). Interestingly, the small GTPases Rac1 has been 
shown to function downstream of M1 and M3 receptors. In the context of Rac 1 
activity but not RhoA activity, M3 muscarinic receptor-mediated activation of 
PLC and PKC triggers cell death 389. The ADP-ribosylation factors are members 
of the Arf arm of the Ras superfamily of guanosine triphosphate (GTP)-binding 
proteins. Physiologically, Arfs regulate membrane traffic and the actin 
cytoskeleton. However, Arf function likely involves many additional biochemical 
activities. Arf activates phospholipase D and phosphatidylinositol 4-phosphate 5-
kinase with the consequent production of PA and PIP2, respectively 390. It has 
been shown that vasopressin V2 receptor and M2 muscarinic receptor processing 
and trafficking are under ARF-6 control 391. Also, Arf 1 and 6 mediate PLD1/2 
activation by M3 muscarinic receptor 334. eEF-1A and other elongation factors 
have been reported to modulate M4 muscarinic receptor subtype function by direct 
interaction with the receptor 392,393. Several serine/threonine phosphatases 
participate in the dephosphorylation of activated GPCRs. Phosphatases of the 
PP2A and PP2B subfamilies have been reported to target GPCRs. M1 receptor 
subtypes stimulate the formation of a multiprotein complex centred on TRPC6 
channels where PP2B plays an active role in the disassociation of the muscarinic 
receptor from the complex 394.  
The most important outcome of our study is the possibility to study and identify 
specific interacting proteins under native conditions. Although we used only one 
set of experimental parameters here for the evaluation of complex composition, 
we will, in the future, systematically modify experimental parameters (both 
pharmacological and physiological conditions) to evaluate the impact of a 
changing environment on complex variability. These studies should help to 
elucidate the dynamics of complex assembly and disassembly for each receptor 
subtype. Moreover, it may be a starting point in deciphering receptor specifies and 
a molecular context for the choice and evaluation of drug targets. 
Another important outcome of our experiments is that, comparing the 
experimental results in the literature with our data-set, we were able to construct a 
muscarinic receptor family network, which allowed us to group interacting 
proteins into cluster complexes. The network that resulted is a functional 
description of the muscarinic receptor interactome at a higher level of 
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organization and revealed some interesting information. Although comparison of 
our data set with literature is straightforward, it is important to keep in mind that 
our IloopTAP approach yields complexes composition data that, in any case, 
produces binary interactions, just as the results from two hybrid methods. This 
supports the view that receptor complex formation is more than the sum of binary 
interactions. 
However, binary analysis methods are of exceptional value for the detection of 
pairwise and transient associations of GPCRs. The success of our approach in the 
characterization of receptor complexes relies on the conditions used for the 
assembly and retrieval of the complexes. These include localization and post-
translational modifications in a manner that closely approximates normal 
physiology. Therefore, because the ILoopTAP method does not provide 
information on the orientations of complex components, complex characterization 
by two-hybrid analysis, or resonance energy transfer methods are ideally 
complementary.  
 In summary, our ILoopTAP protocol allowed a relatively fast large-scale 
purification of GPCR-associated proteins under native conditions by mass 
spectrometry with low number of non-specific proteins. Specific interacting 
proteins from each receptor subtype were identified systematically, representing a 
major methodological advance in the identification of GPCR-interacting protein 
complexes. In addition, collected data allowed for the first time the construction 
of a muscarinic receptor network (interactome), reflecting receptor complex 
properties and tendencies. Through the 'interactome' concept, we are able to 
propose signal roles for interacting partners that had not been previous described. 
This methodology biochemical and theoretical approach can be used 
systematically in the future for the understanding and analysis of other classes of 
receptor and subfamilies of GPCR.  
 
MATERIALS AND METHODS 
 
Materials. [[3H]-NMS (77 Ci/mmol) were from Amersham Biosciences (Germany).  The 
FuGene® transfection reagent was purchased from Roche (USA). The cDNAs of the 
human M1 and M4 muscarinic receptor were kindly provided by F. Ciruela (UB, Spain), 
human M3 muscarinic receptors was provided by T. Bonner (NIH, USA), and human M2 
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and M5 muscarinic receptors was provided by D. Bello (ETH, Switzerland). The 
InterPlay® mammalian TAP system, pNTAP-B vector was purchased from Stratagene 
(USA). Mouse anti-paxillin monoclonal antibodies were purchased from Calbiochem. 
Rabbit anti-GIT1 monoclonal antibodies were purchased from Transduction 
Laboratories. Mouse anti-AKPA79 monoclonal antibodies and rabbit anti-HA 
monoclonal antibodies were purchase from Santa Cruz Biotechnology. Goat anti-mouse 
and anti-rabbit secondary antibodies were obtained from DAKO (Glostrup, Denmark). 
All receptor ligands, protease and phosphatase inhibitor cocktails, and all other reagents 
were obtained from Sigma-Aldrich (Germany).  
DNA constructs. The cDNAs encoding the entire 3ILoop and the C-terminal tail of the 
each human muscarinic receptor subtypes (M1-M5) were subcloned into the InterPlay® 
mammalian TAP system, pNTAP-B vector (Stratagene, USA) resulting in the pTAP-
mini-M1/5 vectors. Basically, the fragments encoding the 3Iloop and C-terminal tail of 
human M3 to M5 receptors were amplified from their cDNAs using the Expand High 
Fidelity PCR System (Roche, USA) with their respective primer pairs (see supplementary 
information Table 1) and spliced into BamHI/EcoRI sites of the pNTAP-B vector after 
agarose gel electrophoresis (Bio-Rad, USA) fragment purification. The reading frame and 
PCR integrity of all cloned constructs were confirmed by DNA sequencing.  
Cell Culture and Transfection. SK-N-MC neuroblastome cells were grown to 70% 
confluence in Dulbecco’s modified Eagle’s medium (DEMEM) supplemented with 10% 
fetal calf serum (FCS) (Invitrogen, USA), 2 mM L-glutamine, 100-IU/ml penicillin and 
100-μg/ml streptomycin at 37°C in a humidified 5% CO2 incubator. Cells were co-
transfected with pTAP-mini-M1/5 and the corresponding human muscarinic plasmid, by 
means of the calcium phosphate precipitation method or using FuGene® transfection 
reagent (Roche, USA). Equivalent amounts of empty vector pcDNA-3.1 were added, in 
all co-transfection experiments, to normalize the total amount of cDNA. Cells were 
harvested 48 h after transfection and collected by centrifuge at 5 000g for 5 min. This 
fraction was frozen and stored at -80°C until needed. 
Purifying the protein complexes. All purification steps were conducted at 4 °C in the 
presence of a protease and phosphatase inhibitor mixture (Roche Applied Science) and 
using the Interplay TM TAP Purification kit following the instructions of the manufactures 
(Stratagene, USA). Briefly, for large-scale experiments, carbachol treated and untreated 
1x109 SK-N-MC cells were resuspended in lysis buffer and subjected to successive 
rounds of freeze-thawing (dry ice/ -80°C/cold water). The supernatant was recovered 
after centrifugation at 16,000 x g for 10 min and incubated under rotation for 4 h with 
washed Streptavidin resin (50 μl of resin by 1ml of supernatant). The resin was colleted 
by centrifugation at 1,500 x g for 5 min and washed three times with 1 ml of Streptavidin 
 Third intracellular loop...  
 108
binding buffer (SBB), resuspended into 100 μl of Streptavidin elution buffer (SEB), and 
incubated for 30 min to elute the protein complexes. The supernatant was collected and 
mixed with 2μl of Streptavidin supernatant supplement and 400 µl of calmodulin binding 
buffer (CBB) per 100 µl of supernatant. It was then incubated for 2 h under rotation with 
25 µl of calmodulin resin per 500 µl of the eluted following centrifugation and washed 
five times using 1 ml CBB. Retained proteins from this second purification step were 
eluted after 30 min of incubation with a 100-µl calmodulin elution buffer (CEB). Elutes 
from three successive purifications were pooled together and concentrated with an 
Amicon Ultra-4 10 000 MWCO centrifugal filter device (Millipore). A sample buffer was 
added to the concentrated sample proteins, which were then separated on a 10% 
SDSPAGE gel and visualized with a colloidal Coomassie staining kit (Invitrogen). 
Mass Spectrometry and Protein Identification. Coomassie Blue-stained bands were 
excised and subjected to in-gel trypsinization as previously described [17]. Digestions 
were carried out overnight at 37 C with sequencing grade trypsin (Promega, USA). 
Resulting peptides were extracted under basic and acidic conditions and subjected to LC-
MS/MS analysis. Nanoflow LC was performed using an Ultimate HPLC system (LC 
Packings, San Francisco, USA) at a flow rate of 200 nL/min over Zorbax SB-C18 reverse 
phase resin (Agilent, Wilmington, USA) packed into 75-µm inner diameter PicoFrit 
columns (New Objective, Woburn, USA) using a 0–50% linear acid gradient of solvent B 
in 50 min (solvent A was 0.2% formic acid in 5% acetonitrile, and solvent B was 0.2% 
formic acid in 90% acetonitrile). The LC effluent was electrosprayed into the sampling 
orifice of a QSTAR quadrupole-TOF mass spectrometer (ABI/MDS Sciex, Concord, ON, 
Canada), which operated to collect the MS/MS spectra in a data-dependent manner. The 
MS/MS data was analysed and matched to all human protein sequences in the Swiss-Prot 
database using the MASCOTsearch engine (Matrix Sciences, London, UK) [18]. 
Searches were performed without constraining protein molecular weight or isoelectric 
point. Cysteine carbamidomethylation, methionine oxidation and one missed trypsin 
cleavage were set as variable modifications.  Identification was considered positive if the 
protein was identified with at least one peptide with an ion score greater than the Mascot 
significance threshold of 36 (p < 0.05). For the protein with a score close to the threshold 
value, the identification was confirmed by manual interpretation of corresponding 
MS/MS data. 
As a consequence of both isolation methods used to recover protein complexes from 
concentrated extracts and the sensitive mass spectrometry used to identify proteins in 
each bands, we detected non-specific contaminants in each purifications. These recurrent 
background species were filtered from the dataset, taking into consideration two criteria: 
structural components of the ribosome and mitochondrion, which were detected in many 
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preparations (see Supplementary Table), and all proteins that detectably bound to TAP-
system alone.  
Network Management. To gain a more comprehensive view of muscarinic receptor 
interactome, interaction data from TAP experiments was combined with interaction 
detected by other biochemical methods and reported in the scientific literature. All data 
was searched using PreBIND (http://bioinfo.mshri.on.ca/prebind/), a support vector 
machine and natural language-processing-based algorithm that can identify publications 
that describe protein-protein interactions. Interactions found in this way were manually 
verified by reading the original abstract. The resulting data sets containing non-redundant 
interactions, combined with our experimental results, were formatted for import into 
BIND, the Biomolecular Interaction Network Database. BIND is built around an ASN.1 
specification standard that stores all relevant information about the interacting partners, 
including experimental evidence for the interaction, subcellular localization, biochemical 
function, associated cellular processes and links to the primary literature. BIND is an 
open source public database implemented by the Blueprint consortium and is freely 
available at http://www.bind.ca and can export an arbitrary molecular interaction network 
as a Cytoscape network file. Visualization and connectivity distribution of the muscarinic 
receptor interactome network was calculated using the Cytoscape software by 
partitioning the network by node degree (protein).  
Validation of the Selected Specific Interacting Proteins. Several newly identified 
putative interacting proteins were validated by co-immunoprecipitation experiments. 
Plasmids encoding the HA-M2, HA-M3 or HA-M5 receptors were transiently transfected 
into SK-N-MC cells. 48 h later, cells were serum-deprived for 4 h. They were then 
exposed to carbachol (20 μM) for 10 min and washed once with PBS before being 
solubilized in immunoprecipitation buffer (PBS, pH 7.5, Nonidet P-40, DTT 2mM, 
phosphatase inhibitors ( NaF 50 mM, Na3VO4 0,1mM, Na4P2O7 10 mM, EDTA 5 mM, 
EGTA 5 mM), and protease inhibitor complete (Roche Diagnostics). Extracts were 
centrifuged at 15, 000g for 15 min at 4°C to remove particulate material and precleared 
with Protein G/A Sepharose (Santa Cruz Biotechnology, USA). After centrifugation, the 
supernatant was transferred to tubes containing either rabbit monoclonal anti-HA (Santa 
Cruz Biotechnology, USA) or nonimmune mouse IgG (Sigma-Aldrich, Germany) with 
the required amount of Protein G/A Sepharose suspension, before rolling at 4°C 
overnight. Beads were collected by centrifugation and washed twice with 
immunoprecipitation buffer before 35 µl of 2x Laemmli buffer (2% SDS, 5% 
mercaptoethanol, 20 Mm Tris, pH 7.4) was added per ml of original supernatant. After 
SDS-PAGE and electroblotting, Western blot was carried out on the sample and the 
original supernatants to detect immunoprecipitated proteins and monitor input levels. The 
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primary antibodies used were an anti-GIT1 rabbit monoclonal antibody, a mouse anti-
paxillin monoclonal antibody and a mouse anti-AKAP monoclonal antibody, followed by 
preabsorbed secondary goat anti-rabbit or anti-mouse antibodies to horseradish 
peroxidase (DAKO, USA). Bands were visualized by ECL (Kodak, USA) and then 
measured by quantitative densitometry.  
Data Annotation. Proteins in our dataset were annotated using terms from the Gene 
Ontology (GO) project (http://www.geneontology.org).  A subset of terms from the 
Biological Process and Cellular Component GO ontologies were selected to form a 
generalized categorization of muscarinic receptor interactome cellular localizations and 
biological processes.  Some related GO terms were collapsed into a single category.  For 
example, "endoplasmic reticulum" and "Golgi apparatus" were combined to form the 
"endoplasmic reticulum/Golgi" category.  
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Rhodopsin mutations are the most common cause for autonomic dominant retinitis 
pigmentosa. A common mechanism of retina degeneration is the activation of apoptotic 
events. Some important biochemical events in light-induced photoreceptor apoptosis 
have been identified, but the therapeutic utility of blocking cell death remains unclear. 
However, it is now clear that G-protein-coupled receptors can regulate programmed cell 
death through a variety of mechanisms that are dependent on receptor subtype.  It has 
been demonstrated that Gq/11-coupled subtypes of the muscarinic receptor family are 
able to protect against apoptotic cell death. In particular, the polybasic region conserved 
within the C-terminal tail appears to be the structural determinant of coupling to the 
anti-apoptotic pathway. In order to investigate whether the anti-apoptotic properties of 
this epitope can be used as a blocking system to inhibit apoptotic effects promoted by 
rhodopsin mutants, we engineered a group of quimeric receptors where the C-terminal 
tail of the human M3 muscarinic receptor was inserted in the C-terminal tail of two 
rhodopsin mutants (R135L and L46R), previously reported for patients with severe 
retinitis pigmentosa. We provide evidence that quimeric construction protects cells from 
H2O2-induced apoptosis. Promoting the early expression of Bcl-2 decreased Bax 
expression and reduced caspase-3 activation. Correspondingly, cytochemical evaluation 
revealed an absence of cytochrome c into cytoplasm and an increased of NF-κβ 
translocation to the nucleus. These effects were blocked only by HA-1077 Rho kinase 
inhibitor, indicating that the insertion of the anti-apoptotic epitope of the muscarinic 
receptor remains functional, reducing many apoptotic markers, and can be used as a 
therapeutic method for late-stage inhibition of apoptosis. 
 
INTRODUCTION 
Retinal degenerations, including retinitis pigmentosa (RP) are a leading cause of human 
blindness 395. In these diseases, initially functional photoreceptor cells of the eye are 
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irreplaceably lost over time 396. There are two main mechanisms by which cells can die: 
necrosis, which is a lytic response to overwhelming stress, and apoptosis 397. Apoptosis 
is non-lytic, morphologically distinct, and its core elements are apparently conserved in 
all cells. Previous results indicate that cell death of RP is apoptotic and about 30% of all 
autosomal dominant RP is caused by mutations in the photoreceptor protein rhodopsin 
398. This suggests that the activation of cell death by such mutations occurs by the 
common mechanism of apoptosis. 
Also, there is a growing amount of evidence that activation of some G-protein-coupled 
receptors can provide protection from a wide variety of potentially lethal toxic insults 
399-402. Prominent among the GPCRs that protect cells from apoptotic stimuli are the 
Gq/11 subtypes of the muscarinic receptor family 403,404. For example, activation of 
endogenous muscarinic M3 receptors protected human neuroblastoma SH-SY5Y cells 
and primary neuronal cultures from apoptosis caused by three common insults: DNA 
damage, oxidative stress, and impaired mitochondrial function 405. In fact, the anti-
apoptotic effect of muscarinic receptors in neuronal models has led to the suggestion 
that this process may play a role in neuronal development, and lesions in cholinergic 
innervation observed in neurodegenerative diseases such as Alzheimer’s may result in 
the loss of the survival stimulus that contributes to neuronal cell death 348. Side-directed 
mutagenesis revealed that a polybasic region in the C-terminal tail of the M3- 
muscarinic receptor, which is conserved amongst the members of the Gq/11-coupled 
muscarinic receptor subtypes, is responsible for and involved in coupling the receptors 
to the anti-apoptotic pathway 406. 
Muscarinic and rhodopsin receptors belong to the class A subfamily of the large family 
of G-protein coupled receptors 407. They share a common structure and signal 
transduction mechanisms in spite of the differences that exists between them 408. This 
discovery raises the possibility that transmission of the ligand-binding signal to the 
cytpoplasmic surface and cytoplasmic loops is similarly conserved. Therefore, a 
quimeric construction where the C-terminal region of the rhodopsin mutants were 
replaced by the anti-apoptotic C-terminal region of the M3 muscarinic receptor might 
keep its functional properties, and provide protection to the cell. Engineering the 
quimeric receptor of two rhodopsin mutants (R135L and L46R), previously reported for 
patients with severe retinitis pigmentosa 409,410, we set out our hypothesis and showed 








Expression in Vitro of quimeric construction in the presence of 11-cis-Retinal 
Construction and analysis of chimeric receptor, consisting of the replacement of part of 
the C-terminal region of the rhodopsin with the anti-apoptotic C-terminal region of M3 
muscarinic receptor, was carried out to determine if the functional domain of the 
muscarinic receptor might keep its functional properties, and provide protection to the 
cell in an opsin receptor background. Engineered quimeric receptors of two rhodopsin 
mutants (R135L and L46R), previously reported for patients with severe retinitis 
pigmentosa 410, and wild type were used (Figure 4.1.1)  
Expression of quimeric constructions in human neuroblastome cells SH-SY5Y was 
carried out in the presence of 11-cis retinal or 9-cis retinal. Upon reconstitution with 11-
cis retinal, all chimeras showed chromophore formation with absorption maxima at 
close to 500 nm. In addition, immunocytochemistry of all chimeras expressed in the 
presence of 11-cis or all-trans retinals were studied. While the chimeric-WT and 
chimeric-L46R receptors exhibited proper plasma membrane localization in presence of 
11-cis retinal, the R135L-quimeric displayed a pattern consistent with endoplasmic 
reticulum accumulation in presence of 11-cis-retinal (Figure 4.1.1B). Under identical 
culture conditions and in the presence of all-trans-retinal or without any retinal, little if 
any chimera receptors could be detected. 
 
Figure 4.1.1 Secondary structure model of bovine rhodopsin. In blue (cluster), C-terminal region 
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Replacement of the C-terminal tail of rhodopsin by the anti-apoptotic C-terminal 
region of M3 muscarinic receptor promotes cell survival 
To determine whether the replacement of the C-terminal tail of rhodopsin by the 
homologue and polybasic region of the C-terminal tail of human M3 muscarinic 
receptor promotes cells survival, SH-SY5Y culture cells expressing chimeras were 
incubated with hydrogen peroxide to induce cell death. 48h after transfection, SH-SY5Y 
cells expressing chimeras and maintained in a medium containing 11-cis retinal were 
photo-bleached in the presence of H2O2 at a concentration of 100 μM for 18 h. Then the 
protective effects of each construction were determined using MTT assay. The viability 
of cells expressing WT (Rho-WT) and growing in a medium containing 100 μM H2O2 
and 11-cis retinal was approximately 55% of that for cells expressing rhodopsin 
chimeric (Rho-M3), indicating that replacement of the C-terminal region did in fact 
protect again peroxide-induced cell death. Similar effects were also observed with 
respect to chimeras of severe retinitis pigmentose mutants (L46R-M3 and R135L-M3) 
when compared to cells expressing receptors mutants alone (L46R and R135L) (Figure 
4.1.2).  
 
Figure 4.1.2 Replacement of the C-terminal tail of rhodopsin by the anti-apoptotic C-terminal region of 
M3 muscarinic receptor promotes cell survival. Cells expressing each quimeric receptor were grown in 
the absence of or presence of hydrogen peroxide (100 μM) for 18 h. MTT assays were carried out to 
determine cell viability. Means ± S.E.M is shown; n=4. **: Significantly different compared to Rho-wt 




Figure 4.1.3 In vitro expression of the opsin quimeric constructions reversed apoptotic effects induced by 
peroxide. Transfected cells were grown in DEMEM in the presence of 11-cis-retinal and peroxide for 18 
h. TUNEL assays were carried out to determine DNA fragmentation. TUNEL-positive cells were very 
darkly stained with a condensed nucleus as visualized by light microscopy. Means ± S.E.M is shown; 
n=7. **: Significantly different compared to L46R  (ANOVA: p<0.01). 
 
Since the MTT assay measures cell viability and accounts for changes in cell survival 
and proliferation, TUNEL staining was used to assess the number of cells dying by 
apoptosis. About 10-22 % of cells expressing rhodopsin receptor and mutants alone 
respectively were TUNEL-positive when grown in the presence of peroxide, whereas 
cell-expressing chimeras significantly reduced the number of apoptotic cells to only 5 to 
8%, a value similar to that which is obtained for cells growing in presence of carbachol 
(10 μM). 
Chimera’s expression protects against H2O2-induced cell death 
Incubation of cells with peroxides triggers the activation of caspase-3, a potent effector 
of apoptosis, by proteolytic cleavage of the 32 kDa pro-caspase into two active 
fragments. Subsequently, activated caspase-3 cleaves susceptible substrates, such as 
PARP, an enzyme involved in DNA repair 411.  
The effects of H2O2-induced caspase-3 activation were reflected in measurements of 
the proteolysis of PARP, which is mediated by caspase-3 and results in the production 
of a stable 85-kDa product cleaved from the 116-kDa intact PARP. Treatment with 100 
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µM H2O2 caused a concentration-dependent increase in PARP proteolysis (Fig. 2B) 
and in caspase-3 activity in all receptor-transfected cells (data not shown). However, 
cells expressing chimera receptors showed a great reduction in both PARP and caspase-
3 proteolysis, induced by 100 µM H2O2 in the presence of 11-cis retinal (Figure 4.1.3 
right panel). Therefore, time-course analysis of caspase-3 activity revealed a significant 
reduction in cells expressing the chimeric Rho-M3 receptor compared with the WT 
(Figure 4.1.3 left panel). Time-course caspase-3 activity also showed that for both 
receptors, WT and Rho-M3 chimeric, caspase-3 activity increased from 2 h to 6 h and 
reached a plateau after 6h. We also evaluated the significance of the protective effect of 
chimeras by compared it with that of a general caspase inhibitor, BAF. These 
experiments demonstrated that the substantial protection provided by chimeras against 
100 µM H2O2-induced PARP proteolysis was similar to that afforded by 1µM BAF 
caspase inhibitor (data not shown).  
 
Figure 4.1.4 Inhibition of peroxide-induced apoptosis by cells expressing quimeric constructions. Left, 
hydrolysis of caspase-3 selective fluorogenic substrate Ac-DEVD-MCA in peroxide-treated SH-SY5Y 
cells was monitored over time. Cells expressing both WT rhodopsin or the quimeric construction were 
treated with 100 μM peroxide for up to 15 h. Whole cell lysate sampled directly from the treatment wells 
was incubated with 40 mM Ac-DEVD-MCA in 250 μl final volume. Data are presented as mean ± SEM of 
three independent experiments, each performed in duplicate. Right, Western blot analysis of caspase-3 
activation and poly (ADP-ribose) polymerase (PARP) cleavage. Procaspase 3 processing was verified 
after 48h treatment with peroxide in the presence of the 17 kDa active subunit on the blot. Detection of 85 
kDa PARP fragment confirmed caspase 3 activation.  
 
Furthermore, we assessed whether chimera constructions up-regulate anti-apoptotic Bcl-
2 and Bcl-xL proteins. The members of the Bcl-2 protein family are widely thought to 
represent a central point of regulation of caspase-mediated apoptosis 412. The balance of 
pro- and anti-apoptotic members of the Bcl-2 family, particularly in relation to their 
mitochondrial membrane localization, determines whether a cell enters apoptosis. In the 
present study, we show that levels of the anti-apoptotic protein, Bcl-2, fall dramatically 
following H2O2 treatment. The fall in Bcl-2 levels correlates closely with an increase in 
caspase activity. Similar results were found in cells expressing receptors and mutants. 
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However, in cells expressing chimeras, significant prevention of the reduction of Bcl-2 
expression levels was observed (Figure 1.4.4). Interestingly, levels of Bcl-2 were not 
significantly affected by R135L-M3 chimeric construction.  
 
Figure 4.1.5 Peroxide induces an increase in the expression of Bcl-xL and Bcl-2 in SH-SY-5Y cells 
expressing the quimeric constructions. This shows the protective effect of the M3 muscarinic polybasic 
sequence in the RP rhodopsin mutants background.  
 
Chimera construction prevents cyto c release during apoptosis 
Previous studies have shown that translocation of cyto c into the cytosol occurs in 
response to multiple apoptotic stimuli and plays an important role in inducing apoptosis 
413,414. Release of cyto c from mitochondria is a potential signaling component for 
regulating apoptosis in many cell types, including neuroblastome cells induced into 
apoptosis by oxidative stress. Therefore we wished to examine next the release of cyto c 
in cytosolic and mitochondrial cellular compartments in cells expressing receptor 
mutants and chimeras following exposure to peroxide. Cyto c was undetectable in the 
cytosol in immunofluorescence images from untreated cells. In contrast, cytosols from 
peroxide-treated cells contained increased cyto c levels starting at 2 h, as detected by 
immunofluorescence. Cyto c levels increased moderately at 4 and 8 h, and more 
significantly at 16 h after peroxide treatment (data not shown). Examination of cyto c 
release from mitochondria compartment in cells expressing the WT rhodopsin receptor 
revealed only a slight reduction in cyto c levels up to 8 h following H2O2 treatment. In 
contrast, there was a dramatic increase of cyto c levels in the cytosol at 16 and 24 h, 
indicating a depletion of cyto c from mitochondria. This effect was prevented in cells 
expressing the chimeric Rho-M3 receptor, where a 35% reduction in Cyto c release was 
observed at 16h of H2O2 incubation.  
                                                                                                                                                          Chapter 4 
 119
 
Figure 4.1.6 Cytocrome c undergoes subcellular redistribution in peroxide-treated cells. Cells expressing 
each quimeric and WT construction were incubated in the presence of 100 μM H2O2 for 15 h. Cells were 
analyzed by immunocytochemistry using an anti-cytochrome c-specific antibody and an Alexa-488-
coupled secondary antibody. MitoTracker staining was performed before fixation. Loss of or diffuse 
cytochrome c staining in apoptotic cells is indicative of cytochrome c release.  
 
This result was not limited to the Rho-M3 chimeric, since the L46R-M3 chimeric 
receptor also is characterized by a reduction in cytosolic levels of cyto c release from 
mitochondria (Figure 1.4.5). Interestingly, cells expressing the L46R mutant showed a 
sustained and early release of cyto c following H2O2 when compared to rhodopsin WT 
receptor expression.   
 
MATERIALS AND METHODS 
 
Material. U72122, coenzyme C3 and BFA were from Calbiochem (Nottingham, U.K.).). All 
tissue culture reagents were purchased from Gibco BRL (Glasgow, U.K.). Carbachol was 
purchased from Sigma (Poole, U.K.). Anti-Bcl-2 antibody was purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA, U.S.A.). 
Cloning of chimeric rhodopsin-M3-C terminal tail. Constructions of chimeric receptors and 
receptor mutants (L46R and R135L, kindly provided by E. Ramon.) were carried out based on 
the nucleotide sequence of the synthetic opsin and human M3 muscarinic receptor genes. 
Basically, using a QuikChange site-directed mutagenesis kit and routine PCR methods, regions 
between the helix-8 and the C-terminal tail of the opsin gene were replaced by a peptide 
corresponding to a polybasic region of the C-terminal tail of human M3 muscarinic receptor. 
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The sense primers used were: 5-
GCGGAAAAGGATGTCACTAGTCAAGGAGAAGAAAGCGGCCC-3; 5-
GCGTACCAAAGAGCTAGCTGGCCTGCAAGCC-3.  The reading frame, PCR integrity of 
the cloned construct and the sequences of the quimeric, were confirmed by DNA sequencing. 
Cell Culture, transfection and treatment. SH-SY5Y human neuroblastome cells were grown 
on 12-well plates to confluences (~2 x 106 cells per well) at 37 °C, 5% CO2 in a humidified 
atmosphere with Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal 
bovine serum, 100 IU/ml penicillin, and 100 μg/ml streptomycin. To discover whether or not 
quimeric constructions protect cells from apoptosis, we studied each construct expressed in vitro 
in the presence of 11-cis retinal with or without 100 μM H2O2. Plasmid cDNAs were 
transfected in human neuroblastome cells (SH-SY-5Y) by using Fugene transfection reagent 
(Roche). 11-cis-Retinal was delivered into the cells as a carrier prepared according to Jones et 
al. (14), except that phosphatidylcholine was used at 5 mg/ml. All experiments involving 
retinals were conducted under dim red light or in the dark. 11-cis-retinal was added to cells at 
125 µl per 150-mm dish at 3 h after transfection and a second aliquot was added 12 h later. A 
second control received liposome only. At the beginning of the experiment, cultures were 
washed three times with serum-free DMEM. Apoptosis was then induced by the addition of 
H2O2 at a concentration of 100 μM, for periods of 6–24 h (usually 16 h). To avoid artefacts in 
time course experiments, all conditions were washed with serum-free DMEM at time 0 and 
were treated (100 μM H2O2) at the appropriate time so that all time points were collected 
simultaneously. 
Visualization of apoptotic nuclei (TUNEL labelling). Transfected SH-SY5Y cells, growing in 
24-well tissue culture plates with poly-D-lysine-coated glass coverslips, treated as described 
above, were washed with PBS and then fixed with 4% paraformaldehyde for 20 min at room 
temperature.  Fragmented DNA (high molecular weight or internucleosomal) was detected by 
incorporating fluorescein-12-dUTP at 3´-OH ends using terminal deoxynucleotidyl transferase 
(TdT)-mediated dUTP nick end labeling (TUNEL) assay, as described [Cui, QL., Almazan G. 
2005]. Anti-fluorescein antibody Fab fragments conjugated with horseradish peroxidase 
detected incorporated dUTP. Stained cells were visualized by light microscopy. Labelled nuclei 
and the total number of cells were counted in at least five different fields. 
MTT assay of cell viability. The number of living cells in 96-well plates (2104 cells per well) 
was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. 
MTT was dissolved in PBS at a concentration of 5 mg/ml. From this stock solution, 10 μl per 
100 μl of medium was added to each well, and the plates were incubated at 37°C for 3 h. Acid-
isopropanol (100 μl of 0.04 M HCl in isopropanol) was then added to the well and mixed in. 
After 15 min at room temperature, the plates were read on a Bio-Rad micro-ELISA 
spectrophotometer at a test wavelength of 550 nm and a reference wavelength of 650 nm. SH-
SY5Y cell growth in DEMEN alone (defined as 100%) were used to normalize absolute MTT 
values. 
Assay for caspase-3/7 activity. Caspase-3/7 activity was measured with the Apo-ONE 
homogeneous assay kit using a synthetic fluorometric substrate for caspase, Z-DEVD-
Rhodamine 110. After treatment with H2O2 for the time indicated, 100  l of homogeneous 
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caspase-3/7 reagent (buffer+substrate) was added to each well of the SH-SY5Y cells in 96-well 
plates. The 96-well plate was incubated at room temperature and assayed on a Cytofluor II 
multiwell fluorescence spectrometer (excitation 485 nm, emission 520 nm). 
SDS-PAGE and Western blot.  Transfected and treated cells were harvested, washed twice 
with phosphate-buffered saline, and lysed in lysis buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 2 
mM EDTA, 2 mM EGTA, 1 mM sodium orthovanadate, 100 µM phenylmethylsulfonyl 
fluoride, 10 µg/ml leupeptin, 10 µg/ml aprotinin, 5 µg/ml pepstatin, 1 nM okadaic acid, and 
0.5% Nonidet P-40). The lysates were sonicated for 10 s on ice and centrifuged at 16,000 x g for 
15 min, and supernatants were collected. Protein concentrations were determined using the 
Bradford method or the bicinchoninic (BCA) method (Pierce). Proteins were resolved in SDS-
polyacrylamide gels (12%), transferred to nitrocellulose membranes, and incubated with 
primary antibodies followed by incubation with horseradish peroxidase-conjugated secondary 
antibodies. The primary antibodies used were: poly (ADP-ribose) polymerase (PARP), 
cytochrome c (BD Pharmingen), bcl-2, Bax, tubulin (Upstate Biotechnology, Lake Placid, NY), 
cytochrome oxidase (Molecular Probes, Eugene, OR). Proteins were visualized by ECL® 
(enhanced chemiluminescence; Amersham Biosciences) and were quantified by densitometry. 
Immunofluorescence analyses.  Cells were grown on Vitrogen-coated coverslips and cultured 
in the presence of 11-cis-, or 9-cis-retinal. 24 h after transfection, they were washed with PBS, 
fixed in ice-cold methanol for 5 min, and stained with anti-rhodopsin antibodies rho-1D4 (C-
terminal specific), followed by Cy3-conjugated goat anti-mouse IgG. 
Cyto c subcellular localization: cells were grown on Vitrogen-coated coverslips, washed with 
PBS, fixed with 2% paraformaldehyde, incubated with anti-cyto c mAb, followed by FITC-
conjugated secondary mAb. MitoTracker Red (100 nM) was used for mitochondrial 
localization, and Hoechst 33258 (10 μg/ml) for nuclear staining in confocal and conventional 
microscopy, respectively. The immunostained slides were examined using a Nikon FXA 
epifluorescence microscope or a Leica TCS-NT confocal laser-scanning microscope with a 
63´objective lens (Leica Lasertechnik GmbH, Heidelberg, Germany). For comparison of triple-
stained patterns the three images were superimposed. MitoTracker Red and Hoechst 33258 were 
from Molecular Probes. 
Statistical analysis. Statistical significance was determined by one-way ANOVA and, if 
significant, group means were compared by post hoc analysis using Tukey multiple comparison 
of means test. Values shown are the mean s.d. of three experiments (three to four cultures per 
experiment). 
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ABSTRACT 
Activation of the M3 Muscarinic receptor by agonist binding is followed by 
conformational changes and recruitment of accessory and scaffold proteins, that 
together with the classical core signalling entities contribute to the formation of a 
signalsome complex. The dynamics of such a complex is not well understood but a 
conserved NPxxY (5,6) F motif located in the transmembrane VII of the receptor was 
found to be critical in G protein activation. We have generated receptor mutants 
(N540A, N540D and F551A) to determine the effect of the mutation on binding, G 
protein coupling, signalling and multiprotein complex reorganization after the 
expression of the mutated receptor in COS-7 cells. The mutated receptor displayed 
similar expression levels and Ligand binding properties compared with the wild type, 
except receptor mutant N540A, which showed a high reduction in level expression and 
slightly reduced antagonist binding sites. In addition, the N540A receptor mutant 
showed a dramatic reduction in G protein activation and completely failed to elicit PLD 
activation and PI response to carbachol stimulation. However, the N540D mutant 
activates G proteins and stimulates PLC and PLD, but with different time course and 
desensitization compared with the WT. Co-immunoprecipitation experiments allowed 
us to show that each mutant retains a different capacity to form stable complexes with 
different populations of G proteins and accessory proteins (ARF1, ARF6, RhoA). 
Different levels of ARF, RhoA and G proteins were observed in the 
immunoprecipitation complexes for N540D mutant. Indicating the role of the NPxxY 
(5,6) F motif as a structural determinant during conformational and selectively 
activation of G proteins and multiprotein complex reorganization.  
INTRODUCTION 
The M3 muscarinic acetylcholine receptor (M3) is a member of a family of muscarinic 
receptors that subserve diverse roles both in central and peripheral nervous system 415. It 
is a class A, rhodopsin-like, G protein-coupled receptor (GPCR) that signals primarily 
through the heterotrimeric G protein Gq/11, activating phospholipase Cβ, with a 
corresponding increasing in intracellular calcium 266. M3 receptors also regulate a 
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network of signalling intermediates, including PKC, small GTPase Rho, phospholipase 
D, phosphoinositide-3 kinase, non-receptor kinases and mitogen-activated protein 
kinases 416. 
Intracellular loop interactions and conserved residues have been described as critical in 
maintaining normal receptor conformation, G protein coupling, signalling and 
regulation. Chimeric construction and site directed mutagenesis indicated that both the 
M3 second intracellular loop and the C-terminal portion of the third intracellular loop are 
important for coupling to the Gq/11 protein 417. In addition, activation is mediated by a 
conformational rearrangement that includes the TM7 and probably, as described for 
rhodopsin, movement in the C terminal tail (Helix-8) 215. 
A sequence alignment of GPCRs of the rhodopsin family reveals that the majority of 
GPCRs, as well as the M3 receptor, contain a conserved NPxxY (5,6) F motif at the end 
of transmembrane VII and the beginning of Helix-8 338. Mutagenesis studies, rhodopsin 
crystal structure and molecular modelling have shown that mutation of residues in the 
motif of different GPCRs is implicated in a network of interactions that modulate 
receptor activity, expression and signalling 418-422. A theoretical model based on a 
computational modelling study has been proposed, which explains that the special 
structural property of the conserved N/DP motif differs from a regular Pro-kink, of ideal 
α-helix, allowing for a major flexibility in the TM7 423. The flexibility introduced by the 
NPxxY (5,6) F motif may play a role in GPCR activation by functioning as a sensitive 
conformational switch and can determine the selectivity and magnitude of signalling, 
regulation and scaffolds protein interaction with the receptor. 
The role of the NPxxY (5,6) F motif in the muscarinic receptor family has been 
associated more directly with translocation of both native ARF1 and transfected ARF1-
HA protein to the plasma membrane following activation of M3 receptor 424,425. 
Interaction between the M3 muscarinic receptor and small-G proteins, ARF and RhoA, 
has been described as critical during the activation of the PLD and ROCK pathway 426-
428. 
Based on the precept that NPxxY (5,6) F motif is involved in the activation and 
potentially in the signalsome complex formation of GPCRs in general and the M3 
muscarinic receptor in particular, we generated a series of mutants. In essence, the Asn 
located in the conserved NPxxY motif was replaced by an Asp (N540D) and Ala 
(N540A), and Phe located at the putative helix-8, by Ala ((F551A). Mutation of Asn to 
Ala switches the M3 receptor to a high affinity inactive conformation for the 
transmission of a signal to different effectors. However, the mutated receptor retains a 
capacity to form stable complexes with Gαq subunits in response to agonists, as 
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demonstrated by coimmunoprecipitation. By contrast, the N540D mutant results in 
slightly higher levels of ERK phosphorylation than those displayed by the WT and 
similar levels of PLC and PLD activity. In addition, this mutant showed different time 
course and desensitisation with respect to the wild type.  Co-immunoprecipitation and 
activation assays for some scaffold proteins that can potentially bind to the muscarinic 
receptor were also analysed. These experiments allowed us to observe that each mutant 
retains a different capacity to form stable complexes with different populations of G 
proteins and accessory proteins (ARF1, ARF6 and RhoA) and the bases of different 
desensitisations can be found here.  
RESULTS 
 
To explore the role of the NPxxY (5,6) F motif in multiprotein complexes formation 
and assembly by human M3 muscarinic receptors upon agonist stimulation, a group of 
single mutations were generated. Exactly, Asp (N540D) and Ala (N540A) replaced Asn 
located in the conserved NPxxY motif, and Ala (F551A) replaced Phe located at the 
putative helix-8. The antagonist and agonist binding properties, phosphoinositide 
hydrolysis stimulation, G protein activation, small G protein RhoA activation and co-
immunoprecipitation of the receptor and mutants with some scaffold protein were 
studies after transient expression in COS-7 cells.  
 
N540D and F551A mutants are expressed on the cell surface and binding ligand 
with affinities similar to the wild type receptor.  
As mentioned above, to determine if the conserved motif NPxxY (5,6) F plays a role in 
the rearrangement, assembly and multiprotein complex formation of the M3 receptor, 
we have mutated the ASN 540 position to Ala and Asp, and also the Phe 551 position to 
Ala (Figure 5.1.1).  
All mutants and the WT receptor were transiently expressed in COS-7 cells and assayed 
for their ability to bind antagonist [3H]-NMS, and the agonist, carbachol. The results of 
radioligand binding studies are summarized in Table 5.1.1. Saturation binding 
experiments showed that all mutant receptors were expressed at densities comparable 
with the WT, with Bmax values ranging from 890 to 924 fmol/mg of protein; with the 
exception of N540A mutant that showed a four-fold reduction in level expression. In 
addition, the various mutant receptors displayed antagonist-binding affinities that did 
not vary more from the values determined for the WT. However, N540A bound 
antagonists with lower affinities than the WT receptor. Agonist-binding parameters 
showed for all mutants non-significantly lower agonist binding affinities than the WT, 
and an important increase in agonist affinity with respect to the WT for the N540A 
mutant. In all cases, agonist-binding studies were carried out in the absence of GTP and 
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GTP analogues, since previous studies had shown that such agents did not affect the 
agonist binding properties of the M3 muscarinic receptor when transiently expressed in 




Figure 5.1.1 Location of the NPxxY (5,6) F motif in the M3 model. A two-dimensional model, with the 
extracellular domain on top and the intracellular domain at the bottom, of the human M3 sequence is 
depicted. Mutated residues are highlighted. Mutations were generated using QuikChange site directed 
mutagenesis kit from Stratagene. A schematic representation of the multiple alignments of the muscarinic 
receptor family and rhodopsin is represented. Residues upstream and downstream of the conserved Pro 
at the end of TM7 (P7.50) are shown in yellow. The region conserved among the family is depicted with 
an asterisk and the putative H-8 is showed in red. 
 
Immunoprecipitation of the WT and mutant receptors was performed using an antibody 
directed against the hemagglutinin epitope (HA) fused to the amino terminus of each 
one and transiently expressed in COS-7 cells. Epitope-tagged WT and mutant receptors 
expressed in COS-7 cells displayed similar agonist affinities and maximal-binding 
capacities compared with untagged WT and mutated receptors. In addition, to confirm 
that the transfection and expression efficiencies of each tagged receptor were similar, 
we performed western blot of COS-7 cells membranes expressing HA-tagged WT and 
mutated receptors with anti-HA antibodies. The human M3 muscarinic receptor was 
expected to migrate at a mass of 67-75 kDa based on their primary sequence and on 
previous reports (Figure 5.1. 6) 430.  
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Table 5.1.1 Ligand binding and functional properties of M3 muscarinic receptor mutants expressed in 
COS-7 cells.  













in IP levels (WT 
taken as 100%) 
M3-WT 90 ± 17 924 ± 37 8.4 ± 2.3 3.4 ± 0.5 100 
N540D 87 ± 15 910 ± 33 12.2 ± 2.8 3.6 ± 0.2 91 ± 4 
N540A 105 ± 69 226 ± 33 1.1 ± 0.8 - - 
F551A 86 ± 14 890 ± 30 9.2 ± 2.1 5.8 ± 0.2 52 ± 3 
 
Affinity constants (Kd)for the radioligand [3H]NMS were determined in saturation binding assays. 
Inhibition constants (Ki) for carbachol agonist were obtained in competition binding experiments as 
described in Materials and methods (nH= Hill coefficients). Bmax values indicated a maximum number 
of binding sites/mg of membrane protein. Data are presented as means ± SEM of three to four 
independent experiments, each performed in duplicate. Agonist binding parameters were obtained in 
competition binding assays as described in M&M using [3H]NMS (200pM) as a radioligand. Kapp 
values were calculated from IC50 values using Cheng and Prussof ecuation and can be consider an 
approximation of Ki values. In all cases, Hill coefficients (nH) was significantly smaller than 1 (P< 0.05). 
EC50 values for carbachol-induced IP1 accumulation were determined graphically from plos of log 
(carbachol) versus percentage responses. Data are presented as means ± SEM of three to four 
independent experiments, each performed in duplicate.   
 
The N540A mutant is unable to activate PLC, PLD and MAPK pathway. 
We then investigated the effects of each mutation on receptor function in COS-7 cells 
by quantifying the activation of three of the main signalling pathways activated by M3 
muscarinic receptor 416. 
PLC activation mediated by M3 muscarinic receptor has been described previously and 
it is the main pathway activated by M3 receptor upon agonist stimulation 184,334. To 
assess the ability of the wild type and mutant receptors to activate the PLC-signalling 
cascade, we measured the accumulation of total inositol phosphate (IP). Non-
appreciable carbachol-stimulated [3H]-myo-InsPs accumulation was detected in un-
transfected cells. Concentration-response curves for the WT and mutant receptor are 
represented in Figure 5.1.2 and Table 5.1.1. A small change in IP accumulation was 
measured between the WT and the N540D mutant receptor, even at highly agonist 
concentration (10-3 M CCh). However, under similar experimental conditions, the 
F551A mutant receptor showed a two-fold reduction with respect to the WT.  
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Figure 5.1.2 Stimulation of PI hydrolysis mediated by wild-type (WT) and mutants expressed in COS-7 
cells. . Effect of 3ILoop-minigene vector and muscarinic receptor subtypes co-expression on PLC activity 
in CCh-stimulated HEK-293 cells. Cotransfected cells with M3 or M5 receptor subtypes and 3ILoop-
minigene (●, ○) or empty vector (■, □) were stimulated with CCh as indicated, for 1 hr at 37°C in 
presence of LiCl as described in Materials and Methods. Data are presented as an increase of InsPs 
(DPM) above basal levels in the presence of carbachol. Basal levels observed with the various receptors 
were not significantly different. Data represents the average ± S.E.M. values of triplicate determinations 
of three independent experiments.  
 
In addition, agonist-mediated [3H]-myo-InsPs accumulation was abolished in cells 
expressing the N540A mutant essentially at all agonist concentrations. Time-course of 
carbachol-stimulated [3H]-myo-InsPs accumulation in WT and mutant transfected cells 
reached a peak between 20 to 60 minutes after agonist exposure, and fifteen percent of 
receptors desensitised 2 hours after agonist stimulation (2 min, 1mM CCh).  
Although the best-established signalling pathway from the M3 receptor is the pertussis 
toxin-insensitive activation of PLC via the heterotrimeric Gq/11 protein, PLD is also 
strongly activated via both the Gq/11 and G12/13 protein 431,432. We then investigated the 
ability of the WT receptor and mutants to activate PLD activity, measured as a 
formation of [3H]-phosphatidylbutanol ([3H]-Ptdbut).  
As illustrated in Figure 5.1.3, carbachol stimulated [3H]-Ptdbut formation in the WT 
with an efficacy of six-fold over basal and a maximal potency of 1.43 ± 0.18 nM. The 
N540D and F551A mutants activated PLD in a similar way with respect to the WT as 
shown in PLC activation, but with lower potency. In addition, no detectable [3H]-Ptdbut 
production was measured with the N540A mutant, even when exposed to 10-4 M CCh.  
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Figure 5.1.3 Stimulation of Pbutnol mediated by wild-type (WT) and mutants expressed in COS-7 cells. 
 
To assure that the EC50 and E max change observed were not due to alterations in the 
receptor density, we plotted the negative logarithm of EC50 vs. receptor density for each 
mutant and WT in both experiments. This plot shows that receptor expression was 
rather variable but that the EC50 shifts were independent of receptor density.  
Finally we decided to test the MAPK pathway that can be activated by M3 receptors in a 
protein kinase C-dependent and –independent fashion 235,303.  
Since not many studies have been performed on COS-7 cells, we first assessed whether 
the WT receptor expressed in COS-7 cells was able to activate MAPK in response to 
carbachol. A maximal increase of 20 folds in ERK½ phosphorylation over basal was 
reached when WT-transfected cells were incubated with 10 μM CCh. In addition, a time 
course study of ERK½ phosphorylation in WT-COS-7 cells using 10 μM of CCh 
resulted in a maximal activation at 5 min (data not shown).  
Figure 5.1.4 shows effects of carbachol-stimulated MAPK activation in cells expressing 
WT and mutant receptors. A significant decrease (up to approximately 85%) in ERK½ 
phosphorylation was observed in the case of the N540A mutant with a less extended 
decrease for F551 mutant when compared to the activation mediated by the WT. Also, a 
non-significant statistic increase for N540D mutant was observed.  
 
Agonist-stimulated N540A mutants are coupled to Gq/11 proteins without activating 
them.  
Previous studies on HEK-293 cells expressing M3 muscarinic receptors showed that a G 
protein of the Gq/11 class mediated carbachol-stimulated PLC activation and PLD 
activation occurred via a G protein of the G12/13 class 433.  Co-expression of both, Gαq or 
Gα12 subunits with the WT receptor and N540D/F551A mutants increased [3H]-myo-
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InsPs and [3H]-Ptdbut productions in a concentration dependent manner that reached a 
maximum when cells were transfected with 5 μg of Gα DNA plasmids. In similar 
conditions, co-expression of both Gα subunits with the N540A mutant did not induce 
any change, in agreement with results described above where this mutant did not 
stimulate PLC and PLD activities. Also, co-immunoprecipitation experiments with 
COS-7 cells co-expressing the 3x HA-WT or 3x HA-mutants and Gα subunits were 
performed. A non-basal association between Gα12 subunits was observed in carbachol-
stimulated N540A-COS-7 cells, correlating with PLD activation results. In contrast, as 
shown in Fig.5.1.6, upper panel, when cells were stimulated with 10 µM CCh and 
subjected to immunoprecipitation with anti-HA antibodies, Gαq subunits co-
immunoprecipitated with both the 3x HA-M3-WT and 3x HA-M3-mutants as a band that 
migrated at 42 kDa. The effect of agonists on Gαq-3x HA-M3 and Gαq-3x HA-N540A 
complex formation was 4.3 ± 1.1 and 4.7 ± 1.8 fold of the basal level respectively 
(mean ± S.E. of five experiments). 
 
























Figure 5.1.4 Agonist stimulated MAPK activation in COS-7 cells expressing WT and mutants. Confluent 
cultures were exposed to serum-free medium 12 h before the addition of carbachol (1mM) for 5 min. 
Cells were washed extensively after agonist treatment and prepared for MAPK extraction. Extracts 
corresponding to 1x105 cells was run on 12.5% SDS-PAGE gel. The proteins were transferred onto 
nitrocellulose, and MAPKs p44 and p42 were detected using a mouse monoclonal antibody against 
human p42/44 MAPK phosphorylation on Thr-202 and Tyr-204, or a rabbit polyclonal antibody against 
total human p42/44 MAPK. The proteins were detected using a horseradish peroxidase-conjugated 
secondary antibody and enhanced chemiluminescence. The intensity of the bands was quantified using 
Imagen Quand Program. Bars represent the means ±S.E.M. of the phospho-ERK (p-ERK) 
immunopositive band intensity expressed as the percentage change from the basal (serum-free medium-
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treated) level calculated from four separate experiments. *P≤ 0.05 compared to basal conditions in WT-
COS-7.  
 
Moreover, as the N540A does not display increased basal level IP accumulation and the 
last results suggest that the mutated receptor forms stable complexes with Gqα subunits 
upon agonist stimulation, we precede to monitored basal guanine nucleotide exchange, 
using [35S] GTPγS assay. In non-stimulated cells, [35S] GTPγS assay gave almost 
identical values for basal binding in both WT receptors and mutants. However, 1 µM of 
carbachol induced an increase in [35S] GTPγS binding (43% over basal) for high and 
low WT receptors and N540A/F551A mutant expression in COS-7 cells. No change 
was observed when cell expressing N540A mutant (data not shown). 
 
A different time-course and desensitization patron characterizes agonist-
stimulated mutant N540D. 
M3 muscarinic receptors activated both PLC and PLD upon agonist stimulation using 
different molecular mechanisms and time kinetics 434. While PLD stimulation showed a 
rapid and long lasting desensitization, agonist stimulation of PLC is not desensitized 
following short-term treatment. 2 min of pre-exposure to agonists led to an about 2-fold 
increase in receptor-mediated PI formation, supersensitivity that disappeared 2 h after 
carbachol removal.  
We then decided to analyze whether or not each mutant (N540A and F551A) could 
maintain its capacity to stimulate both phospholipase, as well as maintain the same 
patron of desensitization and time-course upon agonist incubation. 
The time course of PLD and PLC activation by carbachol in transfected COS-7 cells is 
shown in Figure 5.1.5. There was rapid desensitization of the PLD, but not the PLC 
response, over the times examined. The time-course of carbachol-stimulated [3H]-myo-
InsPs accumulation in the transfected WT and mutants-COS-7 cells reached a peak 
between 20-60 min after agonist exposure and fifteen percent of receptors desensitised 
2h after agonist stimulation (2 min, 1mM of carbachol). In contrast, maximal levels of 
labeled [3H] Ptdbut were already obtained after 2 min of incubation with carbachol 
(1mM), followed by a stable plateau up to at least 30 min of incubation for the WT 
receptor. An identical time-course of [3H]-Ptdbut formation, although at a lower level, 
was obtained in F551A COS-7 cells. Interestingly, COS-7 cells expressing N540D 
mutant showed a time course patron more similar to the patron showed by WT and 
mutants in agonist-stimulated PLC activation. We also observed that the N540D mutant 
was not desensitized following short-term agonist treatment in the same manner as the 
WT. On the contrary, 2 min of preexposure to carbachol led to about 2-folds increase in 
receptor-mediate [3H]-Ptdbut formation 20-30 min after exposition. However, after that 
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time, this supersensitivity disappeared with a long lasting desensitization similar to the 
WT. 


















































































Figure 5.1.5 PLD and PLC responses of wild type, N540D mutant receptors expressed in COS-7 cells. 
Upper panel, show the time course of [3H]-myo-inositol phosphate ([3H]-myo-InsPs) and [3H]-
phosphatidylbutanol ([3H]-Ptdbut) production evoked by 1 mM carbachol. Values are folds of basal 
control (means ± s.e.m; n= 4-6). Lower panel, desensitisation of muscarinic-stimulated PLD and PLC. 
COS-7 cells expressing wild type and N540D mutant receptors prelabeled with [3H]-myo-InsPs and [3H]-
Ptdbut were pretreated for 2 min with 1mM carbachol.  After wash-out of carbachol, the carbachol 
(1mM) induced formation of  [3H]-myo-InsPs and [3H]-Ptdbut was measured at the indicated periods of 
time for 10 min. Basal accumulation of  [3H]-Ptdbut was unchanged. Basal accumulation of  [3H]-myo-
InsPs, on the other hand, was different depending on whether carbachol-pretreated cells or untreated 
were utilized. Data are from one experiment (means ± s.e.m, triplicate culture dishes). Similar results 





Different interacting proteins are associated with agonist-stimulated mutant 
receptors. 
 Taking into consideration the last result, where a WT receptor and N540D mutant 
showed different desensitization and time-course in PLD activation, as well as, in 
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various cell types ARF and Rho proteins were specifically implicated in M3 receptor-
mediated PLD activation; we decided to analyze weather G proteins (Gq/11 and G12/13) or 
scaffold/associate proteins were affected and might be responsible for the variability of 
phospholipase regulation. 
First, by western blot analysis we demonstrated that in WT cells, both subtypes of G 
protein (Gαq and Gα12) remain associated with the M3 muscarinic receptor. Our studies 
using an antibody specific for Gαq/11/Gα12/13 (Santa Cruz Biotech) did not detect 
endogenous Gα in the COS-7 cells consistent with previous report (Ref). Both mutant 
receptors, N540D and F551A were found to be associated with Gαq and Gα12 to the 
same extent as WT. In contrast, as mentioned above, the coupling of N540D mutant 
receptor with Gα12 was severely abrogated (Figure 5.1.6). 
 
Figure 5.1.6. Differential coupling of WT and mutants to Gq/11, G12/13, RhoA and ARF1/ARF-6 proteins. 
Receptors present in crude membrane preparations of non-stimulated and stimulated cells expressing WT 
or mutants were solubilized with 4 mM CHAPS and immunoprecipitated with anti-HA. The 
immunoprecipitates were subjected to SDS-PAGE and Western blotting using anti-M3, anti-Gq/11, anti- 
G12/13, anti-RhoA and anti-ARF 1/6 antibodies. The experiment shown was repeated twice with identical 
results. 
 
Also, Figure 5.1.6 shows that a solubilized M3 receptor can be immunoprecipitated 
using an anti-HA antibody, which causes co-precipitation of immunoreactive ARF and 
Rho A after priming with carbachol. Co-immunoprecipitation of WT-RhoA complex 
required pre-exposure to agonists. Little co-immunoprecipitation was observed when 
using control immunoreagents (non-immune IgG) or in the presence of excess peptide 
antigen. However, ARF1 and ARF6 proteins seem to be specifically associated with the 
WT receptor without activation. In addition, densitometry analysis indicated that after 
carbachol priming, the WT-ARF1 complex co-immunoprecipitated with increase of on 
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average 4.21 ± 1.36-fold (n=4) over WT under basal conditions. The corresponding 
value for WT-ARF6 was lower (1.03 ± 0.57-fold (n=6) increase over Wt under basal 
conditions) but only the increased ARF1 was statistically significant (p<0.05, n=4). We 
observed that the carbachol induced on ARF1 coimmunoprecipitation with the WT 
receptor was reduced to basal levels in COS-7 cells expressing N540D mutant. As 
before, the concentration of ARF1-myc present in the lysates was very similar between 
the different conditions and the number of receptors immunoprecipitated was also even 
(Figure 5.1.6. top). However, upon agonist stimulation ARF6 coimmunoprecipitation 
levels are closing similar for both the WT and N540D mutant. Observations using 
immunoprecipitation of the WT and mutants receptor indicate that ARF1, and to a 
lesser extent ARF6, form a stable complex with the WT receptor that can be increased 
in the presence of an agonist, correlating with the functional studies on PLD activation. 
But, these levels can be varied when receptors is mutated in key domain or position, as 
shown in results for the N540D mutant, where the associated of the ARF1 isoform is, in 
part, abrogated after agonist priming. 
We then asked whether the apparent change in affinity for ARF isoforms and small G 
proteins caused by the N540D mutation affects the signalling function of the WT and 
N540D mutant receptors. To examine interacting protein-independent and interacting 
protein-dependent receptor activation we measured agonist-induced activation of PLC 
and PLD in COS-7 cells transfected with either WT or N540D receptor under different 
inhibitory conditions. 
The activation of PLD by WT and N540D mutant in COS-7 cells was differentially 
inhibited by brefeldin A (BFA), an inhibitor of guanine-nucleotide exchange in ARF, 
and C3 exoenzyme, an inhibitor of small G protein RhoA. Activation of PLD by WT 
receptors in these cells (as for WT receptors expressed in HEK 293 and endogenous 
expressed in 1321N1 human astrocytoma cells) was sensitive to BFA (100 µM) whereas 
activation of PLD by the N540D mutant was BFA-resistant (Figure 5.1.7 upper panel). 
The WT receptor but not the N540D mutant responses were attenuated by a C3 
exoenzyme inhibitor (Figure 5.1.7 upper panel). In previous work, it has been showed 
that changing the sequence of the carboxyl-terminal tail domain (CT) of the 5-HT2A 
receptor in a GST-fusion protein construct from N376PxxY to D376PxxY reduced the 
affinity of the construct for ARF1 isoform 422,435. PLC activation by the WT receptor 
was inhibited by U73122 (IC50 of 11± 1µM) but not the PLD activation, whereas with 
either PLC or PLD, N540D mutant response was sensitive to U73122 in concentrations 
of up to 20 µM (Figure 5.1.7 upper and lower panel).  
We decided to also test the effect of inhibition of the βγ subunit in both WT and N540D 
mutants. Co-transfection of the WT or N540D mutant with pREP4-GRK2-Ct plasmid 
(plasmid containing an inhibitory peptide of βγ subunit) resulted in a decrease in PLD 
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activation for the WT receptor and no significant statistical change in N540D mutants. 






















































































































































































Figure 5.1.7 Properties of agonist-evoked PLD and PLC responses in COS-7 cells 
expressing wild type and N540D mutant receptors. Upper panel and lower panel 10 
mM carbachol-induced PLC and PLD signalling responses of wild type and N540D 
mutant receptors respectively. Comparison of their susceptibility to inhibition by co-
transfection of pREP4-GRK2-Ct plasmid (plasmid containing an inhibitory peptide of 
βγ subunit), U73122 inhibitor (15 μM), BFA inhibitor (100 μM), C3 exoenzyme (4,8 
μg/ml: Coe3). In control and inbibitor-treated cells, an amount of empty vector 
equivalent to that used for pREP4-GRK2-Ct was contransfected with the receptor 
constructs. Values are means ± s.e.m, n=5, *p<0.05. 
 
With the discrepancy between the variable increased in ARF1/ARF6 isoform binding to 
agonist stimulated WT receptors and mutants, our results suggest that there exists a 
correlation between M3 multiprotein complex formation and PLD/PLC extension of 
activation and regulation. These results concur with the idea that agonists produce a 
conformation change in the receptor during activation that can selectively induces 
translocation of ARF1/RhoA/ βγ subunit to the membrane, promoting their involvement 
in some form of complex with the muscarinic receptor, and may ultimately enhance 
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A sequence alignment of GPCRs of the rhodopsin family reveals that the majority of 
GPCRs contain an NPxxY (x) 5,6F sequence 408. Mutation in this domain affects ligand 
affinity, receptor expression, G protein coupling, and receptor association with 
interacting proteins such as small G proteins ARF and Rho 418,422,436-439. The function of 
this motif during multiprotein complex organization by the M3 muscarinic receptor is 
not well understood. Therefore, we set out to elucidate the role of this region by using 
site direct mutagenesis in combination with coimmunoprecipitation experiments and 
signal transduction assays. This study demonstrates for the first time that change at the 
level of residue N540D/F551A in M3 muscarinic receptors contributes to heterotrimeric 
G protein (Gq/11 and G12/13 ) regulation but not G protein binding itself. Residue N540D 
is also implicated in the receptor desensitization process and also in PLC/PLD signal 
transduction efficacy. Furthermore, given the variety of affects observe in these studies, 
as well as previously results which demonstrated that change from NPxxY (x) 5,6F to 
DPxxY (x) 5,6F   in some GPCRs produced selective interaction with small G proteins 
422, we can conclude that this region, perhaps in cooperation with other intracellular 
loops, controlled interacting protein association/selectivity and determined in part, the 
mechanism of activation of PLD. 
Our results support and expand upon previous studies of GPCRs that these residues, 
because they are located deep inside in transmembrane helix-VII and seem to allow a 
local flexibility in the conformational rearrangement, are not directly involved in ligand-
binding sites but are key positions in hydrogen bound formation and stability upon 
agonist stimulation 440,441. Agonists could activate the N540D and F551A mutant 
receptor with a non-lower agonist binding affinity, as the antagonist-binding affinities 
did not vary more from the values determined for the WT. However, compared with the 
WT, N540A mutation resulted in a significant reduction in receptor level expression, 
bound antagonists with lower affinities, and with an important increased in agonist 
affinity. An explanation would be that the drastic change of Asn by Ala completely 
abrogates the formation of hydrogen bound than can keep receptor under stable 
conformation before and after activation. Ala replacement in position N7.49 in 
rhodopsin M1 muscarinic receptor and the TRFR receptor did not facilitate 
conformational organization of the active state showing variable change in 
agonist/antagonist affinity with respect to Wt (). 
With the N540A/D and F551A mutations, we demonstrated a selective regulation of 
downstream signal transduction by a different conformational arrangement of M3 
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receptor. The WT and N540D mutant resulted in a small change in IP accumulation 
even at highly agonist concentration. However, the F551A mutant receptor showed a 
two-fold reduction with respect to WT and the N540A mutants completely lost their 
capacity to activate the PLC signal. Also, carbachol stimulated [3H] Ptdbut formation 
resulted in a six-fold increase for the WT receptor and N540D mutant, with lower 
activation for the WT receptor and N540D mutant, lower activation for the F551A 
mutant, and no detectable [3H] Ptdbut production for the N540A mutant, but with a 
lower potency in all cases. We also corroborated that theses results were observed at the 
level of the MAPK PLC/PLD pathway and the changes of Asn by Asp keep a relatively 
stable conformation that does not substantially perturb the conformation change 
produced during receptor activation upon agonist stimulation. 
Schmidt and Jakobs showed that activation of M3 muscarinic receptor in HEK cells 
leads to stimulation of both phospholipase (PLC/PLD), but with distinct efficacies and 
with very distinct durations of each response, but this study did not identify the essential 
transducing component responsible for the variable desensitisation 442. Mitchell and 
Johnson demonstrated in COS-7 cells that the M3 muscarinic receptor substantially 
utilized an ADP-ribosylation factor (ARF)-dependent route for PLD activation 443. The 
M3 receptor displayed a major ARF1-dependent route for PLD1 activation, whereas the 
ARF-6 dependent pathway activates both PLD1 and PLD2 444. However, these studies 
did not show in detail if the selective coupling by different ARF factors is responsible 
for desensitization. 
Comparing the time course of PLD and PLC activation of the WT and N549D/F551A 
mutant, we demonstrated the active role of the NPxxY (x) 5,6F motif during the 
desensitization process of the receptor, and more specifically the importance of residue 
position 7.49. We observed, as previously reported, that the time-course of carbachol-
stimulated [3H]-myo-InsPs accumulation in the transfected WT-COS-7 cells reached a 
peak between 20-60 min after agonist exposure and fifteen percent of receptors 
desensitized 2 h after agonist stimulation (2 min, 1 mM of carbachol). In contrast, 
maximal levels of [3H] Ptdbut were already obtained after 2 min of incubation with 
carbachol (1mM), followed by a stable plateau of at least 30 min of incubation for the 
WT receptor. Although at a lower level, the F551A mutant showed similar time-course 
and desensitization, and the N540D mutant did not desensitize following short-term 
agonist treatment in the same manner as the WT for PLD response. On the contrary, 2 
min of pre-exposure to carbachol led to about a two-fold increase in receptor-mediate 
[3H] Ptdbut formation 20-30 min after exposition. 
Our co-immunoprecipitation studies demonstrated that although WT and mutants are 
associated to a same extent with the two subtypes of g protein (Gαq and Gα12) and RhoA 
protein, different levels of association were observed for ARF1/6 factors. We observed, 
using co-immunoprecipitation experiments, that WT and mutants can bind ARF1, and 
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to a lesser extent ARF6, forming a stable complex which is increased upon agonist 
priming. But these levels can be varied when the receptor is mutated in a key domain or 
position, as shown in the result for the N540D mutant, where the association of the 
ARF1 isoform does not increase to a similar extent as the WT after agonist incubation. 
Previous experiments reported that N376 to D mutation in the conserved NPxxY (x) 5,6F 
motif of the 5-HT2A receptor alters the binding preference of GST-fusion protein 
constructs of the Ct domain from ARF1 to an alternative isoform of ARF6 422,445. They 
also reported that the presence of an N or D residue within the conserved motif cannot 
be the sole determinant of ARF1 or ARF6 selectivity, since some NPxxY (x) 5,6F 
containing receptors such as the M3 receptor utilized both isoforms. We are in 
agreement, in part, with previous results; because we find that despite that the M3 
receptor can bind both isoforms (ARF1/6), with a change in the N7.49 position they lost 
their capacity to increase the binding level of ARF1 isoform upon agonist stimulation. 
In the case of M3 muscarinic receptor, we confirm that the presence of the DPxxY (x) 
5,6F motif does not promote any coupling with ARF6, as happens for other receptors, 
but determines the magnitude of the ARF1 coupling upon agonist activation. The 
activation of PLD/PLC by the WT and N540D mutant was differentially inhibited by 
brefeldin A (BFA), an inhibitor of guanine-nucleotide exchange on ARF1, and C3 
exoenzyme, an inhibitor of small G protein Rho. WT receptor PLD response was 
sensitive to BFA (IC50=100 µM), C3 exoenzyme inhibitor (IC50=100 mM), and no 
changes were observed when the PLC specific inhibitor U73122 up to 20 µM of 
concentration was used. However, the N540D mutant showed a PLD response sensitive 
to the PLC specific inhibitor U73122 (IC50=100 µM), but with resistance to BFA 
(IC50=100 µM), and to the C3 exoenzyme inhibitor. In addition, for both the WT and 
N540DD mutant receptor, the U73122 inhibitor reduced PLC activity. All inhibitors’ 
sensitivity was seen at low and high agonist concentrations, indicating that coupling to 
this pathway was not restricted to a particular level of agonist occupancy. 
The long lasting desensitization of the M3 receptor-stimulated PLD observed in our 
experiments and described in previous reports 446 suggests that either an inhibitory 
factor is formed upon receptor activation or that the activated receptor induced the loss 
or permanent inactivation of an essential coupling component. Since ARF1 and PLD1 
are not normally localized to a large extent at the plasma membrane, either the receptor 
or theses mediators may need to undergo translocation to enable WT receptor-induced 
PLD activation. Our findings showed that ARF1 and PLD1 were clearly and selectively 
increased in plasma membranes following agonist stimulation (data not shown). Also 
Mitchell et al., using a dominant negative mutant dynamin 1, inhibited endoncytosis of 
agonist-occupied M3 receptor without any inhibitory effect on PLD response 447. These 
results seem to be inconsistent with the idea of endoncytic mechanism. 
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More recently, Kumar-Saini et al. demonstrated that the spatiotemporal response of G 
protein subunits in living cells to receptor activation showed 6 of the 12 members of the 
G protein γ subunit family translocating specifically from the plasma membrane to the 
endomembrane 448. The γ subunit translocated βγ complexes, where the α subunit 
retained on the PM. Chisiari and Gautam, using fluorescent recovery after 
photobleaching, also demonstrated the rapid shuttle between plasma membrane and 
intracellular membranes (t1/2<1min) 449. Azpiazu and Gautam also reported that G 
protein activation by M3 muscarinic receptor caused a rapid reversible translocation of 
the G protein γ11 subunit from the plasma membrane to the Golgi complex 450. The rate 
of γ11 subunit translocation is sensitive to the rate of activation of the G protein α 
subunit. In addition, in rhodopsin the coupling of the γ subunit in the junction between 
the end of the TM-VII and the C terminal tail was demonstrated. We tested the effect of 
inhibition of the βγ complex and its translocation on PLD response. We observed that 
for the WT receptor inhibition of both, the βγ complex on their translocation 
significantly affected [3H] Ptdbut production and ARF1 co-immunoprecipitation. 
However, the N540D mutant showed a resistant-sensitivity to βγ complex inhibition.  
The data presented here indicates that stimulation of PLD/PLC in COS-7 cells by 
transfected M3 muscarinic receptors are affected by change in the NPxxY (x) 5,6F motif. 
These changes can cause different degrees of structural flexibility, resulting in the 
regulation of the interacting proteins, such as ARF factors, and the selective regulation 
of desensitization mechanisms. Mutation in the N 4.79 position resulted in a very rapid 
change (less than 2min) in PLD response upon agonist-stimulation. This phenomenon 
may be the result of the different recruitments of ARF1/ARF6 factors, and the resistant-
sensitive βγ complex inhibition and translocation (Figure 5.1.8.). This demonstrates for 
the first time the active role of the NPxxY (x) 5,6F motif in the selective process of 
multiprotein complex formation and reorganization by human M3 muscarinic receptors, 
and their role during G protein regulation and desensitization. 
 
 
Figure 5.1.8 Recruitment of specific proteins to the plasma membrane by M3. After receptor activation by 
neurotransmitter acetylcholine (ACh), or pharmacological agonists, many proteins may participate in a 
larger receptor-centered scaffolding complex (β-arrestin, kinases, small G-proteins and others). 
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Flexibility introduced by the NPxxY motif, upon activation, may play a role in GPCR activation by 
functioning as a sensitive conformational switch, and can determine the selectivity and magnitude of 
signalling, regulation and scaffold-protein binding to the receptor. 
 
MATERIALS AND METHODS 
 
Material. [35S]-GTPγS (1.202 Ci/mmole), [3H]-myo-inositol (3.0 Ci/ml), and [3H]-NMS (77 
Ci/mmole), were from Amersham Biosciences (Germany). FuGene tranfection reagent was 
purchased from Roche (USA). All receptor ligand, protease and phosphatase inhibitor cocktails, 
and all other reagents were purchased from Sigma-Aldrich. 
Numbering of Residues: Residues were numbered according to their position in the human M3 
receptor sequence. We also indexed residues relative to the most conserved residue in the TM, 
which is according to a consensus-numbering scheme described in detail previously 
(Ballesteros) 
DNA Constructs:  The cDNAs of the human M3 muscarinic receptor (kindly provided by T. 
Bonner, NIH, USA) were subcloned into the mammalian expression vector pcDNA-3.1-3xHA 
(gift from P. Calvo, SFU, CA) giving the 3xHA-M3-pcDNA vectors. Basically, a 1.9-kb 
fragment encoding the human M3 receptor was amplified from their cDNA using primer pair 
Fm3EcoRV, 5_-ACCGATATCTTGCACAATAACAGTACAACCTCGCC-_3 AND Rm3XbaI, 
5_-CCCTCTAGA-CTACAAGGCCTGCTCGGGTGC-3_, utilizing the Expand High Fidelity 
PCR system (Roche Applied Science, USA) according to the manufacturer’ instructions. The 
1.9kb fragment was purified by agarose gel electrophoresis (Bio-Rad, USA) and the subcloned 
into the mammalian pcDNA-3.1-3xHA vector using EcoRV/XbaI. All single point mutations 
were made in the NPxxY (x) 5,6F motif located in the TM7 and at the beginning of the putative 
H-8. Exchanging the endogenous residues to Alanine or aspartic in the 3xHA-M3.-cDNA 
sequences with the QuikChange site directed mutagenesis kit from Stratagene generated 
mutants. The sense primers used were: N540A, 5_-CTGTTT CTG CTG GGC CCC CGC CTT 
TG_-3; N540D, 5_-ACC TCT CTG GCT GTC CTA CTC ACC_-3; F551A, 5_- CTG TTT 
CTG CGC GGCCCC CTT CTT_-3.  The reading frame, PCR integrity of the cloned construct 
and the sequences of the mutants were confirmed by DNA sequencing. 
Cell Culture and Transfection. HEK 293 cells were grown to 70 % confluence in Dulbecco's 
modified Eagle's medium supplemented with 10% (v/v) fetal calf bovine serum (Invitrogen, 
USA), 2 mM L-glutamine, 100 IU/ml penicillin, and 100 µg/ml streptomycin at 37 °C in a 
humidified 5% CO2 incubator.  Cells were transfected with xHA-M3.-cDNA, by means of the 
calcium phosphate precipitation method or using FuGene tranfection reagent (Roche, USA). 
Cells were harvested 48 h after transfection and centrifuged at 3000xg for 30 min to obtain two 
separate fractions (membrane and supernatant). These fractions were frozen as aliquots in 5mM 
phosphate buffer, pH7.4, and stored at -80oC until required. 
Membrane Preparation and Radioligand Binding Assays. About 48 h after transfection, 
HEK 293 cells were washed twice with of cold phosphate buffer saline (PBS), harvested and 
homogenized in binding buffer (25mM HEPES, pH 7.4, 5 Mgcl2, 1mM EDTA) using Polytron 
tissue homogenizer. Cells membranes were colleted by centrifugation at 20000xg for 15 min 
                                                                                                                                  NPXXY (5,6) F motif... 
 141
and homogenized as above. After centrifugation at 40000xg for 20 min at 4oC, the final pellet 
was resuspended in binding buffer, and membranes were either used immediately or frozen in 
liquid nitrogen and stored at -80 oC until required. Protein concentration was determined by 
using the Bradford protein assay kit (Bio-Rad, USA). In order to determine the affinity of NMS 
for each sample, membranes were incubated with different concentrations of [3H]-NMS 
(ranging from 12.5 pM to 3.2 nM) in 5 mM phosphate buffer at 25 oC for 60 min. The 
incubations were stopped by filtration through Whatman GF/B filters and washed extensively 
with ice-cold 40 mM PBS prior to scintillation counting. Non-specific binding was determined 
in the presence of 10 µM atropine. Agonist binding potencies were determined in competition 
with [3H]-NMS. Membranes were incubated with 0.1 nm [3H]-NMS and concentration from 
10pM to 10 mM of carbachol in 5 mM phosphate buffer at 25 oC for 3h. The assays were 
terminated by filtration and counting, as described above. 
[35S]-GTPγS binding assay. HEK-293 cell membranes were diluted in an ice-cold buffer 
containing 10 mM HEPES and 0.1 mM EDTA, 5mM deoxycholate (pH 7.4) as previously 
described, pelleted and resuspended in a binding buffer consisting of 10 mM HEPES, 10 mM 
MgCl2, and 100 mM NaCl (pH 7.4) at a final protein concentration of 125 μg/ml. Incubations 
were conducted in a final assay volume of 1 ml (125µg total protein) for 1 h at 30°C in the 
presence of 1 µM GDP and 0.3 nM [35S]-GTP S (1,202 Ci/mmol) and the appropriate ligand 
concentration (carbachol from 1 nM to 1 mM). The reaction was stopped by addition of 5 ml of 
ice-cold buffer containing HEPES/NaOH (10 mM) (pH 7.4) and MgCl2 (1 mM), immediately 
followed by rapid filtration through glass fibre filters (Whatman GF/C) presoaked in the same 
buffer. The filters were washed twice with 5 ml of buffer and the radioactivity was measured by 
scintillation counting. Nonspecific binding was determined in the presence of 10 μM GTP S. 
Assays were performed in triplicate.  
PLD and PLC assay activities. PLD and PLC activities were monitored as production of [3H] 
phosphatidylbutanol and [3H] inositol phosphate respectively, as described previously (): in 
brief, tranfected COS-7 cells in 12-well plates were labelled by incubation for 18-24 h with [3H] 
palmitate (2µCi/well) and myo-[3H] inositol (3µCi/ml) in serum-free medium. Agonist 
responses (100 µM carbachol) were measured usually over 30-40 min in the presence of 10 mM 
liCl before cells were lysed in ice-cold 10mM formic acid and [3H] inositol phosphate was 
separated on Dowex AG1-X8 ion exchange columns (Bio-Rad, USA). For [3H] 
phosphatidylbutanol ([3H] Ptdbut) production, agonist response (100 µM carbachol) was 
measured usually over 30-40 min in the presence of 30 mMbutan-1-ol. Assays were terminated, 
phospholip was extracted into chloroform/methanol, and [3H] Ptdbut was separated on 
Whatman LK5D thin layer chromatography plates (Whatman, UK). For desensitization 
experiments, in both assays, prelabelled cells were treated with 2 min of agonist in HBSS and 
then washed twice with HBS. Then, agonist was added in the conditions described above for the 
indicated periods of time. Inhibitory agents and the butan-1-ol were added 30 min prior to and 
immediately before agonist, respectively. For assays in acute permeabilized cells, prelabelled 
COS-7 cells were primed with agonist (100 µM carbachol), 10 min at 37 oC or control before 
intracellular buffer was added  (2mM  MgATP, 10 µM NAD, 8 µM digitonin, and 30 mM 
butan-1-ol) as well as the test agents (BFA, C3 exoenzyme, GPTγS, GPPCH2P or F-( NaF in the 
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presence of 30 µM BeCl2)). All data were colleted from scintillation counted and are expressed 
as means ± S.E from between 4 and 6 separate determinations. 
MAPK assay. Co-transfected HEK-293 cells expressing M3 receptor subtypes were grown to 
80% confluence and rendered quiescent by serum starvation overnight prior to MAPK 
phosphorylation assay; an additional 2h incubation in fresh serum-free medium was performed 
to minimize basal activity. Cells were subsequently stimulated by the addition of a medium with 
or without the muscarinic agonist carbachol. Rapid rinsing with ice-cold PBS completed the 
stimulation, and cell lysis was performed during 10 min by the addition of 500 µl ice-cold lysis 
buffer (50 mM Tris-HCL, pH 7.4, 150 mM NaCl, 1% TritonX-100, protease and phosphatase 
inhibitor cocktail). The cellular debris was removed by centrifugation at 13, 000g for 5 min at 
4°C, and the total protein content was measured using BCA Protein Assay Reagent (Pierce, 
USA). Aliquots corresponding to 5 μg of protein were mixed with sodium dodecyl sulfate 
(SDS) loading buffer, applied to 12% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
and analyzed by Western blot. Extracellular signal regulated kinase ½ (ERK ½) and protein 
kinase B (AKT) activation were assayed by incubating PVDF blots with a mouse anti-phospho-
ERK ½ antibody (Sigma-Aldrich, Germany) and phospho-AKT antibody (New England 
Biolabs, UK) respectively. Control blots were also run in parallel and probed with rabbit anti-
ERK ½ antibody (Sigma-Aldrich, Germany) and total-AKT antibody that recognized both 
unphosphorylated and phosphorylated forms. The immunoreactive bands were visualized using 
horseradish peroxidase-linked secondary anti-mouse and anti-rabbit antibodies (Dako, USA) 
and SuperSignal West Pico Chemiluminescent Substrate (Pierce, USA). 
Immunoprecipitation. In order to immunoprecipitate the wild-type M3 muscarinic receptor 
with its associated proteins, plasmids encoding the HA-M3 receptor and the  Gαq, Gα12, Gβ, 
Gγ, β-arrestin-GFP, Flag-ARF-1 or Flag-ARF-6 expressing vectors were transiently co-
transfected into HEK-293 cells. 48 h later, cells were serum-deprived for 4 h., then exposed to 
carbachol (20 μM) -or no drug- for 10 min and washed once with PBS before being solubilized 
in immunoprecipitation buffer (PBS, pH 7.5, 1% CHAPS, 0.75% sodium deoxycholate, 
protease and phosphatase inhibitor cocktail). Carbachol was re-added where appropriate. 
Extracts were centrifuged at 15, 000g for 15 min at 4°C to remove particulate material and 
precleared with Protein G/A Sepharose (Santa Cruz Biotechnology, USA). After centrifugation, 
the supernatant was transferred to tubes containing either rabbit monoclonal anti-HA (Santa 
Cruz Biotechnology, USA) or nonimmune mouse IgG (Sigma-Aldrich, Germany) with the 
required amount of Protein G/A Sepharose suspension, before rolling at 4°C overnight. Beads 
were collected by centrifugation and washed twice with immunoprecipitation buffer before 35 
µl of 2x Laemmli buffer (2% SDS, 5% mercaptoethanol, 20 Mm Tris, pH 7.4) was added per ml 
of original supernatant. After SDS-PAGE and electroblotting, Western blot was carried out on 
the sample and the original supernatants to detect immunoprecipitated proteins and monitor 
input levels. The primary antibodies used were an anti-Flag M5 mouse monoclonal antibody 
(Sigma-Aldrich, Germany) and a rabbit polyclonal anti-GFP (gift from Y. Mesa; UB, Spain), 
followed by preabsorbed secondary antibodies to horseradish peroxidase (Santa Cruz 
Biotechnology, USA). Bands were visualized by ECL (Kodak, USA) and then measured by 
quantitative densitometry. 
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Data analysis. All binding data were analysed using the commercial program GraphPad PRISM 
4.0 (GraphPad Software, USA). In the [35S]-GTPγS binding assay, basal binding was defined as 
[35S]-GTPγS binding in the absence of agonist. For each agonist concentration, the percentage 
of binding over basal was calculated to determine the agonist-stimulated [35S]-GTPγS binding. 
Data were fit to a sigmoidal dose-response curve. For statistical evaluation of the biochemical 
data, unless otherwise specified, one-way analysis of variance (ANOVA) was used. Group 
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ABSTRACT 
Muscarinic acetylcholine receptors (mAChRs) comprise a large family of G protein-
coupled receptors (GPCR) involved in regulating the activity of many important 
functions of the central and peripheral nervous system. In order to relay such a diversity 
of physiological outcomes, mAChRs not only interact with heterotrimeric G proteins to 
activate or inhibit classical downstream effectors, but also with a number of accessory 
proteins that physically interact with their intracellular domains. Such proteins are 
diverse in nature, involving scaffold molecules, ion channels, and enzymatic activities, 
as well as other GPCRs, thus leading to receptor homo- or heterodimerization and 
playing a critical role in their distribution in specific areas of the cells, their trafficking, 
and the fine modulation of their signal transduction properties. Extensive 
characterization of proteins interacting with some mAChRs by means of proteomic 
approaches using pull-down show that receptor-interacting proteins and the function of 
their association with muscarinic receptors differs from one receptor subtype to another. 
The specificity of receptor association with such proteins may be largely determined by 
the occurrence of protein-interacting specific motifs, posttranslational modifications and 
the differential tissue distribution of the GPCR-interacting proteins. Such receptor 
interactions can explain key physiological differences among muscarinic subtypes as 




Muscarinic acetylcholine receptors (mAChRs) have been shown to mediate various 
functions in the central and peripheral nervous systems (CNS, PNS) 451. These include 
modulation of exocrine glandular secretion, vasodilatation and smooth muscle 
contraction 452, cell proliferation or survival 453, neural development and synaptic 
plasticity 454.   Muscarinic receptors are activated by both endogenously produced 
acetylcholine and exogenously administered muscarinic compounds. Pharmacological, 
anatomical and molecular studies have demonstrated the existence of five muscarinic 
receptor subtypes, denoted as muscarinic M1, M2, M3, M4 and M5, which belong to class 
I family of heptahelical, transmembrane G-protein coupled receptors (GPCRs) 183.  
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Each receptor subtypes are characterized by a distinct selectivity for heterotrimeric G 
protein coupling. Thus, M1, M3 and M5 are coupled to Gq/11 proteins and stimulate 
phospholipase C activity, resulting in the generation of the second messengers inositol 
(1,4,5)-trisphosphate (IP3) and diacylglycerol (DAG), the mobilization of intracellular 
Ca2+ and the activation of protein kinase C (PKC) 184. On the other hand, M2 and M4 
are coupled to Gi/0 proteins, which results in the inhibition of adenilate cyclase, as well 
as prolonging potassium channel, non-selective cation channel, and transient receptor 
potential channel opening 455,456. By means of this differential set of G protein partners, 
muscarinic receptors can initiate distinct signalling pathways within a same cell in order 
to trigger diverse, even opposed, functional outcomes in response to the same stimuli. It 
has been proven as well that mAChRs regulate a baste network of signalling 
intermediates, including small GTPase Rho, phospholipase D, phosphoinositide-3 
kinase, non-receptor kinases and mitogen-activated protein kinases 322,457,458. 
Although the first proteins found to have functional interactions with muscarinic 
receptors were, of course, G proteins, an increasing amount of evidence in the field 
suggests that this simplistic model defined as “one receptor -one G protein -one effector 
no longer exists. A great number of proteins have been identified as interacting with 
mAChRs, including GPCRs, kinases, and scaffolding proteins such as arrestin 459. 
Determining in part the signalling efficiency/specificity for mAChRs 64.  Thus, 
receptors are now considered as complex signalling units, or signalosomes, that 
dynamically couple to multiple G proteins or other molecular entities or scaffold 
proteins in a temporally and spatially regulated manner, and even can form homodimers 
or heterodimers with distinct GPCRs or other non-GPCR membrane receptors, resulting 
in pharmacologically and functionally distinct receptor populations 79. 
In this review, effort will be made to discuss novel muscarinic receptor interacting 
partners that link the receptors to alternative signalling pathways beyond G proteins. We 
will put emphasis on explaining how muscarinic receptors regulate signal transduction 
pathways mediated by these proteins, including receptor dimerization. Such knowledge 
will allow us to address some fundamental questions concerning the importance of 
molecular mechanisms hidden behind the pharmacology properties for each receptor 
subtype.  It may also uncover factors that modulate synaptic transmission and provide 
insights into a variety of physiologic and pathophysiologic processes.   
 
Physiological roles of muscarinic receptors 
Uncovering the physiological roles of the distinct muscarinic subtypes has been possible 
thanks to the gradual development of more selective receptor agonists and blockers, and 
with the detailed phenotypic characterization of mice knockout 460. Different 
experimental approaches, including immunohistochemical and mRNA hybridization 
studies, show that mAChRs are present in virtually all organs, tissues, or cell types 
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(Table 6.1.1) 461-463. Muscarinic acetylcholine receptors are expressed pre- and 
postsynaptically and have discrete distribution throughout the central and peripheral 
nervous systems 464. 
Peripheral mAChRs mediate the classical muscarinic actions of acetylcholine on organs 
or tissues that are innervated by parasympathetic nerves. Muscarinic receptors are found 
in visceral smooth muscle, in cardiac muscle, in secretory glands, and in the endothelial 
cells of the vasculature 280,465. Except for endothelial cells, each of these sites receives 
cholinergic innervation. The most common responses mediated by these peripheral 
mAChRs include reduction of heart rate, stimulation of exocrine glandular secretion, 
vasodilatation and smooth muscle contraction. Central mAChRs are involved in 
regulating an extraordinarily large number of cognitive, behavioural, sensory, motor, 
and autonomic functions 460. 






Organ and Tissue Functional Rol (es) or 
Response 
Refs. 
M1 Gαq/11 Autonomic ganglion including 
myenteric plexus, cerebral 
cortex, canine saphenous vein, 
Lymphocyte and keratinocyte 
Depolarization, 
contraction, increased 
gastric acid secretion, IL-
2 production, proliferation 
460,466-470 
M2  Gαi/0 Heart, atrium, ileum smooth 
muscle, sinu-atrial node 
Reduce Ach release, 
contractile force and rate 
471-476 
M3 Gαq/11 Urinary bladder, iris circular 
muscle, blood vessels-
endothelium, Smooth muscle 
and salivary glands, pancreatic β 
cells, Lymphocyte and 
keratinocyte, colon and thyroid 
cancer cells 
Contraction, 
vasodilatation via release 
of NO, inhibition of 




M4  Gαi/0 Corpus striatum, Uterus (guinea 
pig), lung, muscle (rabbit), 
keratinocyte 
Contraction, NO-
dependent relaxation, cell 
migration 
460,469 
M5 Gαq/11 Substantia nigra pars compacta, 
ventral tegmental area, brain 
microvasculature 
Growth and proliferation 481,482 
 
There is also evidence that mAChRs are expressed in several non-innervated tissues 483. 
They are expressed in primary and metastasis tumour cells which act as the inductors of 
transformation, growth and proliferation 484,485. This has been described in vascular 
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endothelium, keratinocytes, lymphocytes and placenta 486-488, whereas acetylcholine 
acts, via mAChRs activation, in an autocrine fashion 489. 
 
Structural basis of interactions 
A critical question in GPCRs signalling is what determines the specificity of signal 
transduction processes. One of the most important steps in answering this question is 
the analysis of control signal specificity by a multiprotein complex formation, in 
contrast with the classical model, one receptor -one G protein -one effector 490. 
Extended observations related to GPCR signalling mechanisms have demonstrated that 
the cytoplasmic face of these receptors and, particularly, the third intracellular loop and 
the C-terminal tail, are critical in mediating the signal transfer to G proteins and play 
specific roles in mediating protein-protein interactions 491.  
Sequence analysis of the cytoplasmic hydrophilic domains of the five muscarinic 
receptor subtypes reveals high sequence similarity in the case of the first and second 
intracellular loops, which comprise about 90% of amino acid identity. Nevertheless, 
fewer similarities are observed when analysing the third intercellular loop, which has a 
sequence similarity near 50% and a high degree of variability in length or size, 
depending on the receptor subtype. A deeper analysis of the potential positive and 
negative charge distribution showed a great number of cluster formations at the level of 
the third intracellular loop and the C terminal tail (Figure 6.1.1)  
 
Figure 6.1.1 Representation of ionisable amino acid on the cytoplasmic face of the M3 muscarinic 
receptor 2D-topology model (basic (dark circles) and acidic (light circles) residues).  
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Site-directed mutagenesis studies showed that the N-terminal portion of the third 
intracellular loop of muscarinic and other G protein-coupled receptors represents one of 
the most fundamental structural determinants for direct G protein interaction 349,492. 
Insertion mutagenesis studies with the rat M3 muscarinic receptor suggested that this 
region forms an amphiphilic alpha helix and that the hydrophobic side of this helix 
represents an important G protein recognition surface. Further analysis of this receptor 
segment showed that Tyr254 located at the N-terminus of the 3ILoop and specific 
residues located in the second intracellular loop of the M3 muscarinic receptor play a 
key role in muscarinic receptor-induced Gq activation 493. 
Other experimental strategies involving the coexpression of hybrid M2/M3 muscarinic 
receptors with hybrid G alpha-subunits correlated with the proposed model 338. Using 
this approach, it was demonstrated that the C-terminus of G protein alpha i/o-subunits is 
recognized by a short sequence element in the M2 muscarinic receptor ("VTIL") which 
is located at the junction between the sixth transmembrane domain (TM VI) and the 
3ILoop. This interaction is a critical part of determining coupling selectivity and 
triggering G protein activation.  
On the other hand, expression of a peptide encompassing the entire 3ILoop of 
muscarinic receptors abrogated the interaction of receptors with G proteins and 
disrupted signalling of other GPCRs that couple to the same G protein population 494. 
This suggests that the 3ILoop of muscarinic receptors can be considered an inhibitor 
that targets and interacts directly with Gq/11 proteins. In addition, this domain also 
serves for the direct binding of Gβγ complexes, calmodulin and RGS protein 495,496.  
The C-terminal domain of GPCRs which has been termed “the magic tail” is recognized 
as one of the most important domains for the regulation of GPCR function 497. This 
region is also implicated in post-translation modifications and is crucial for receptor 
phosphorylation, desensitization and trafficking in some GPCRs 498. The sequence, the 
length, and the different recognition motifs involved in protein-protein interactions are 
specific to each GPCR C-terminus. Despite the number of protein interactions 
associated with the C terminal tail of many GPCRs (as in the case of muscarinic 
receptors), as so far as we know only a few groups of putative interactions have been 
reported 64. The predicted C-terminal tails of the muscarinic receptors is a highly 
conserved domain both in sequence similarity and length.  This domain contains a 
conserved region following the seventh transmembrane domain composed of a cluster 
of basic amino acids that confer anti-apoptotic properties to the receptor, but molecular 
details remain known 348.  
Figure 6.1.1 shows examples of sequence motifs associated with protein interaction in 
the muscarinic receptor family. The ability of mAChRs to interact with different 
proteins probably begins at the sequence motif level of the cytoplasmic face, where a 
great number of charged amino acid clusters have been observed and a quantity of post-
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transductional modification takes place. As mentioned above, special interest is given to 
the 3Iloop, which represents a docking site for the protein-protein interaction of many 
receptor subtypes. 
 
Transmembrane muscarinic receptor interacting proteins 
Homo and Heterodimerization 
It is well established that a variety of cell surface receptors interact with each other to 
form dimers, and that this is essential for their activation 499. Although the existence of 
muscarinic receptor dimers was predicted from early pharmacological and biochemical 
analysis, solid evidence supporting dimerization has come within the past few years 
using different experimental approaches such as co-immunoprecipitation of distinctly 
tagged versions of the receptor, light resonance energy transfer techniques FRET and 
BRET (fluorescence and bioluminescence resonance energy transfer, respectively), as 
well as analysis of cooperative ligand binding 500,501. Pioneering studies by Wess and 
colleagues have demonstrated that in a heterologous expression system of COS-7 cells, 
M3 receptor are able to form functional homodimers 502,503. Purification and co-
immunoprecipitation experiments in Sf9 cells also showed oligomers formation by 
muscarinic M2 acetylcholine receptors 504. In addition, as different subtypes of 
muscarinic receptors are coexpressed in the same cell type in several tissues, for 
example, M1 and M2 receptors in neurons and M2 and M3 receptors in smooth muscle 
cells, it has been proposed that mAChR subtypes may heterodimerize 505. Maggio and 
Wess showed that M3 dimerization/oligomerization is receptor subtype specific and 
occurs in both transfected cells and native tissues 506. Using bioluminescence resonance 
energy transfer, it has been demonstrated that M1, M2, and M3 mAChR can form 
constitutive homo- and heterodimers in living HEK 293 cells. And that the cell receptor 
population for theses single subtypes is predominantly composed of high affinity 
homodimers 507 (Figure 6.1.2). In the same report, saturation curve analysis of cells 
expressing two receptor subtypes demonstrates the existence of high affinity M1/M2, 
M2/M3, and M1/M3 mAChR heterodimers, although the relative affinity values were 
slightly lower than those for mAChR homodimers.  
A relatively controversial issue concerning GPCR oligomerization is the effect of ligand 
binding on the formation of oligomers. Although for many GPCRs, the role of agonists 
in dimerization for the muscarinic receptor M3 has been described, the activation of thse 
receptors by the agonist produces no change or effect on the dimerization process. 508 
Similar behaviour has been described for the M2 receptor subtype, where 
dimerization/oligomerization of the M2 receptor is independent of the presence of the 
agonist carbachol or the inverse antagonist atropine 509. In addition, FRET and BRET 
experiments showed that short-term agonist treatment did not modify the oligomeric 
status of homo- and heterodimers for M1/M2 and M3 subtypes. Nevertheless, when 
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expressed in JEG-3 cells, the M2 receptor exhibits much higher susceptibility than the 
M3 receptor to agonist-induced down-regulation. Coexpression of M3 mAChR with 
increasing amounts of the M2 subtype in JEG-3 cells resulted in an increased agonist-
induced down-regulation of M3, suggesting a novel role of heterodimerization in the 
mechanism of mAChR long-term regulation 510. Whereas in some cases agonist induced 
increases were observed in the level of dimers, in others no change at the level of 
receptor dimers has been observed.  
At present, it has been firmly established that there are some classes of GPCRs where 
oligomerization already occurs 511. From the evidence gathered so far, it appears that 
class A hetero-oligomers are formed before or during translocation form endoplasmic 
reticulum/Golgi to the plasme membrane 512. However, measuring BRET or FRET 
signals in cell fractions collected from sucrose gradient, used to separate cell surface 
proteins from intracellular material, revealed that homo-oligomers could already be 
detected in light weight fractions for the β2-AR 513, α1A-AR 514  as well as hetero-
oligomers between D1R and D2R 515. With respect to the muscarinic receptor family,  
there have to this day been no reports analyzing the oligomerization of these receptors 
from a biogenesis perspective. 
In principle, dimerization/oligomerization of mAChRs can result from either 
noncovalent (ionic or hydrophobic) or covalent association of the receptor protomers. In 
the M3 receptor, a cysteine pair (Cys140 and Cys220) is thought to be critically 
involved in the formation of covalently linked M3 receptor 516. These two cysteine 
residues are highly conserved within GPCRs of the rhodopsin family, and are able to 
form an intramolecular disulphide bond, thus covalently linking the first and second 
extracellular loops. But they may also participate in the formation of intermolecular 
disulfide bonds. Apart from covalent interactions mediated by cysteine residues, it has 
been demonstrated that the 3ILoop actively participates in the heterodimerization of M2 
and M3 muscarinic receptors. Deleting 196 amino acids from the 3ILoop of short 
chimeric alpha2 adrenergic/M3 muscarinic receptors resulted in the loss of 
intermolecular interaction compared with receptors that kept the entire loop 517 (Figure 
6.1.2).  
At the moment, the functional implications and biological significance of (homo and 
hetero) dimerization of mAChRs is still poorly understood. A large body of evidence 
has progressively substantiated the role of receptor homodimerization and 
heterodimerization in different functional aspects of GPCRs 281. Dimerization can be 
required for receptor maturation and correct transport from the endoplasmic reticulum 
to the plasma membrane. Receptor dimerization can also influence ligand recognition 
by each of the constituent protomers 518. Thus, ligand binding to one protomers might 
increase or decrease binding affinity to the other protomers 519. As ligand-binding sites 
for muscarinic receptors are buried in a hydrophobic pocket formed by transmembrane 
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domains, it is possible that interactions between protomerss through such domains 
might rearrange ligand-binding sites (domain swapping) and modify ligand selectivity 
and affinity 520.  
Ionic channels interaction 
Interaction amongst members of divergent families of receptors presents an additional 
layer of complexity when considering the mechanisms of receptor cross talk in cells. 
Recent reports provide compelling biochemical and functional information about direct 
interaction between GPCRs and receptor channels 521,522. However, modulation of ion 
channels by mAChR agonists appears increasingly complex. It was observed that K(+) 
channels may be activated by M2 and M4 receptor subtypes after agonist stimulation, 
although in the rat superior cervical ganglion, topographical constraint effects appear to 
be limited the effect to the M2 mAChR 523.  
G-protein-gated inwardly rectifying K+ channels (GIRK1) were first identified in atrial 
myocytes where they are activated by acetylcholine at muscarinic M2 receptors 524. It 
was subsequently shown that this activation was membrane-delimited, mimicked by 
non-hydrolysable GTP analogues, and involved a direct interaction with the Gβγ 
dimmer, not the G  subunit 525,526. Using the techniques two-hybrid and pull-down 
assay, it was demonstrated that Gβγ interacts directly with the protein GIRK1, an 
interaction which takes place at the C Terminal.  527  In parallel, it has been observed 
that Regulators of G protein Signalling proteins (RGSs) accelerate the activation and 
deactivation kinetics of GIRK channels 528. Co-expression of RGS4 accelerated all the 
PTX-insensitive Gαi/0-coupled GIRK currents to a similar extent. In contrast to RGS4, 
RGS7 selectively accelerated Gα0-coupled GIRK currents. Co-expression of 
Gbetagamma, in addition to enhancing the kinetic effects of RGS7, caused a significant 
reduction in steady-state GIRK currents indicating RGS7-Gbetagamma complexes 
disrupt Gα0 coupling. Altogether these results provide further evidence for a GPCR-
Galphabetagamma-GIRK signalling complex that is revealed by the modulatory effects 
of RGS proteins on GIRK channel gating. These functional experiments demonstrate 
that the formation of this signalling complex is markedly dependent on the 
concentration and composition of G protein-RGS complexes. 
Other example of complex regulation between muscarinic receptors and receptor 
channels is the activation of endogenous transient receptor potential-canonical subtype 6 
channels (TRPC6) in neuronal PC12D cells 529 by the M1 muscarinic subtype. 
Activation of TRPC6 channels correlates with the formation of a multiprotein complex 
containing M1 mAChRs, TRPC6 channels, and protein kinase C (PKC). Formation of 
the M1 mAChR-TRPC6-PKC complex is transient, with the highest levels reached 
approximately 2 min after stimulation of M1 mAChRs PKC in the complex 
phosphorylates TRPC6 on a conserved serine residue in the carboxyl-terminal domain 
(S768 in the TRPC6A isoform and S714 in the TRPC6B isoform). The immunophilin 
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FKBP12, the phosphatase calcineurin, and Ca2+-binding protein calmodulin are also 
recruited to the M1 mAChR-TRPC6-PKC complex following activation of M1 mAChRs 
and remain stably associated with the TRPC6 channels after M1 mAChRs and PKC 
have disassociated. The activated TRPC6 channels form the center of a dynamic 
multiprotein complex that includes PKC and calcineurin, which respectively 
phosphorylate and dephosphorylate the channels. Phosphorylation of the TRPC6 
channels by PKC is required for the binding of FKBP12, which in turn is required for 
the binding of calcineurin and calmodulin. Subsequent dephosphorylation of the 
channels by calcineurin is required for the disassociation of M1 mAChRs 530,531. 
But in all of these examples, many of the details related to the pathway, second 
messengers, or interacting protein remain unclear. In none of these cases has a direct 
interaction between divergent receptors been observed; only a functional modulation 
mediated by second messengers or interacting proteins, as is the case with betagamma 
dimmer and the RGS protein532,533. As far as we know, only activation by the 
muscarinic M3 receptor of the Ca2+ release channels, present in the entoplasmic 
reticulum membrane, suggests that there is an underlying a mechanism in which 
receptor-channel coupling is independent of intracellular messengers 534. 
 
Scaffolding and soluble interacting proteins with intracellular loops 
3ILoop: the predominant target of muscarinic receptor interacting proteins 
Nowadays, it is well established that the third intracellular loop of muscarinic receptors 
is not only one of the main target domains for interaction with G proteins, but also a 
binding site for direct interaction with different proteins. The physical interaction of the 
third intracellular loop with a large number of proteins, in some cases, forms a 
multiprotein complex bypassing the need to couple with the heterotrimeric G-proteins 
for signalling. One of theses cases is the activation of small G proteins by a large 
number of the GPCR vie Gα subunit activation or by direct interaction with the receptor 
535,536.  
The muscarinic-mediated regulation of small G-proteins has been viewed typically as a 
downstream consequence of heterotrimeric G-protein activation, particularly Gαq, Gα11 
or Gα12 activation, as ocurrs in many other GPCR 537. G12/13-mediated RhoA activation 
involves direct interactions with RhoGEF proteins (RhoGEF, LARG and p115-
RhoGEF) 538-540.  In a similar manner,  Gαq/11-coupled receptors can couple with 
activation of Rho, via direct association of Gq/11 with Rho GEF 541,542,  albeit with less 
efficacy when compared with Gα12/Gα13 543. However, there are evidences to show 
direct activation of small G-proteins by mAChRs. One of the examples, is the activation 
of the enzyme phospholipase D (PLD) by the small G-proteins Arf and RhoA via M2 
and M3 muscarinic receptor 322,544,545. Both Arf and RhoA can be coimmunoprecipitated 
with the 3Iloop of muscarinic acetylcholine M3 receptor. Dominant negative constructs 
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of ARF1/6 and PLD1/2 proved that the characteristic BFA-sensitive PLD activation 
shown by the M3 receptor appears to involve ARF1-mediated activation of PLD1, 
where additional ARF6-mediated component may involve PLD1 or PLD2 546,547. 
Mutation in the conserved NPXXY amino acid sequence in their transmembrane VII 
domain prevent the association of these receptors with ArF or Rho and also signalling to 
PLD 548. All the experimental results lead to the conclusion of a complex formation, 
stabilized by exposition of a docking site for the Arf and Rho protein between the 
carboxyl terminal of the 3ILoop and the NPXXY conserved motif localized in the 
transmembrane domain VII. 
However, the muscarinic receptor coupled to Gq can activate RhoA, it is generally 
proposed that Gi coupled receptors activate Rac1, but not RhoA, a process involving 
Gbetagamma-dimers and phosphatidylinositol 3-kinase (PI3K) 549. It has been proposed 
that this selectivity can be redirected by the Regulatory G-protein signalling 3 (RGS3L), 
which can function as a molecular switch, changing Gi-coupled receptor via 
Gbetagamma-dimers and PI3K from Rac1 to RhoA activation 550.  
In addition, the binding of the SET protein to M2 and M3 mAChRs is another case that 
illustrates that muscarinic receptor-mediated signalling is triggered by the 3ILoop and 
does not always depend on G-protein coupling. The SET protein, also called TAF-1 for 
template activating factor I, was first described as part of the SET-CAN fusion gene in 
patients with acute undifferentiated leukemia 551. The cellular role of SET is not clearly 
defined, but many functions have been described for this protein. It is involved in the 
control of gene transcription as a component of the INHAT complex (inhibitor of 
histone acetyltransferase), and is also considered an inhibitor of PP2A, which is 
involved in cell cycle progression and GPCR traffiking and regulation 552,553. Co-
immunoprecipitation experiments and mass spectrometry demotrated that SET interacts 
directly with the 3Iloops of M2 and M3 muscarinic receptor, and that for the latter, the 
interaction involves the last 17 amino acids of the 3Iloop (I474-Q490) 554 (Figure 6.1.3). 
Using siRNA knockdown, Violaine et al. demonstrated that SET acts to provide a brake 
on M3 muscarinic signalling. It has been proposed that SET interaction could impede G-
protein coupling to the receptor. The last 17 amino acids found to interact with SET in 
the C-terminus of the third intracelullar loop are also involved in G-protein coupling 
and the activation of various GPCR 555,556. A second possibility is that SET, by virtue of 
its ability to inhibit PP2A, may increase the basal level of receptor phosphorylation and 
can regulate the magnitude or duration of agonist-induced receptor phosphrylation. 
Theses changes in the phosphorylation status may play an important role in the maximal 
response observed following receptor activation, as well as in receptor trafficking 557,558. 
The isolation of SET as a receptor’s binding partner, as well as the functional 
characterization of this interaction, represents a totally unappreciated mechanism for 
regulation of muscarinic receptor signalling and it capacities. 
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Likewise, using the 3ILoop as bait, Bernstein et al. examined whether GPCRs 
selectively recruit RGS proteins to modulate linked G protein signalling, and 
demonstrated a direct interaction between RGS2 and the 3Iloop of the M1 muscarinic 
receptor 559. Based on the fact that closely related RGS16 does not bind to the M1 
receptor, they postulated that GRS2-M1 interacts in a selective way. Probably, RGS2 
strongly inhibits M1 muscarinic-mediated phosphoinositide hydrolysis in the cell 
membrane by acting as an effector’s antagonist. A model has been postulated in which 
the 3Iloop of mAChRs, and the larger GPCR family, selectively recruit specific RGS 
protein(s) via their N-termininal to regulate the linked G protein, a critical step in the 
activation/ desensitization mechanism 560. 
 
Figure 6.1.3. Molecular dissection of sequence motifs those are associated with protein interaction in M3 
muscarinic receptor. A two-dimensional topology, with the extracellular space at the top and the 
intracellular space at the bottom, of the M3 human muscarinic receptor sequence are represented. The 
residues highlighted and described in the legend are sites of recognition by protein interacting with the 
intracellular face of the receptor. Note that in the case of the N-termine of the 3Iloop coincides more than 
one recognition site by protein interacting. This particularity can be the response to many question 
related with the desensitization and regulation process of muscarinic receptor activation and signal 
transduction mechanism. Also, the consensus motif that can be phosphorylated are specifically and 
different for each protein kinase.  
 
McClatchy et al found a novel interaction between the M4 mAChR and elongation 
factor 1A2 (eEF1A2) both in vitro and in vivo 561. eEF1A is a GTP-binding protein that 
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is essential in protein synthesis mediating the binding of the aminoacyl-tRNA to the 
acceptor site of the ribosome 562,563. It is also only expressed in skeletal muscle, heart 
muscle, and brain in adult mammals 564,565. The M4, via the 3Iloop, can modulate 
translation process as well as protein synthesis through its interaction with eEF1A2. 
In the last years it has been demonstrated that CaM can interact with a motif located in 
the C-termini juxtamembrane regions of the M1 and M3 muscarinic receptor 3ILoop566 
(Figure 6.1.3). Binding of CaM to muscarinic receptors was found to be antagonistic 
with PKC-mediated receptor phosphorylation, suggesting a role in receptor 
desensitization 229. This interaction may also be critical for muscarinic receptor-
mediated activation of the ERK signalling pathway, which is dependent on Ca2+/CaM 
and involves agonist-induced receptor internalization and arrestins 567. In this regard, a 
recent study has demonstrated a direct interaction of all arrestin subtypes with CaM 
bound to Ca2+ 568. The CaM binding site on arrestins overlaps with the binding site for 
GPCRs, indicating that receptors and CaM should compete for interacting with 
arrestins. This also suggests that arrestin-CaM interaction may regulate the availability 
of both proteins for interacting with receptor partners. The specific implication of this 
interaction on elucidates receptor-mediated induction of ERK1, 2 signalling pathway 
and internalization remains to be determined.  
 
The C terminal tail 
Although there is increasing evidence that the “magic tail” of GPCRs constitutes the 
main anchoring domain for soluble interacting proteins (more than 50 GIPs interacting 
with GPCR C-termini have been identified 569), in the case of muscarinic receptor 
family only the third intracellular loop has been reported as critical domain capable of 
binding adaptor and scaffold proteins. Nevertheless, a few examples have been reported 
with a functional role in receptor regulation and signalling570.  
Many proteins proposed to be involved in post-endocytotic sorting of receptors were 
probed for interactions with the C terminal tail of muscarinic receptors using GST pull-
down assays 571, which routinely have been used to confirm protein interactions 
identified by co-immunoprecipitation and yeast two-hybrid screening.  Interaction with 
N-ethylmaleimide-sensitive factor (NSF) was identified in all members of the 
muscarinic receptor family, which has been suggested to be responsible for the 
recycling of the β2-adrenergic receptor 572. In contrast, sorting nexin 1 (SNX1), which 
was originally demonstrated to be required for the lysosomal sorting of the epidermal 
growth factor receptor, was only suggested to be involved in the lysosomal sorting of 
M1, M4 and M5 subtypes 573. Another protein called G protein-coupled receptor-
associated sorting protein (GASP) was recently suggested to be involved in the 
preferential lysosomal sorting of the δ-opioid receptor and confirmed to bind to all 
subtypes of muscarinic receptors 574,575. 
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Despite the small role of the C terminal tail of muscarinic receptor in the recruitment 
and anchoring of adaptor and scaffolds protein, it is well established that the C-terminal 
tail of the M3 muscarinic receptor is an essential structural element for signalling to the 
anti-apoptotic pathway 348. Experimental evidence has shown that the removal of the 
distal portion of the C-terminal tail results in a receptor that is coupled normally to the 
Gq/11/phospholipase C pathway and the mitogen-activated protein kinase pathway, but is 
unable to couple to the anti-apoptotic pathway 576. Furthermore, it has been 
demonstrated that a poly-basic region conserved within the C-terminal tail of the Gq/11-
coupled muscarinic receptor subtypes (CDKRKRRKQ) appears to be the structural 
determinant of coupling to the anti-apoptotic pathway 348. Today it is still unclear what 
protein or proteins are implicated in the connection of the muscarinic receptor with the 
anti-apoptotic pathway, and which anti-apoptotic signalling is implicated.  
 
Muscarinic receptor interactome 
Until a few years ago it was thought that the interactions between GPCRs, G-proteins 
and their effectors could describe the whole system. However, we now know that it is 
much more complex, with many other proteins binding to GPCRs and influencing their 
activity 577. Indeed, several reports have shown that a particular complex is not 
necessarily of invariable composition, nor are all its building blocks uniquely associated 
with that specific complex. One complex may be the result not only of physical 
interaction between the receptor and the partners’ protein, but also of the participation 
of many non-“direct” associations resulting in the formation of a network that 
interconnects the receptor with a number of other pathways, determining receptor 
specificities 578. This is a phenomenon that has received several names: interactome, 
signalsomes or receptosome; but essentially describes the complexity of receptor 
association, signalling and their regulation throughout the formation of multiprotein 
complexes 578,579. 
A well-documented example of networks and their receptor-specificities is the 
description of the internalization process of muscarinic receptors upon agonist 
stimlation. For mAChRs and most other GPCRs, agonist-induced phosphorylation of 
the receptor causes receptor internalization 580. Alanine substitution mutagenesis of the 
putative phosphorylation sites in the third cytoplasmic loops of the human M1, M2 and 
M3 mAChR robustly decreases receptor internalization 581,582. In addition, three 
threonine residues in the C-terminus of the human M3 mAChR (T550, T553, and T554) 
have been identified as being important in the internalization and desensitization of the 
receptor in HEK293 cells 583. The role of the various GRKs in mAChR internalization is 
critically dependent on mAChR subtype, as well as on the cell type involved. For 
instance, expression of GRK2 K220W mutant in COS-7 cells increase M1 mAChR 
internalization, whereas M3 mAChR internalization in the same cell type is unaffected 
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584. While expression of GRK2 K220W reduces M2 mAChR internalization in COS-7 
cells 585, it does not change M2 mAChR internalization in BHK-21 and CHO cells 
586,587. 
GRK mediated arrestin binding also initiates receptor internalization/sequestration, 
which occurs via the association of the receptor-arrestin complex with components of 
clathrin-coated pits 588-590. Various groups have confirmed the role of β-arrestins and 
clathrin-coated vesicles in mAChR internalization. Expression of a dominant-negative 
β-arrestin-1 mutant, which binds with high affinity to clathrin, but is significantly 
impaired in its ability to interact with phosphorylated GPCRs, significantly suppresses 
internalization of M1, M3, and M4 mAChRs in HEK293 cells 591,592. In similar way, 
expression of another dominant-negative β-arrestin mutant, β-arrestin S412D, which 
binds to phosphorylated GPCRs with unchanged affinity, but not to clathrin, inhibits M1 
mAChR in HEK293 cells 593. These results are consistent with the observations that 
expression of a dominant-negative clathrin mutant strongly inhibits M1, M3, and M4 
mAChR internalization 594. Interestingly, in HEK293 cells, M2 mAChRs internalize in a 
β-arrestin- and clathrin-independent manner 595,596. These experiments suggest that 
phosphorylated M2 mAChRs do not readily interact with β-arrestin in HEK293 cells. 
Indeed, Wu et al. proved that a peptide sequence derived from the 3Iloop of the M2 
mAChR, which contains the GRK2 phosphorylation sites and a putative β-arrestin 
binding site, does not bind β-arrestins derived from a brain cytosolic fraction. In 
contrast, a peptide sequence from the thirdintracellular loop of the M3 mAChR is 
capable to do so 597. These observations increase the possibility that other cytosolic 
adaptor proteins associate with phosphorylated M2 mAChRs to mediate non-clathrin-
mediated internalization of the receptor. 
The ability of β-arrestins to promote GPCR internalization does not arise solely as a 
consequence of their ability to bind clathrin. The binding of arrestins to clathrin is, per 
se, not capable of triggering internalization. Endocytosis and trafficking are enhanced 
by the fact that arrestin recruits phosphoinositides, adapter molecule AP-2, another 
endocytic protein, and intracellular trafficking proteins such as the N-ethylmaleimide-
sensitive factor (NSF), the ADP-ribosylation factor ARF6, and its exchange factor 
ARNO 598. ARF6 regulates vesicle budding by recruiting vesicle-coat proteins including 
COP1 coatomers. It is possible that mAChR internalization requires the interaction of 
the receptors with other proteins as well. Wu et al. have shown that the Gβγ subunit is 
able to bind to a peptide (C289-D329) corresponding to the 3Iloop of the M3 mAChR. 
Although M3 mAChR mutants lacking the Gβγ binding site exhibit unchanged ligand 
binding properties and functional responsiveness, they are unable to promote receptor 
internalization 599. Downstream of the Gβγ binding motif are the putative GRK2 
phosphorylation sites (332SSS334 and 349SASS352). It has been proposed that the 
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marked reduction in internalization of the Gβγ subunit binding-defective M3 mAChR 
mutants may be due to impaired phosphorylation of the receptor by GRK2 600.  
The network of proteins that interact with GPCRs may be particularly important for 
signalling, trafficking and targeting these receptors to particular cellular compartments. 
Different types of connections to different types of receptors allow both positive and 
negative cross talk, and this fine-tuning allows the cell to respond differently to ligand 
binding. The fact that we have so far been unable to model this complexity in assays 
may explain why we are still unable to reliably design GPCR-targeted drugs that will be 
free of side effects. 
 
Compartimentalization of muscarinic receptors. The cell context 
Much has been written concerning the influence of receptors on cell function. Discussed 
far less often is the reverse relationship, the influence of the cellular context on receptor 
function and regulation. Spatial organization of muscarinic receptor complexes into 
specific membrane domains has been shown to influence or determine signal 
transdcution 601. The cell background imposes phenotypic selectivity, by concentrating 
components of the cellular signalling cascade within microdomains and, in specific 
cases, determining the spatial and temporal-relationship of interacting proteins with the 
resulting change in receptor pharmacology properties 602. 
The localization of GPCRs and their downstream signalling partners to specific 
membrane lipid compartments (so-called “lipid rafts” and in particular caveolae) 
perhaps provides a more widely applicable paradigm for the regulation of receptor 
signalling 603. An interesting property of caveolae is that they selectively accumulate a 
variety of signal components, including GPCRs, G-protein and second messenger-
regulated kinases, prompting the proposal that they might regulate signal transduction 
604. In cardiac myocytes, as well as specialized conduction and pacemaker cell, the M2 
muscarinic receptor has been demonstrated to translocate out and into caveolae upon 
agonist stimulation, resulting in a clear demonstration that multiprotein complex 
composition and regulation may be tightly linked to their localization in the lipid 
microdomain 605,606. Also, in airway smooth muscle cells, caveolae facilitated the 
muscarinic receptor–medited intracellular Ca2+ mobilization and cell contraction 607. 
And the loss of caveolin-1 has been associated with disruption of M3 muscarinic 
receptor activity in bladder 608. It has been recently demonstrated that caveolin 2 has an 
active role in the regulation of M1 muscarinic receptor endocytosis and trafficking in 
MDCK epiteail cells. Association of the M1 muscarinic receptor with caveolin 2 
inhibits receptor endocytosis through the clathrin-medited pathway or retains the 
receptor in an intracellular compartment 609. This intracellular association and the 
attenuation of receptor trafficking is rescued by the co-expression of caveolin 1. 
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One of the most striking examples of the effect of cellular embiroment on muscarinic 
receptosome is observed in striatal neurons. Intraneuronal trafficking of M4 muscarinic 
receptors has been observed in vivo-- that is, under regulation of the cholinergic 
environment 610. M4 receptor subcellular compartimentalization and function will be 
dependant on the phenotype of the cholinoceptive neuron and on its neurochemical 
environment. On the other hand, acute and chronic acetylcholinesterase inhibition 
regulates in vivo the localization and quantity of M2 and M4 receptor subtypes at the cell 
surface and in the cytoplasme 611.  
 
The bad face of muscarinic receptor interactions 
We are now discussing the active role of the muscarinic receptor interacting protein in 
receptor regulation and function. We discussed above the importance of assesory 
protein in receptor specificities and signal efficiency/efficacy. And we determined that 
improved molecular understanding of the mechanism underlying receptor-protein 
interaction is likely to provide us with previously unrealized opportunities to achieve 
greater muscarinic pharmacology specificity and drug development. But receptor 
interacting protein doesn’t always show us the best face of the physiological behaviour 
of the cells. Evidence accumulated over the last decade gives adequate proof of the 
existence of circulating antibodies in different autoimmune diseases, which binds to 
muscarinic receptors, converting the cells in pathologically active cells.  
One of these examples is Chagas' disease, caused by a parasite, Trypanosoma cruzi, 
which is widely distributed in Latin America 612. Dysautonomias (that is, derangements 
of sympathetic and parasympathetic nervous system functions), are seen fairly often 
during the chronic course of Chagas' disease. Many infected patients develop, in the 
course of the disease, neurogenic cardiomyopathy or digestive damage 613. Existence of 
circulating antibodies that bind to beta-adrenergic and M2 muscarinic receptors has been 
reported as a basis for Chagas' disease 614. The anti-M2 receptor antibodies recognize an 
epitome on the second extracellular loop. The neurotransmitter receptor-autoantibody 
interaction triggers in the cells intracellular signal transductions that alter the 
physiological behavior of the target organs, leading to tissue damage. Moreover, the 
deposit of autoantibodies on the myocardial receptors, behaving like an agonist, could 
induce desensitization and/or down regulation of the receptors. This in turn can lead to a 
progressive blockade of them with sympathetic and parasympathetic denervation 615. 
Sjögren syndrome (SS), the second most common autoimmune rheumatic disease, 
refers to keratoconjunctivitis sicca and xerostomia resulting from immune lymphocytes 
that infiltrate the lacrimal and salivary glands 616. However, differential diagnosis 
remains confusing due to the high prevalence of vague symptoms of dryness, fatigue, 
and myalgias in the general population. Previous studies have demonstrated that 
antibodies against muscarinic receptors from exocrine glands correlate with Sjögren 
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syndrome in the majority of patients 617. Experimental evidence has demonstrated that 
serum IgG antibodies-stimulating M3, M4, and M1 cholinoreceptors exerted an increase 
in COX-2 mRNA without affecting COX-1 mRNA expression and increased PGE (2) 
production 618. This results in the chronic inflammation and cognitive dysfunction 
characteristic of SS patients 619  
Isolated congenital heart block may be associated with autoimmune disorders such as 
Sjögren Syndrome and systemic lupus erythematosus 620. It has been demonstrated that 
the circulation of autoantibodies against neonatal heart M1 muscarinic acetylcholine 
receptors in the sera of children correlated with congenital heart block 621. 
Autoantibodies were able to react with the second extracellular loop of the human M1 
receptor and decreased contractility, activated nitric oxide synthase activity, and 
increased production of cyclic GMP 622.  
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G-protein-coupled receptors (GPCRs) form the largest superfamily of proteins in 
the human body. About 1% of the human genome encodes for over 1000 GPCRs 
1. They are located at the cell surface and are expressed ubiquitously. GPCRs 
regulate diverse intracellular responses and are therefore involved in all kinds of 
diseases, making them interesting therapeutic targets 2. Acetylcholine, an 
endogenous amine, acts on a subfamily of these GPCRs, the muscarinic receptors, 
causing physiological effects such as increase in basal locomotors activity and 
gastric acid release 266.  
Muscarinic acetylcholine receptors (mAChRs) have been shown to mediate 
various functions in the central and peripheral nervous systems (CNS, PNS) 623. 
These include modulation of exocrine glandular secretion, vasodilatation and 
smooth muscle contraction 624, cell proliferation or survival 625, neural 
development and synaptic plasticity 626.   Muscarinic receptors are activated by 
both endogenously produced acetylcholine and exogenously administered 
muscarinic compounds. Pharmacological, anatomical and molecular studies have 
demonstrated the existence of five muscarinic receptor subtypes, denoted as 
muscarinic M1, M2, M3, M4 and M5, which belong to class I family of 
heptahelical, transmembrane G-protein coupled receptors (GPCRs) 183.  
Each receptor subtypes are characterized by a distinct selectivity for 
heterotrimeric G protein coupling. Thus, M1, M3 and M5 are coupled to Gq/11 
proteins and stimulate phospholipase C activity, resulting in the generation of the 
second messengers inositol (1,4,5)-trisphosphate (IP3) and diacylglycerol (DAG), 
the mobilization of intracellular Ca2+ and the activation of protein kinase C 
(PKC) 184. On the other hand, M2 and M4 are coupled to Gi/0 proteins, which 
results in the inhibition of adenilate cyclase, as well as prolonging potassium 
channel, non-selective cation channel, and transient receptor potential channel 
opening 627,628. By means of this differential set of G protein partners, muscarinic 
receptors can initiate distinct signalling pathways within a same cell in order to 
trigger diverse, even opposed, functional outcomes in response to the same 
stimuli. It has been proven as well that mAChRs regulate a baste network of 
signalling intermediates, including small GTPase Rho, phospholipase D, 
phosphoinositide-3 kinase, non-receptor kinases and mitogen-activated protein 
kinases 322,629,630. 
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Although the first proteins found to have functional interactions with muscarinic 
receptors were, of course, G proteins, an increasing amount of evidence in the 
field suggests that this simplistic model defined as “one receptor -one G protein -
one effector no longer exists. A great number of proteins have been identified as 
interacting with mAChRs, including GPCRs, kinases, and scaffolding proteins 
such as arrestin 631. Determining in part the signalling efficiency/specificity for 
mAChRs 64.  Thus, receptors are now considered as complex signalling units, or 
signalosomes, that dynamically couple to multiple G proteins or other molecular 
entities or scaffold proteins in a temporally and spatially regulated manner, and 
even can form homodimers or heterodimers with distinct GPCRs or other non-
GPCR membrane receptors, resulting in pharmacologically and functionally 
distinct receptor populations 79. 
In this work, it is discuss novel muscarinic receptor interacting partners that link 
the receptors to alternative signalling pathways beyond G proteins. Emphases on 
explaining how muscarinic receptors regulate signal transduction pathways 
mediated by these proteins, including receptor dimerization have been putting out. 
This allows us to address some fundamental questions concerning the importance 
of molecular mechanisms hidden behind the pharmacology properties for each 
receptor subtype. 
Homo- and heterodimerization of M3 and M5 muscarinic receptor 
subtypes 
It is well established that a variety of cell surface receptors interact with each 
other to form dimers, and that this is essential for their activation 499. Although the 
existence of muscarinic receptor dimers was predicted from early 
pharmacological and biochemical analysis, solid evidence supporting 
dimerization has come within the past few years using different experimental 
approaches such as co-immunoprecipitation of distinctly tagged versions of the 
receptor, light resonance energy transfer techniques FRET and BRET 
(fluorescence and bioluminescence resonance energy transfer, respectively), as 
well as analysis of cooperative ligand binding 632,633. Pioneering studies by Wess 
and colleagues have demonstrated that in a heterologous expression system of 
COS-7 cells, M3 receptor are able to form functional homodimers 634,635. 
Purification and co-immunoprecipitation experiments in Sf9 cells also showed 
oligomers formation by muscarinic M2 acetylcholine receptors 636. In addition, as 
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different subtypes of muscarinic receptors are coexpressed in the same cell type in 
several tissues, for example, M1 and M2 receptors in neurons and M2 and M3 
receptors in smooth muscle cells, it has been proposed that mAChR subtypes may 
heterodimerize 637. Maggio and Wess showed that M3 
dimerization/oligomerization is receptor subtype specific and occurs in both 
transfected cells and native tissues 638. Using bioluminescence resonance energy 
transfer, it has been demonstrated that M1, M2, and M3 mAChR can form 
constitutive homo- and heterodimers in living HEK 293 cells. And that the cell 
receptor population for theses single subtypes is predominantly composed of high 
affinity homodimers 639 (Figure 6.1.2). In the same report, saturation curve 
analysis of cells expressing two receptor subtypes demonstrates the existence of 
high affinity M1/M2, M2/M3, and M1/M3 mAChR heterodimers, although the 
relative affinity values were slightly lower than those for mAChR homodimers. 
However, the existence of homo- and hetero-oligomers constituted by M5 
muscarinic receptor subtypes has not been reported yet, despite the large amount 
of experimental evidence that supports the active role of this receptor subtype in 
the non-neuronal cholinergic system. 
In chapter 2, we provide for a first time biochemical, biophysical, and functional 
evidence of the existence of receptor-receptor interaction between M3 and M5 
muscarinic receptors and with each other. Our results from quantitative BRET 
saturation analysis show that M3 and M5 can form homoligomers in intact HEK 
293 cells. Analysis of BRET parameters (BRET50 and BRETmax) supported the 
existence of constitutive M3 and M5 mAChR homodimers in live cells (Table 2.2). 
Results in agreement with previous pharmacological and BRET signal 
demonstrated M1, M2 and M3 muscarinic receptor homodimerization 163, although 
BRET50 values for M5 muscarinic receptors were significantly higher than those 
determine for M3 homodimers. This indicated that the likelihood of homodimer 
formation of the M3 subtype appears to be slightly but consistently higher than 
with M5 receptors subtypes. Therefore, our data suggests that both mAChR 
subtypes in a given tissue results in a combination of homodimers, whose 
proportions depend on both the relative affinity between interacting species and 
their expression levels, and a minor complement of monomers. 
Following the quantitative BRET saturation curve approach, we also 
demonstrated that co-expression of M3 and M5 muscarinic receptor subtypes can 
Discusión and conclusions  
 167
form heterodimers in HEK-293 living cells. Our results from BRET saturation 
curves clearly indicate that M3 and M5 receptors can form heterodimers. These 
results are also confirmed by co-immunoprecipitation experiments.  BRET50 
values from M3/M5 heterodimerization did not differ from values found for M3 
mAChR homodimerization curves. However, they were significantly lower than 
those determined for M5 mAChR homodimers. These results support the idea that 
thr M5 muscarinic receptor subtype exists as a combination of a high affinity 
homo- and hetero-dimers receptor population, but with a high affinity to form 
heterodimers when it is co-expressed with M3 subtypes.  
Although previous reports have demonstrated that GPCR agonist binding induces 
or stabilized receptor oligomerizatio, we cannot observe any change in the BRET 
parameters when cells were incubated in the presence of a carbachol agonist. It 
seems that for the muscarinic receptor family, agonist binding does not promote 
any conformational changes that disestablish the receptor dimerization state. By 
using SDS-PAGE and Western blot analysis of membrane extracts from COS-7 
cells expressing a mutant M3 mAChR, Zeng and Wess showed that agonist-
induced receptor stimulation had no significant effect on M3 mAChR dimerization 
291. In addition, carbachol treatment of HEK 293 cells expressing homologous or 
heterologous combinations of M1, M2, and M3 mAChR fusion proteins revealed 
no significant changes in the BRET signal, as compared with control untreated 
co-transfected cells 163. 
In an attempt to better understand the structural determinants involved in M3/M5 
heterodimerization, we investigated the effects of the third intracellular loop on 
structural dimer organization. Previous studies using peptide strategies have 
identified structural determinants that can affect both GPCR dimers and function. 
For instance, a peptide derived from the TM6 domain of the 2-AR was found not 
only to decrease the amount of receptor dimers detected in co-
immunoprecipitation studies, but also to inhibit receptor-stimulated AC activity, 
leading the authors to conclude that dimerization may be important in receptor 
function 309. Likewise, Banères et al. found that a peptide mimicking the TM6 
domain inhibited the dimerization of the BLT 1 receptor and affected the ability of 
the receptor to interact with the G protein 310. In addition, Granier et al. 
demonstrated that a peptide mimicking the V2 receptor third intracellular loop 
inhibits the receptor function through a modification of its dimeric structural 
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organization and direct action on G proteins 306. In our studies, cells co-expressing 
M3-Rluc and M5-GFP2 in the presence or absence of minigene construction 
encoding for a peptide for the third intracellular loop of the M5 receptor subtype 
revealed a low but significant difference in BRET50. Therefore a significant 
inhibition in the BRETmax signal was observed. These results strongly suggest that 
the minigene construct would modify the distance and/or orientation between M3-
Rluc and M5-GFP2 engaged in dimer formation affecting the oligomerization state 
itself. It also supports the notion that the peptide changes the conformation of a 
pre-existing dimer with promoting disassembly of protomers. 
However it is important to notice that this effect was not higher (increased in 1,1 
fold respect to BRET50 of cell without minigene expression). Probably indicating 
that in muscarinic receptor heterodimerization, specifically for M3 and M5, other 
structural components can actively participate in protomer organization and 
assembly. Based on mutagenesis and cross-linking experiments, helix VI for -AR 
309, helix IV for dopamine D2 137, or helices I and II for Ste2 pheromone receptor 
oligomers 311 have been proposed to provide inter-monomeric contacts. In the 
prototypical GPCR, rhodopsin, intradimeric contacts involving helices II, IV and 
V, as well as the cytoplasmic third intracellular loop are too involved in the 
formation of dimer rows 312.  Whereas the C terminus is implicated in the 
GABAB-R1/GABAB-R2 receptor oligomerization 313, the glycophorin motif 
seems to be involved in the formation of 2-AR homo-oligomers 309, and the role 
of the N terminus int the oligomerization of the bradykinin and calcium receptors 
was reported 314,315. Also, in the muscarinic receptor family, specifically the M3 
subtype, the functional role of the third intracellular loop in receptor dimerization 
has been demonstrated 640. Altogether, these results support the notion that GPCR 
oligomerization involves the participation of different structural determinants 
whose role might differ among receptors. 
The documented coexpression of M3 and M5 receptors in many acetylcholine-
sensitive tissues like striatal dopamine neurons 317, the gastrointestinal tract 318 
and T and B lymphocytes cells 297, suggests that heterodimerization could indeed 
occur in native mammalian tissues, assuming simultaneous expression of both 
receptors in the same cells. As shown for the M5 receptor, some receptors may 
form homodimers but preferentially engage with heterodimers. This may also be 
the case for the 1D-adrenergic receptor (1D-AR) 113, reflecting that a large 
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spectrum of affinities is likely to exist for the formation of different GPCR 
heterodimers. 
The determination of functional consequences of muscarinic receptor 
heterodimerization is difficult to achieve using classic radioligand competition 
binding assays and a specific pharmacological profile, particularly for 
heterodimers composed of M3-M5 subtypes that display similar affinities for the 
same radioligand. Understanding, in part, the structural determinants of M3-M5 
heterodimers allows us to study the role of heterodimerization in signal 
transduction and cytokine production in lymphocytes T-cells by the use of a 
minigene construct which promotes a disestablishing effect in M3/M5 
heterodimerization.  
When Molt-3 cells endogenously expressing M3 and M5 receptor subtypes were 
transfected with the minigene construct, agonist stimulation led to a low level in 
ERK phosphorylation. Similar extensions were observed in agonist enhanced 
PHA-induced-IL-2 production. Theses results revealed that proper receptor 
heteromer is required for proper acetylcholine receptor response and function.  
Our previous results demonstrated that the heterogeneous population of both M3 
and M5 mAChR is composed of homodimers together with a significant fraction 
of heterodimers, whose proportion depends on both receptor subtypes and the 
relative affinity values for both homodimers and the M3/M5 heterodimer. Such a 
heterogeneous population of receptors oligomerization will provide a molecular 
mechanism for an increased diversity of cholinergic signalling in lymphocytes 
cells, a fact which might be considered during therapeutic treatment of the 
immune system. 
The third intracellular loop as a key structural determinant in receptor-
protein interactions 
The third intracellular loop of muscarinic receptors is not only one of the main 
target domains for interaction with G proteins, but also a binding site for direct 
interaction with different proteins. Indeed, previous observations using receptor-
derived peptides from specific regions of the M1 and M2 receptors have shown 
that the C-terminal tail of the 3ILoop is critical for functional receptor-G-protein 
interaction 641. These observations have confirmed that there are different 
structural determinants for receptor-G-protein coupling and G-protein activation. 
More recently, specific motifs in the 3ILoop of M1 and M3 receptor have been 
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shown to bind some accessory proteins with high affinity (calmodulin, oncogenic 
SET, and small GTPase Rho) 64,334,642,643.  
These observations point to a specific role of 3ILoop in receptor-G protein 
coupling, signal transduction and multiprotein complex formation. In chapter 3, 
using a minigene construct capable of expressing the   human M3 muscarinic 
receptor 3Iloop (TAP-3ILoop-minigene), it was demonstrated that the soluble 
expressed 3ILoop could act as an analogue of the receptor 3ILoop, and as a 
scaffold protein as well, competing with the receptor for its interacting proteins, 
and therefore inhibiting the specific G-protein-mediated downstream effects.  
The rationale of our approach was to explore the ability of this structural 
determinant to interfere with G protein interaction or to compete for other 
interacting proteins that participated in a putative multiprotein complex formation, 
and to analyze its capacity to compete for functionally relevant processes. Our 
efforts were specifically focused on the third intracellular loop of the M3 
muscarinic receptor subtype, because this region was reported to be involved in 
direct G protein binding and activation, and the putative site for interaction of a 
group of scaffold or accessory proteins (arrestin binding, calmodulin and small G 
proteins interactions) 169,340,644. The antecedent for our experimental design can be 
found in previous studies of cellular expression of fragments, or in vitro G protein 
activation assays, which reported the ability of the intracellular loops --or peptides 
derived from these loops-- to interact with the same molecular partners as the 
intact receptor 342,344,645. Experimental evidence was available showing that these 
co-expression experiments could act mimicking the intact receptor, or coupling 
with and activating the relevant G protein346,646. In the current series of 
experiments, the third intracellular loop domain of the M3 receptor was shown to 
have a recognizable impact on the function of the intact M3 receptor subtype. In 
our experiments, proximal events occurring at the level of the plasma membrane 
were dramatically affected as shown by the impairment of receptor-accessory 
protein co-immunoprecipitation in cells co-expressing the minigene construct. 
The co-expression of the minigene construct along with the wild-type receptor 
exhibited decreased G protein activation, phosphatidylinositol production, and 
subsequent signalling, but normal ligand binding and receptor membrane 
expression (Figure 3.1.7). Therefore, our results indicate that the co-expression of 
the 3ILoop of the M3 receptor with the M5 subtype produce similar effects, as 
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with previous studies in which the expression of the third intracellular loop of the 
μ-opioid receptor altered the functionality not only when co-expressed with the 
intact μ -opioid receptor but also when co-expressed with other classes of GPCR 
347.  
The third intracellular loop is 256 residues long, containing multiple motifs of 
basic and acid residues and some currently recognized functional sequence 
motifs. This primary sequence pattern is not conserved throughout the G protein-
coupled receptor superfamily and not even within the class A rhodopsin-like 
receptor subfamily that represents the closest structurally-related class of GPCR. 
It is possible that this will ultimately constitute a conformational structural motif 
that will be more broadly representative and determine part of the specificity for 
each receptor in these families. However, no structural data is currently available 
to confirm or refute this hypothesis.  
Interacting proteins for such motifs appearing in modular form can be identified 
by affinity purification approaches, such as yeast two-hybrid screening and 
immunoprecipitation. Our current work, in which the minigene construct 
representing the third intracellular loop of the M3 muscarinic receptor specifically 
influences the intracellular signalling of the intact receptor, probably blocking a 
putative multiprotein complex formation, supports the notion that important 
motifs could be present in this region. The fact that this loop is significantly long 
and that it is a recognized site for post-translational modifications should make it 
an ideal tool for exploring potential molecular partners that might mediate the 
observed effect under different cellular conditions.  
The use of this TAP-system strategy that complements the co-expression 
experiments of the construct with the intact receptor under different physiological 
condition, together with immunoaffinity purification followed by mass 
spectrometry analysis, allow us to systematically identified new interacting 
protein of muscarinic receptor family (chapter 3.2).  
The ILoop-TAP proteomic approach presented in this work contributes to the 
largest analysis of protein-protein interaction in muscarinic receptor family.  
Maximizing sensitivity and reproducibility over other methods to detect receptor 
binding partners, we identified 148 different interacting proteins, of which 57 had 
been detected previously as muscarinic receptor-binding partners. 
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The GO classification of the proteins identified by Iloop-TAP strategy revealed 
some interesting avenues of further consideration: first, the presence of 
heterotrimeric G proteins in all receptor subtype-associated protein purifications. 
Consistent with the known coupling of muscarinic receptors to G proteins, we 
identified four Gα-protein for M1/M3/M5 receptor subtypes (Gα-q, Gα-11, Gα-12 
and Gα-13) and three Gα-i isoforms (Gα-i1, Gα-i2 and Gα-i3) for M2/M4 receptor 
subtypes, as well as two different Gβ isoforms (Gβ1 and Gβ4) and three Gγ 
isoforms (Gγ2, Gγ7 and Gγ11). This demonstrates that our approach can clearly 
be used as a method for large-scale protein-protein interaction detection, not only 
for the muscarinic receptor family, but also for other GPCRs. Second, we 
identified several cytoskeletal proteins, including those associated with GPCRs’ 
reorganization and regulation (α- and β-tubulin, filamin A, annexin A2, dynamin 
2, clathrin, IQ-GAP1/3 and paxillin), some of them existing in a common 
complex with specific receptor subtypes. This suggests that muscarinic receptors 
selectively bind to different structural components in the cell and may have a role 
in receptor internalisation and the regulation of cell spreading, migration, and the 
attachment at sites of focal adhesion 384. In support of this notion are recent 
reports pointing toward different mechanisms of internalisation using M2 and M4 
receptors depending of the cellular type 385,386, as well as the active roles of 
tubulin and microtubule reorganization in PLD activation mediated by Gq/11 
muscarinic receptor subtypes 387. More interestingly, using drugs that stabilized or 
destabilized microtubule organization, it was found that the activation of 
muscarinic leads to modulation of ion currents in cardiac myocyte cells 388, 
functions mediated by the direct interaction of the receptor and the G protein with 
the microtubule cytoskeleton. The third and last consideration is the identification 
of several muscarinic receptor subtypes-specific signalling proteins such as ADP-
ribosylation factors, elongation factor 1-A (eEF-1A), oncogenic SET protein, 
Rac1, and different isoforms of phospholipase C and the protein kinase C (β-1, β-
3, γ and α, δ, τ respectively). Interestingly, the small GTPases Rac1 has been 
shown to function downstream of M1 and M3 receptors. In the context of Rac 1 
activity but not RhoA activity, M3 muscarinic receptor-mediated activation of 
PLC and PKC triggers cell death 389. The ADP-ribosylation factors are members 
of the Arf arm of the Ras superfamily of guanosine triphosphate (GTP)-binding 
proteins. Physiologically, Arfs regulate membrane traffic and the actin 
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cytoskeleton. However, Arf function likely involves many additional biochemical 
activities. Arf activates phospholipase D and phosphatidylinositol 4-phosphate 5-
kinase with the consequent production of PA and PIP2, respectively 390. It has 
been shown that vasopressin V2 receptor and M2 muscarinic receptor processing 
and trafficking are under ARF-6 control 391. Also, Arf 1 and 6 mediate PLD1/2 
activation by M3 muscarinic receptor 334. eEF-1A and other elongation factors 
have been reported to modulate M4 muscarinic receptor subtype function by direct 
interaction with the receptor 392,647. Several serine/threonine phosphatases 
participate in the dephosphorylation of activated GPCRs. Phosphatases of the 
PP2A and PP2B subfamilies have been reported to target GPCRs. M1 receptor 
subtypes stimulate the formation of a multiprotein complex centred on TRPC6 
channels where PP2B plays an active role in the disassociation of the muscarinic 
receptor from the complex 394.  
The most important outcome of our study is the possibility to study and identify 
specific interacting proteins under native conditions. Although we used only one 
set of experimental parameters here for the evaluation of complex composition, 
we will, in the future, systematically modify experimental parameters (both 
pharmacological and physiological conditions) to evaluate the impact of a 
changing environment on complex variability. These studies should help to 
elucidate the dynamics of complex assembly and disassembly for each receptor 
subtype. Moreover, it may be a starting point in deciphering receptor specifies and 
a molecular context for the choice and evaluation of drug targets. 
Another important outcome of our experiments is that, comparing the 
experimental results in the literature with our data-set, we were able to construct a 
muscarinic receptor family network, which allowed us to group interacting 
proteins into cluster complexes. The network that resulted is a functional 
description of the muscarinic receptor interactome at a higher level of 
organization and revealed some interesting information. Although comparison of 
our data set with literature is straightforward, it is important to keep in mind that 
our IloopTAP approach yields complexes composition data that, in any case, 
produces binary interactions, just as the results from two hybrid methods. This 
supports the view that receptor complex formation is more than the sum of binary 
interactions. 
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However, binary analysis methods are of exceptional value for the detection of 
pairwise and transient associations of GPCRs. The success of our approach in the 
characterization of receptor complexes relies on the conditions used for the 
assembly and retrieval of the complexes. These include localization and post-
translational modifications in a manner that closely approximates normal 
physiology. Therefore, because the ILoopTAP method does not provide 
information on the orientations of complex components, complex characterization 
by two-hybrid analysis, or resonance energy transfer methods are ideally 
complementary.  
The C terminal tail 
Although there is increasing evidence that the “magic tail” of GPCRs constitutes 
the main anchoring domain for soluble interacting proteins (more than 50 GIPs 
interacting with GPCR C-termini have been identified 648), in the case of 
muscarinic receptor family only the third intracellular loop has been reported as 
critical domain capable of binding adaptor and scaffold proteins. Nevertheless, a 
few examples have been reported with a functional role in receptor regulation and 
signalling570.  
Despite the small role of the C terminal tail of muscarinic receptor in the 
recruitment and anchoring of adaptor and scaffolds protein, it is well established 
that the C-terminal tail of the M3-muscarinic receptor is an essential structural 
element for signalling to the anti-apoptotic pathway 348. Experimental evidence 
has shown that the removal of the distal portion of the C-terminal tail results in a 
receptor that is coupled normally to the Gq/11/phospholipase C pathway and the 
mitogen-activated protein kinase pathway, but is unable to couple to the anti-
apoptotic pathway 649. Furthermore, it has been demonstrated that a poly-basic 
region conserved within the C-terminal tail of the Gq/11-coupled muscarinic 
receptor subtypes (CDKRKRRKQ) appears to be the structural determinant of 
coupling to the anti-apoptotic pathway 348. Today it is still unclear what protein or 
proteins are implicated in the connection of the muscarinic receptor with the anti-
apoptotic pathway, and which anti-apoptotic signalling is implicated. However, in 
chapter 4, we demonstrated by using quimeric receptors where the C-terminal tail 
of the human M3 muscarinic receptor was inserted in the C-terminal tail of two 
rhodopsin mutants (R135L and L46R), previously reported for patients with 
severe retinitis pigmentosa, that the anti-apoptotic properties of this epitope can 
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be used as a blocking system to inhibit apoptotic effects promoted by rhodopsin 
mutants. We provide evidence that quimeric construction protects cells from 
H2O2-induced apoptosis. Promoting the early expression of Bcl-2 decreased Bax 
expression and reduced caspase-3 activation. Correspondingly, cytochemical 
evaluation revealed an absence of cytochrome c into cytoplasm and an increased 
of NF-κβ translocation to the nucleus. These effects were blocked only by HA-
1077 Rho kinase inhibitor, indicating that the insertion of the anti-apoptotic 
epitope of the muscarinic receptor remains functional, reducing many apoptotic 
markers, and can be used as a therapeutic method for late-stage inhibition of 
apoptosis. 
Roles of Receptor-interacting proteins in subtype-specific receptor signalling 
A sequence alignment of GPCRs of the rhodopsin family reveals that the majority 
of GPCRs contain an NPxxY (x) 5,6F sequence 408. Mutation in this domain affects 
ligand affinity, receptor expression, G protein coupling, and receptor association 
with interacting proteins such as small G proteins ARF and Rho 418,422,650-653. 
Activation of the M3 Muscarinic receptor by agonist binding is followed by 
conformational changes and recruitment of accessory and scaffold proteins, that 
together with the classical core signalling entities contribute to the formation of a 
signalsome complex. The dynamics of such a complex is not well understood but 
a conserved NPXXY (5,6) F motif located in the transmembrane VII of the 
receptor was found to be critical in G protein activation. In chapter 5, we set out 
to elucidate the role of this region by using site direct mutagenesis in combination 
with coimmunoprecipitation experiments and signal transduction assays. We have 
generated receptor mutants (N540A, N540D and F551A) to determine the effect 
of the mutation on binding, G protein coupling, signalling and multiprotein 
complex reorganization after the expression of the mutated receptor in COS-7 
cells. The mutated receptor displayed similar expression levels and ligand binding 
properties compared with the wild type, except receptor mutant N540A, which 
showed a high reduction in level expression and slightly reduced antagonist 
binding sites. In addition, the N540A receptor mutant showed a dramatic 
reduction in G protein activation and completely failed to elicit PLD activation 
and PI response to carbachol stimulation. However, the N540D mutant activates 
G proteins and stimulates PLC and PLD, but with different time course and 
desensitization compared with the WT. Co-immunoprecipitation experiments 
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allowed us to show that each mutant retains a different capacity to form stable 
complexes with different populations of G proteins and accessory proteins 
(ARF1, ARF6, RhoA). Different levels of ARF, RhoA and G proteins were 
observed in the immunoprecipitation complexes for N540D mutant. Indicating the 
role of the NPXXY (5,6) F motif as a structural determinant during 
conformational and selectively activation of G proteins and multiprotein complex 
reorganization.  
With the N540A/D and F551A mutations, we demonstrated a selective regulation 
of downstream signal transduction by a different conformational arrangement of 
M3 receptor. The WT and N540D mutant resulted in a small change in IP 
accumulation even at highly agonist concentration. However, the F551A mutant 
receptor showed a two-fold reduction with respect to WT and the N540A mutants 
completely lost their capacity to activate the PLC signal. Also, carbachol 
stimulated [3H] Ptdbut formation resulted in a six-fold increase for the WT 
receptor and N540D mutant, with lower activation for the WT receptor and 
N540D mutant, lower activation for the F551A mutant, and no detectable [3H] 
Ptdbut production for the N540A mutant, but with a lower potency in all cases. 
We also corroborated that theses results were observed at the level of the MAPK 
PLC/PLD pathway and the changes of Asn by Asp keep a relatively stable 
conformation that does not substantially perturb the conformation change 
produced during receptor activation upon agonist stimulation. 
Schmidt and Jakobs showed that activation of M3 muscarinic receptor in HEK 
cells leads to stimulation of both phospholipase (PLC/PLD), but with distinct 
efficacies and with very distinct durations of each response, but this study did not 
identify the essential transducing component responsible for the variable 
desensitisation 654. Mitchell and Johnson demonstrated in COS-7 cells that the M3 
muscarinic receptor substantially utilized an ADP-ribosylation factor (ARF)-
dependent route for PLD activation 655. The M3 receptor displayed a major ARF1-
dependent route for PLD1 activation, whereas the ARF-6 dependent pathway 
activates both PLD1 and PLD2 656. However, these studies did not show in detail 
if the selective coupling by different ARF factors is responsible for 
desensitization. 
We observed, as previously reported, that the time-course of carbachol-stimulated 
[3H]-myo-InsPs accumulation in the transfected WT-COS-7 cells reached a peak 
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between 20-60 min after agonist exposure and fifteen percent of receptors 
desensitized 2 h after agonist stimulation (2 min, 1 mM of carbachol). In contrast, 
maximal levels of [3H] Ptdbut were already obtained after 2 min of incubation 
with carbachol (1mM), followed by a stable plateau of at least 30 min of 
incubation for the WT receptor. Although at a lower level, the F551A mutant 
showed similar time-course and desensitization, and the N540D mutant did not 
desensitize following short-term agonist treatment in the same manner as the WT 
for PLD response. On the contrary, 2 min of pre-exposure to carbachol led to 
about a two-fold increase in receptor-mediate [3H] Ptdbut formation 20-30 min 
after exposition. 
Stimulation of PLD/PLC in COS-7 cells by transfected M3 muscarinic receptors 
are affected by change in the NPxxY (x) 5,6F motif. These changes can cause 
different degrees of structural flexibility, resulting in the regulation of the 
interacting proteins, such as ARF factors, and the selective regulation of 
desensitization mechanisms. Mutation in the N 4.79 position resulted in a very 
rapid change (less than 2min) in PLD response upon agonist-stimulation. This 
phenomenon may be the result of the different recruitments of ARF1/ARF6 
factors, and the resistant-sensitive βγ complex inhibition and translocation (as 
demonstrated by co-immunoprecipitation experiments). This demonstrates for the 
first time the active role of the NPxxY (x) 5,6F motif in the selective process of 
multiprotein complex formation and reorganization by human M3 muscarinic 




Until a few years ago it was thought that the interactions between muscarinic 
receptor, G-proteins and their effectors could describe the whole system. 
However, we now know that it is much more complex, with many other proteins 
binding to muscarinic receptors and influencing their activity. Indeed, in these 
five years of work, we demonstrated by different approach (from resonance 
energy transfer to tandem affinity purification and mass spectrometry) the active 
role of interacting protein in muscarinic receptor regulation and signalling. We 
shown that a particular complex is not necessarily of invariable composition, nor 
are all its building blocks uniquely associated with that specific complex. One 
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complex may be the result not only of physical interaction between the receptor 
and the partners’ protein, but also of the participation of many non-“direct” 
associations resulting in the formation of a network that interconnects the receptor 
with a number of other pathways, determining receptor specificities.  
1. We demonstrated that M5 muscarinic receptor subtype form homodimers. 
These homodimers are the functional units at the cell surface. In addition 
to homodimerization, M5 receptor subtype is able to form heterodimers 
with M3 receptor subtype. M3/M5 heterodimers have been detected in 
living cells and agonist activation of the two receptors does not seem to 
modify the degree of heterodimerization.  BRET analysis showed that the 
third intracellular loop is an important domain in receptor interaction and 
heterodimers formation.  
2. In T-cell M3/M5 heteromeric receptor complexes seem to play an active 
role in modulation of regulation of immune response 
3. Using a novel TAP-3ILoop approach it was systematically identified 
interacting protein of each muscarinic receptor subtype.  
4. Comparative analysis of experimental results together with scientific 
literature, allowed the representation of muscarinic receptor network 
interactome. 
5. Quimeric construction where the anti-apoptotic C-terminal region of the 
M3 muscarinic receptor was used keep its functional properties, and 
provide protection to the cell. Engineering the quimeric receptor of two 
rhodopsin mutants (R135L and L46R), previously reported for patients 
with severe retinitis pigmentosa 410,657, it was demonstrated the  evidence 
of protection against apoptosis and common activation mechanisms 
among GPCRs.  
6. NPXXY (5,6) F motif is involved in the activation and potentially in the 
signalsome complex formation of the M3 muscarinic receptor subtype. The 
flexibility introduced by the NPXXY (5,6) F motif play a role in 
muscarinic receptor activation by functioning as a sensitive 
conformational switch and also determine the selectivity and magnitude of 
signalling, regulation and scaffolds protein interaction. 
Much progress has been made in the understanding of the molecular 
pharmacology and function of muscarinic receptor family, but still many 
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questions remain unanswered, while new finding, often add more questions. 
Therefore, the muscarinic receptor family deserves to receive the same (if not 
more) attention and continuous research efforts it has received so far, for 
many years to go.  
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Most conserved residues located in rhodopsin family (A). Residues number is 
based on the sequence of bovine rhodopsin.  
 
TM Domain Residue type Residue number 
H-I N  55 
H-II D  83 
H-III R 135 
H-IV W 161 
H-V P 215 
H-VI P 267 
H-VII P 303 
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Appendix 2:  
Titration of Donor and Acceptor Fusion Proteins—Expression levels of mAChR-RLuc and 
mAChR-GFP constructs were monitored by measuring luminescence and fluorescence, 
respectively, as described in MATERIALS AND METHODS. This procedure is based on the 
observation that luminescence and fluorescence levels of several receptor-RLuc and receptor-GFP 
(or receptor-YFP) fusion proteins have been found to be linearly correlated with receptor numbers. 
Because this correlation is an intrinsic property of each fusion protein, we tested whether our 
mAChR fusion proteins followed a linear correlation pattern. Thus, we expressed each mAChR-
RLuc or mAChR-GFP at different levels in HEK 293 cells and assessed the relationship between 
luciferase activity or fluorescence, respectively, and the amount of mAChR-binding sites in the 
same cells. Luminescence and fluorescence (arbitrary units) were plotted against total binding 
sites, and linear regression curves were obtained. These standard curves generated for each single 
experiment were used to transform fluorescence and luminescence values into femtomoles of 
receptor. Thus, the fluorescence/luminescence ratios were transformed into (receptor-
GFP)/(receptor-RLuc) ratios, which allowed us to determine accurate BRETmax and BRET50 
values.
M3-GFP2











































































































Appendix 3.1 and 3.2: 
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RLuc or mAChR-GFP at different levels in HEK 293 cells and assessed the relationship between 
luciferase activity or fluorescence, respectively, and the amount of mAChR-binding sites in the 
same cells. Luminescence and fluorescence (arbitrary units) were plotted against total binding 
sites, and linear regression curves were obtained. These standard curves generated for each single 
experiment were used to transform fluorescence and luminescence values into femtomoles of 
receptor. Thus, the fluorescence/luminescence ratios were transformed into (receptor-
GFP)/(receptor-RLuc) ratios, which allowed us to determine accurate BRETmax and BRET50 
values.
M3-GFP2

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































AC Adenylyl cyclase 
ATP Adenosine 5’-triphosphate 
BRET Bioluminescence resonance energy transfer 
CaMK Ca2+/calmodulin dependent protein kinase 
cAMP Adenosine 3’,5’-cyclicmonophosphate 
cDNA complementary deoxyribonucleic acid 
CHO Chinese hamster ovary 
DMSO Dimethylsulfoxide 
EDTA Ethylendiaminetetraacetic acid 
ER Endoplasmatic reticulum 
ERK-1/2 Extracellular regulated kinase-1/2 
FITC Fluorescein isothiocyanate 
FRET Fluorescence resonance energy transfer 
GFP Green fluorescent protein 
GRK G-protein coupled receptor kinase 
GST Glutathione-S-transferase 
GTP Guanosine 5’-triphosphate 
MAPK Mitogen-associated protein kinase 
mRNA Messenger ribonucleic acid 
PD98059 2-(2-Amino-3-methoxyphenyl)-4-H-1-benzopyran-4-one 
PKC Protein kinase C 
PLC Phospholipase C 
PVDF Polyvinylidene difluoride 
Rluc Renilla luciferase 
RT-PCR Retro-transcriptase polymerase chain reaction 
SDS-PAGE Sodium dodecyl sulfate polyacrilamide gel electrophoresis 
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